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PREFACE
This thesis describes research started while I was a Research Fellow at the Bath 
Institute for Rheumatic Diseases from April 1993 to May 1995. The Institute is 
associated with the University of Bath and Royal National Hospital for Rheumatic 
Diseases. The work was completed part-time whilst I held a Senior Registrar post at 
the same hospital from June 1995 to May 1998.
The thesis contains a number of closely linked studies designed to increase our 
understanding of the link between joint, skin and nail disease in psoriatic arthritis 
and factors which may influence its onset, progression and outcome. The studies use 
clinical descriptive, epidemiological, immunohistological and immunogenetic 
techniques.
A brief general summary, including major research goals, results and interpretation 
of each study, precedes a general introduction which surveys the literature which 
lead to the hypothesis and study aims. Full details of the methods and results of each 
study are reported together to aid comprehension. They are collected into three 
distinct chapters reflecting broad research thrusts. Each section of chapter 2 and 
chapters three and four are preceded by structured summaries and brief 
introductions. A short discussion completes each section so that each section of 
chapter 2 and chapters 3 and 4 are complete in themselves. The results of the studies 
are synthesised in a concluding general discussion, which draws on contemporary 
research to assist evaluation, and outlines possible areas for future research.
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CLA cutaneous lymphocyte antigen
CRP C-reactive protein
DIP distal interphalangeal
DMARD disease-modifying anti-rheumatic drug
ERO erosions
E-selectin endothelial selectin
ESR erythrocyte sedimentation rate
HAQ health assessment questionnaire
HDL high density lipoprotein
IP interphalangeal
JSA joint space abnormality
LDL low density lipoprotein
Lp(a) lipoprotein (a)
MCP metacarpophalangeal
MHC major histocompatibility complex
NSAID non-steroidal anti-inflammatory drug
OA osteoarthritis







SEM standard error of the mean
SF synovial fluid
SM synovial membrane
SMR standardised mortality ratio
TNF tumour necosis factor
VLDL very low density lipoprotein
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SUMMARY
The first part of this thesis focuses on the clinical expression and natural history of 
psoriatic arthritis, the relationship of joint disease to skin and nail disease and the 
identification of factors that may predict disease progression. The pattern of disease 
was documented in 100 patients attending a psoriatic arthritis clinic in whom the 
mode of onset was known. These patients were prospectively followed up at five 
years. The mode of onset did not predict outcome in the majority, the majority of 
patients progressing from oligoarthritis to polyarthritis. After five years, the 
peripheral joint disease of many of these patients continued to deteriorate both 
clinically and radiologically. Hence peripheral joint disease in psoriatic arthritis is 
progressive in the majority of patients and requires effective monitoring and 
treatment.
There was no association between the severity, activity or type of skin disease and 
the severity or activity of joint disease either at the initial presentation or five year 
follow-up although 23/87 patients reported simultaneous exacerbations of their skin 
and joint disease. A separate prospective study of 24 patients who were documented 
at regular intervals showed that simultaneous exacerbations occurred only slightly 
more often than would be expected by chance, and this characteristic did not define a 
separate subgroup of patients. The number of patients with nail disease increased 
with time, nail disease was more common in patients with DIP joint disease and was 
significantly associated with adjacent DIP joint disease, suggesting a common local 
inflammatory mechanism.
There was a significant positive correlation between the initial viscosity and rate of 
progression of joint damage, suggesting that a raised plasma viscosity may be a 
predictive factor. The prevalence of the rheumatoid arthritis HLA DR1 and DR4 
‘shared epitope’ was similar in psoriatic arthritis to a control population and was
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unrelated to disease pattern or progression. This further distinguishes psoriatic 
arthritis from rheumatoid arthritis. Pregnancy and other hormonal factors may 
trigger or modify peripheral joint disease in some women.
The second part of this thesis focuses on immunological mechanisms that may 
explain the link between joint and skin disease in psoriatic arthritis. The study 
investigated whether skin-homing T lymphocytes identified by the cutaneous 
lymphocyte antigen (CLA) are increased in the synovial membrane of patients with 
psoriatic arthritis. Synovial samples were obtained from involved knees and lesional 
skin biopsies were taken from patients with psoriatic arthritis and psoriasis alone. All 
samples were single and dual-stained for CLA and CD3, a T cell marker, using 
monoclonal antibodies. The ligand for CLA on endothelial cells is E-selectin and its 
expression was also determined. The percentage of dual-stained lymphocytes was 
significantly greater in psoriatic skin than in synovium and similar between psoriatic 
and rheumatoid synovium. There was no significant difference in the percentages of 
CLA-positive cells in psoriatic skin in patients with psoriatic arthritis compared with 
psoriasis alone. The intensity of endothelial E-selectin expression was significantly 
greater in skin psoriasis than in synovium, and rheumatoid synovium had 
significantly greater expression of E-selectin than psoriatic synovium. However, 
there was no significant correlation between E-selectin expression and the 
percentages of CLA-positive lymphocytes. This study provides further evidence that 
the CLA antigen is enriched on skin-homing lymphocytes. Conversely, the link 
between skin and joint inflammation in psoriatic arthritis does not seem to be 
explained by increased trafficking of CLA T cells to psoriatic synovium.
Other factors may influence the morbidity and mortality of patients with psoriatic 
arthritis. In the third and final study of this thesis, the lipid profile in psoriatic 
arthritis is characterised in relation to a control population to determine whether 
there is an atherogenic lipid profile in psoriatic arthritis, which may have a bearing
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on mortality. Fasting lipids, lipoproteins and their subfractions were measured in 50 
patients with psoriatic arthritis and their age and gender matched controls. High 
density lipoprotein-cholesterol (HDL-cholesterol) and, specifically, its third 
subfraction, HDL-3-cholesterol, were significantly reduced in the psoriatic 
arthritis patients. The most dense subfraction of low density lipoprotein (LDL), 
LDL-3, was significantly increased in the psoriatic arthritis patients. Twenty patients 
with active synovitis had significantly lower total cholesterol, LDL-cholesterol and 
HDL-3-cholesterol than their controls. Twenty-five per cent of the psoriatic arthritis 
patients had elevated Lipoprotein (a) (Lp(a)) levels (> 300mg/l) compared with 19% 
of controls.
In conclusion, elevated levels of LDL-3 combined with low levels of HDL- 
cholesterol, in addition to Lp(a) levels > 300mg/l, are associated with coronary 





Psoriatic arthritis has a long history:- there are reports of its existence in a fifth 
century Judean monastery (Zias and Mitchell 1996), and characteristic radiographic 
features have been observed in medieval skeletons (Rogers et al 1982). The 
association between psoriasis and joint disease was first recognised by Alibert in 
1822 and later coined “ Psoriasis Arthritique” by Bazin (1860) although the 
inflammatory, proliferative skin lesions were thought to be lepromatous. Bourdillon 
is credited with proposing its existence in his Doctoral Thesis (Bourdillon 1888). He 
noted the typical involvement of the distal interphalangeal joints of the hands and 
feet, which seemed to distinguish psoriatic arthritis from other rheumatic diseases.
Throughout the 1950s and 1960s, a number of studies have indicated a significant 
association between psoriasis and arthritis (Vilanova and Pinol 1951, Coste et al 
1958, Wright 1959a and 1959b, Bauer 1965). The prevalence of psoriasis in arthritis 
patients is 2.6 to 7%, whereas psoriasis has a prevalence of 1.5-3% (Camp 1992). 
The prevalence of arthritis in the general population is 2 - 3%, while in psoriatic 
patients it has varied from 7 to 42% in different populations (Gladman 1993a and 
1994), although 5% is still quoted by some (Pitzalis 1996). The overall prevalence of 
psoriatic arthritis may therefore approach that of rheumatoid arthritis and ankylosing 
spondylitis.
Despite the antiquity of psoriatic arthritis and strong epidemiological evidence, its 
existence as a specific entity is still questioned by some (Van Roumude et al 1984a, 
b and c; Cats 1990). Also the distinction of psoriatic arthritis from rheumatoid 
arthritis and its relationship to the sero-negative spondyloarthritides have remained a 
subject of debate. It was the discovery of rheumatoid factor and its absence in the
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majority of patients with psoriasis and arthritis that lead to its recognition as a 
distinct entity by the Arthritis and Rheumatism Council in 1964 (Blumberg et al 
1964). Nevertheless, the precise definition of psoriatic arthritis remains 
controversial, with rheumatoid factor positivity used as an exclusion criteria by some 
(Wright 1956), but not others (Gladman et al 1986, 1995a and b; Little et al 1975, 
Leonard et al 1978, Kammer et al 1979). Psoriatic arthritis usually differs from 
rheumatoid arthritis in its clinical presentation, which is often asymmetrical, the 
presence of distal joint diseases, and the presence of a spondyloarthritis, with no 
gender predilection. In some patients, the controversial issue of whether the 
diagnosis is psoriatic arthritis or rheumatoid arthritis with psoriasis, cannot be 
resolved (Helliwell and Wright, 1994). However, the discovery that rheumatoid 
arthritis improves with the depletion of T helper lymphocytes secondary to HIV 
infection, whereas psoriasis or psoriatic arthropathy get worse (Espinoza et al 1988, 
Amett 1991, Espinoza et al 1992a) supports the distinction between the two 
diseases. Furthermore, family studies have been important in establishing the 
concept of the sero-negative spondyloarthritides including ankylosing spondylitis, 
Reiter’s syndrome, enteropathic arthropathies as well as psoriatic arthritis, which 
share common clinical features and have an increased frequency of HLA B27 (Moll 
et al 1974; Wright and Moll 1976; Eastmond 1994; Moll 1994, Alenius 1997). 
Clinically, psoriatic arthritis when it occurs with pustular psoriasis may be 
indistinguishable at onset from Reiter's syndrome with keratoderma blenorrhagia 
although Reiter's syndrome tends to be a more systemic illness (Keat 1994). 
Similarly patients with a spondyloarthropathy and psoriasis may resemble idiopathic 
ankylosing spondylitis in the expression of their joint disease. However psoriatic 
arthritis has unique features which include the predominance of a characteristic 
peripheral arthropathy and spondyloarthropathy which is less symmetrical, causes 
less spinal dysfunction and differs radiologically from ankylosing spondylitis. In 
addition, HLA B27 is present in less than 50% of patients with psoriatic arthritis.
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Therefore psoriatic arthritis may be considered to be a disorder distinguishable from 
both rheumatoid arthritis and ankylosing spondylitis.
Psoriatic arthritis has been divided into subgroups according to the distribution and 
number of joints involved. In 1941, two clinical patterns were defined (Bauer et al 
1941, Sherman 1952) - 1. an arthritis with rheumatoid-like features; 2. an arthritis 
exclusively involving the DIP joints associated with nail disease. The original five 
subgroups described by Moll and Wright may still be the most widely used in 
clinical practice: 1. asymmetrical, oligoarticular arthritis chiefly affecting the MCPs. 
PIPs and DIPs and associated with sausage digits (70%); 2. symmetrical, 
rheumatoid-like arthritis distinguishable from rheumatoid arthritis by DIP 
involvement and negative rheumatoid factor (15%); 3. the ‘classical’ pattern of 
psoriatic arthritis in which the DIP joints are predominantly involved and nail 
changes are invariable (5%); 4. arthritis mutilans, a severe deforming arthritis 
affecting young patients in which sacroileitis is frequently present (5%); 5. 
spondylitis in which symptoms may be minimal despite marked radiological changes 
(5%) (Moll and Wright, 1973). The distinctions between these subgroups are 
controversial, and difficult to apply consistently in research studies . Others have 
proposed fewer subgroups (Kammer et al 1979, Veale et al 1994, Helliwell et al
1991). Kammer et al (1979), and later Veale et al (1994), emphasised the rarity of 
exclusive DIP joint involvement, its presence in other subgroups, and the frequent 
overlap of mutilans with all other articular forms of arthritis. Kammer et al described 
an oligoarthritis group (frequently asymmetrical), a symmetrical arthritis and a 
spondyloarthritis. Based on radioisotope bone scanning, Helliwell et al (1991) also 
proposed three subgroups, a large group with peripheral arthritis, a group with 
predominant spondylitis and a group with extra-articular osseous manifestations, 
closely linked to the SAPHO syndrome (see below). Gladman et al (1986) described 
seven subgroups based on the association with immune response genes and 
recognising patients with an overlap of spondylitis and peripheral arthritis belonging
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to DIP, oligoarticular or polyarticular groups. Gladman et al (1987) later described 
the disease as a heterogeneous spectrum of features and severities, although has 
continued to use seven subgroups in later studies (Gladman, 1995a and b). Whatever 
subgroup classification is used, it is unclear whether the subgroups are homogeneous 
or whether they become established at some stage in the course of the disease. In 
Chapters 2a and b subgroup homogeneity is assessed both by retrospective study of 
the mode of presentation of 100 patients and by prospective five year follow-up of 
these patients.
Historically, psoriatic arthritis has been considered to be a milder form of arthritis 
than rheumatoid arthritis with short-lived synovitis, involving less pain and residual 
damage and consequent disability in the majority of patients (Scarpa et al 1984 and 
1992b, Oriente 1994). Wright compared patients with psoriasis and erosive arthritis 
with classical rheumatoid arthritis and noted that psoriatic arthritis was less often 
polyarticular at onset and tended to be less severe than rheumatoid disease with 
fewer affected joints and fewer deformities (Wright 1956). Kammer et al (1979) 
studied 100 patients with psoriatic arthritis and found the asymmetrical 
oligoarticular pattern to be most prevalent. They suggested that the disease course in 
this subgroup was less aggressive and disabling than that in other forms of psoriatic 
arthritis. Patients with symmetrical arthritis were more likely to develop destructive 
and potentially deforming disease, and the majority were women. Although there are 
certainly fewer extra-articular features than either rheumatoid arthritis or ankylosing 
spondylitis, there has been little further evidence to suggest that the arthritis is less 
severe in terms of deforming radiological changes or disability. Evidence for this is 
that erosive disease has been reported in up to 57% (Torre Alonso et al 1991) and a 
follow-up study revealed that polyarthritis became more common, the majority had 
an arthritis indistinguishable from rheumatoid arthritis, 16% had DIP disease and 5% 
a mutilating arthritis (Roberts et al 1976, Wright 1992). Later cross-sectional work 
by others has consistently found polyarthritis to be the most common, although the
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pattern of arthritis in many of these patients may be asymmetrical and not 
rheumatoid-like (Scarpa et al 1984, Gladman et al 1987, Veale et al 1994). 
Clinically, psoriatic arthritis may appear to be less severe than rheumatoid arthritis 
because there is less joint tenderness (Buskila et al 1992). It is well recognised 
however that pain may not be directly related to joint damage and deformity. This is 
illustrated by the recent observation that arthritis mutilans, the most severe 
consequence of psoriatic arthritis, with telescoping of the digits and the ‘opera-glass’ 
hand, may be associated with Charcot joints (Cuellar et al 1996).
The detailed natural history of psoriatic arthritis, the homogeneity of disease 
subgroups, and predictive factors for disease progression have been infrequently 
studied (Gladman et al 1994 and 1995a and b). In rheumatoid arthritis, radiographic 
changes in the hands have been found to reflect clinical joint damage and 
progression, and have been used as important outcome measures in therapeutic trials 
(Kirwan 1995). However, data on the pattern and rate of progression of radiological 
changes in the hands in patients with psoriatic arthritis is limited (Roberts et al 1976, 
Gladman et al 1990). A thorough understanding of the natural history of a disease is 
an essential prerequisite for the prediction of outcome. The heterogeneity of psoriatic 
arthritis make the establishment of reliable predictive factors particularly complex 
and important. Furthermore there has been a tendency to avoid giving disease 
modifying medication in patients with psoriatic arthritis, a fact that is reflected in the 
paucity of drug trials in psoriatic arthritis (Gladman 1992). Prognostic indicators are 
vital for both patients and rheumatologists, influencing both follow-up and treatment 
decisions. Some of these factors are addressed in Chapter 2b.
Clinical descriptive and epidemiological studies have conclusively established a link 
between psoriasis, nail disease and arthritis. However, the precise relationship 
between the three manifestations of the disease remains uncertain. Some individuals, 
20% in most studies, present with joint symptoms before skin lesions appear
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whereas, in the majority, up to 80%, skin problems manifest themselves first. 
Psoriasis tends to be more severe in patients with psoriatic arthritis and nail disease 
tends to be more common (Camp 1992). The temporal relationship between the 
activity and severity of joint disease and the activity and extent of skin disease and 
nail disease has never been assessed prospectively. Gladman reported that 35% of 
patients have simultaneous exacerbations of skin and joint disease (Gladman et al 
1987), but the data was not obtained prospectively, although the figure has often 
been quoted in reviews (Gladman 1994). It is unclear whether the severity of skin 
disease may be an independent prognostic factor for psoriatic arthritis. It is possible 
that there may be a subset of patients with psoriatic arthritis, distinguished by 
simultaneous exacerbations of their disease that share a common immunogenetic 
profile. The aims of the study presented in Chapter 2c was to prospectively evaluate 
the temporal association of skin and joint involvement. The frequency of 
simultaneous exacerbations of joint, skin and nail disease was assessed in patients 
attending the psoriatic arthritis clinic who had active skin and joint disease at 
baseline.
Many of the genes implicated in susceptibility to rheumatic conditions map to the 
major histocompatibility complex (MHC) at the centromeric end of the short arm of 
chromosome six (Stastny et al 1983). Several genes in this region are essential to the 
mounting of normal cellular and humoral inflammatory responses. The human 
leucocyte antigen (HLA) genes are a small component of this region. There are 
three primary elements involved in initiating a specific immune response - an HLA 
Class I or Class II molecule, an antigen (in the form of a peptide) that associates in 
the antigen-binding site of the HLA Class II molecule, and the T-cell antigen 
receptor found on the surface of all T cell populations. The MHC can be divided into 
three regions, Classes I to HI, each containing a series of homologous loci. Encoded 
within the Class II region are the classical Class II genes, HLA-DR, -DQ and -DP. 
Each Class II molecule is a trans-membrane glycoprotein heterodimer, consisting of
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a non-covalently bound a  - and p - chain. Polymorphism of the HLA-DR molecule 
is confined to DR p chains, encoded at several distinct loci (Bell et al 1989).
Genetic susceptibility is likely to be of major importance in the development of 
psoriatic arthritis and may be critical in determining its pattern of expression and 
severity. HLA typing has been used to identify the role of HLA genes in 
susceptibility to diseases by comparing the prevalence of certain specificities among 
patient populations and healthy controls (Tiwari and Terasake 1985). To date, HLA 
studies in psoriatic arthritis have been performed primarily using serologic 
techniques. The associations have generally been with Class I antigens, encoded by 
the A, B and C loci of the MHC. Class II antigens, encoded by the HLA-D loci of 
the MHC have also been studied in psoriasis and psoriatic arthritis. The associations 
of the MHC Class I molecules are well established, with B13, B17, B27 and Cw6 
occurring with increased frequency in both psoriasis and psoriatic arthritis (Al - 
Jaralah et al, 1993; Eastmond 1994) and HLA B16 and its splits B38 and B39 
occurring in association with psoriatic arthritis (McHugh et al 1987, Gladman et al 
1995a). In psoriasis, it has been established that HLA Cw6 is the primary association 
and that the other HLA Class 1 associations are in linkage disequilibrium with this 
allele (Green et al 1988). Of the immunoresponsive MHC Class II molecules, 
HLA-DR7 has been consistently found to be increased in both psoriasis and psoriatic 
arthritis (Armstrong et al 1983, McHugh et al 1987, Espinoza et al 1992, Gladman et 
al 1995a). In psoriatic arthritis HLA-DR4 has been found to be associated with 
peripheral arthritis resembling rheumatoid arthritis by some (Gerber et al 1982, 
Kanter et al 1984, Espinoza et al 1982 and 1985) but not others (Beaulieu et al 1983, 
McKendry et al 1984, Gladman et al 1986, Salvarani et al 1989), and has been 
associated with erosive disease (McHugh et al, 1987). HLA-DR1 has also been 
found to be increased in some studies (Armstrong et al 1983).
It has been established for over 20 years that certain HLA-DR4 and HLA-DR1 
serotypes are associated with the presence of rheumatoid arthritis in different 
populations. The further definition of HLA-DR4 and HLA-DR1 subtypes and the 
discovery that not all subtypes are associated with rheumatoid arthritis has lead to 
the “ shared epitope” hypothesis (Gregarson 1987). This provides an explanation for 
the population association between rheumatoid arthritis and different, serologically 
defined class-II antigens at the DR loci on the basis of the ‘shared possession’ of a 
short sequence of amino acids in the third hypervariable region of the DRB1 gene. 
In rheumatoid arthritis, several authors have reported a hierarchy of disease 
susceptibility with a more pronounced association with 0401 (Dw4) and 0404 
(Dwl4). Also, there is good evidence that HLA-DR4 is associated with disease 
severity, with increased representation in patients with rheumatoid arthritis attending 
hospital specialists (van Zeben et al 1991). Homozygosity for the ‘shared epitope’ or 
compound heterozygosity (two different alleles containing the ‘shared epitope’) has 
been found to be linked to severe erosive disease (McDonagh et al 1997). All 
previous HLA studies in psoriatic arthritis used serological immunocytotoxicity 
techniques, so did not examine genetic subtyping in sufficient detail to evaluate the 
“ shared epitope” hypothesis.
The objectives of the study presented in Chapter 2d were therefore to determine 
whether the ‘shared epitope’ conferred susceptibility or was linked to the severity of 
psoriatic arthritis. Specifically, I wished to determine to prevalence of HLADRB1 
alleles and the “ shared epitope” in hospital outpatients with psoriatic arthritis 
compared with healthy controls and to determine the association of the “ shared 
epitope” with subgroups of disease and erosive disease, and the progression of joint 
scores and erosions over five years.
Hormonal factors may also have a role in determining outcome in psoriatic arthritis. 
There is a growing awareness of the role of pregnancy and other hormone-associated
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events in influencing the onset, expression and outcome of rheumatic diseases, 
particularly systemic lupus erythematosus and rheumatoid arthritis which both have 
a marked female predominance (Petri et al 1997, Buyan et al 1993, 0stensen and 
Lee Nelson 1995). Onset of rheumatoid arthritis closely related to pregnancy has 
been described and a greater than five-fold increase in risk of rheumatoid arthritis 
onset during the first 3 months post-partum has been reported, particularly following 
the first pregnancy (Silman et al, 1992). In rheumatoid arthritis post-partum onset is 
positively associated with breast feeding, possibly related to hyperprolactinaemia.
There have been fewer studies in the sero-negative spondyloarthropathies, including 
psoriatic arthritis, but it has been suggested that hormone-associated events may also 
be important modifiers of the disease (0stensen and Husby, 1983 and 0stensen,
1992). A preliminary study of 15 mothers with psoriatic arthritis suggested that 
pregnancy may trigger an earlier onset of psoriatic arthritis in the post partum period 
(McHugh and Laurent 1989). Both retrospective and prospective work by Ostensen, 
found that the pregnancy related remissions and post-partum flares of peripheral 
joint disease occurred in psoriatic arthritis (0stensen 1992). The aims of the study 
presented in Chapter 2e was to assess the relationship between hormonal-associated 
events including pregnancy, menstruation and the menopause and the onset and 
expression of arthritis and psoriasis in psoriatic arthritis.
A topographic relationship between nail and DIP joint disease was noted in some of 
the earliest studies of psoriatic arthritis, but not statistically analysed (Wright 1956). 
In Chapter 2a, a statistically significant topographic association between nail and 
DIP disease is demonstrated, demanding a pathophysiological explanation for the 
link. Although the inflammatory processes which link skin, nail and joint disease 
remain elusive, an immune-mediated pathology is implicated. Decker described 
“noxious substances'* that may traffic from the nail to the joint and our 
understanding of the immunological processes involved in linking joint, skin and
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nail involvement has evolved little to date (Decker 1985). However the infiltration of 
skin and synovial tissue with mononuclear cells including T lymphocytes, an 
association with major histocompatibility antigens, and the response to 
immunotherapy all suggest an immune-mediated pathology.
Immunopathogenic mechanisms involving T lymphocytes in psoriasis and arthritis 
appear similar. Both the skin and synovium are infiltrated with activated T 
lymphocytes (Barker 1994, Panayi 1994) with a preponderance of CD4RO+ve cells, 
which are known to migrate preferentially to peripheral tissues (Panayi 1994). The 
associations with major histocompatibility haplotypes, the only known function or 
which is to present antigen to T cells, have been summarised above and further 
assessed in Chapter 2d (NcHugh et al 1987, Eastmond et al 1994). Both psoriasis 
and arthritis increase in severity with the depletion of T helper lymphocytes 
secondary to HIV infection (Espinoza et al 1992a, Arnett et al 1991, Keat 1994) and 
both improve in response to immunotherapy such as cyclosporin A (Salvarani et al 
1992a).
The skin is a functionally unique immune site with apparently a specific homing 
mechanism for T cells. The cutaneous lymphocyte antigen (CLA), defined by the 
monoclonal antibody HECA-452 identifies a population of skin-homing memory T 
cells (Picker et al 1990). The receptor for CLA on dermal endothelium is the 
inducible cell adhesion molecule E-selectin (Picker et al 1991), a protein which also 
acts to tether neutrophils during their initial rolling interaction with the blood vessel 
wall at the onset of an inflammatory response (Bevilacqua et al 1994, Berg et al 
1991). It has been proposed that E-selectin on venules at sites of acute inflammation 
supports neutrophil recruitment, whereas in sites of chronic inflammation in the skin 
mediates accumulation of CLA-positive T cells (Picker et al 1991).
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The principal aim of the study presented in Chapter 3 is to determine whether skin 
and joint disease in psoriatic arthritis may be linked through the inappropriate 
expression of CLA molecules, E selectin or both. I have therefore investigated the 
percentages and distribution of skin-homing (CLA-positive) T lymphocytes and their 
counter-receptor E-selectin in the skin, synovium and peripheral blood of patients 
with psoriatic arthritis and appropriate controls.
Metabolic factors may also be of significance in the management and ultimate 
outcome of psoriatic arthritis patients. Patients with rheumatoid arthritis have an 
accelerated mortality compared with the general population, which may be attributed 
in part to an increased risk of cardiovascular disease (Pincus 1995a). Active 
rheumatoid arthritis is associated with an abnormal lipid profile (dyslipidaemia), 
although the relative contribution of this to the increased mortality is uncertain. 
Altered concentrations of serum lipids and lipoproteins (London et al 1963, Rossner 
and Lofinark 1977, Lorber et al 1985, Lazarevic et al 1992, Svenson et al 1987), and 
synovial lipids (Winyard et al 1993) and lipoproteins may occur including a reduced 
serum cholesterol (London et al 1963), decreased serum triglycerides (Rossner and 
Lofinark 1977, Lorber et al 1985, Lazarevic et al 1992, Svenson et al 1987) and 
altered apoprotein concentrations (Rossner and Lofinark 1977). In addition 
decreased cholesterol in LDL, and cholesterol in HDL have been found, especially in 
association with active disease (Lorber et al 1985). The causes of mortality in 
psoriatic arthritis patients is less well documented, although there is evidence that 
both psoriasis alone and psoriatic arthritis may be associated with an increased risk. 
The largest mortality study in psoriatic arthritis to date showed a 1.59 fold increased 
risk for death in women and 1.65 fold increased risk for men (Wong et al 1996). 
Thirty per cent of the deaths were from circulatory disease. A pattern of 
dyslipoproteinaemia similar to that seen in rheumatoid arthritis has previously been 
reported in psoriatic arthritis, which normalises with a reduction in disease activity 
(Lazarevic et al 1992).
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Routine plasma lipid measurement, which does not take account of lipoprotein 
composition may not identify patients with risk factors for atherosclerosis. For 
instance, the reduction in HDL-cholesterol contributes to a risk of atheroma, 
whereas a concomitant reduction in LDL - cholesterol may be protective. Increased 
knowledge of lipoprotein composition and the identification of lipoprotein 
subtractions has added to our understanding of the mechanisms of metabolic 
disturbance in lipid disorders (Lindgren et al 1972). Detailed lipoprotein 
composition has not been previously measured in studies of arthritis. In population 
studies, a low HDL-cholesterol associated with a high LDL-cholesterol has been 
associated with an increased risk of atherosclerosis (Castelli et al 1986). Recently, it 
has been found that the smallest, most dense component of LDL, ( LDL-3), is the 
most important factor in contributing to atheroma (Austin et al 1988).
Lipoprotein (a) (Lp(a)) has emerged as an important and independent contributing 
factor to the risk of arteriosclerosis (Rosengren et al 1990, Terres et al 1995, Maher 
and Brown 1995). Lp(a) is a high density lipoprotein in which apoBioo, the protein
moeity of LDL, is linked to apo (a) by one or two disulphide bridges. Increased 
levels of Lp(a) have been found in rheumatoid arthritis, but have not previously been 
measured in psoriatic arthritis (Rantapaa-Dahlqvist 1991).
The objectives of the study presented in Chapter 4 are 1. to characterise in detail 
lipoprotein composition, including Lp(a), in psoriatic arthritis and investigate 
whether there are similarities to the dyslipoproteinaemia reported in rheumatoid 
arthritis and other inflammatory forms of joint disease; 2. to investigate whether 
there is an atherogenic lipid profile in psoriatic arthritis, which may have a bearing 
on mortality.
To conclude, until recent years psoriatic arthritis has not been prominently featured 
in the clinical or scientific literature and this may be reflected in our lack of 
understanding of pathogenic mechanisms. Although there have been a number of 
clinical descriptive and family studies there has been little prospective work and few 
studies investigating the mechanisms linking skin and joint disease. The natural 
history of the disease and response to DMARDs remain uncertain. Also inadequate 
recognition of the disease by clinicians, and under representation by existing arthritis 
charities has lead to the institution of a patient support group, the Psoriatic 
Arthropathy Alliance. These factors have lead to the studies presented in this thesis.
SUMMARY OF HYPOTHESES AND STUDY AIMS
The specific hypotheses and aims of my studies are:- 
Hypotheses 1: Chapter 2a
(i) The mode of onset predicts outcome in psoriatic arthritis.
(ii) There is a significant association between nail and DIP joint disease in 
psoriatic arthritis.
Study Aim: Chapter 2a
To characterise the patterns of joint, skin and nail disease in the first 100 
patients attending a psoriatic arthritis clinic, in relation to the reported mode 
of onset.
Hypothesis 2: Chapter 2b
Psoriatic arthritis is a progressive disease, with increasing joint 
involvement in the majority.
Study Aim: Chapter 2b
To perform a prospective 5 year clinical and radiological follow-up study 
the patients included in Chapter 2a.
Hypothesis 4: Chapter 2c
There is a temporal relationship between arthritis, psoriasis and nail 
disease in some patients, which may define a subset of disease.
Study Aim: Chapter 2c
To characterise prospectively the temporal relationship between skin and 
joint inflammation in psoriatic arthritis.
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Hypothesis 3: Chapter 2d
Immunogenetic factors important in rheumatoid arthritis, i.e. the ‘shared 
epitope’ may influence susceptibility and severity in psoriatic arthritis, and 
may have implications for its pathogenesis.
Study Aim: Chapter 2d
To determine the frequency of the MHC class II ‘shared epitope’ in 
psoriatic arthritis and to relate the patterns of MHC Class II alleles to the 
pattern and progression of joint disease.
Hypothesis 5: Chapter 2e
Hormonal factors may influence the onset and expression of joint and skin 
disease in psoriatic arthritis.
Study Aim: Chapter 2e
To determine the relationship between pregnancy and other factors in 
influencing the onset and expression of skin and joint disease in psoriatic 
arthritis.
Hypothesis 6: Chapter 3
Selective T cell recruitment to skin and joint tissue and subsequent activation 
may explain the observed relationship between skin and joint disease in 
psoriatic arthritis.
Study Aim: Chapter 3
To investigate the distribution and characteristics of skin homing (CLA 
positive) T lymphocytes and their counter-receptor E-selectin in the skin and 
the synovium of patients with psoriatic arthritis.
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Hypothesis 7: Chapter 4
Dislipoproteinaemia occurs in psoriatic arthritis and may be related to 
disease activity and atherogenic potential.
Study Aim: Chapter 4




The first part of this thesis focuses on the clinical expression of psoriatic arthritis, its 
natural history and the relationship of joint disease to skin and nail disease and 
predictive factors for disease progression.
CHAPTER 2a 
PSORIATIC ARTHRITIS: OUTCOME OF DISEASE SUBSETS 
AND RELATIONSHIP OF JOINT DISEASE TO NAIL AND SKIN 
DISEASE: A CROSS-SECTIONAL STUDY 
SUMMARY
Introduction. Subgroups of psoriatic arthritis have been described but their 
relationship to the mode of onset of arthritis, to distal interphalangeal joint disease 
and nail and skin disease remains controversial.
Hypothesis. (i) The mode of onset predicts outcome in psoriatic arthritis, (ii) There 
is a significant association between nail and DIP joint disease in psoriatic arthritis. 
Study Aims. To characterise the patterns of joint, skin and nail disease in the first 
100 patients attending a psoriatic arthritis clinic.
Study Design. Cross-sectional, clinical observational, and retrospective.
Methods. The pattern of disease was documented in the first 100 patients to attend a 
psoriatic arthritis clinic in whom the mode of onset was known. A proforma was 
completed on all patients including a standardised examination of joints, nails and 
skin, HAQ score and inflammatory markers. The patients were divided into six 
subgroups:- monoarthritis, DIP joint disease only, oligoarthritis, polyarthritis, 
spondyloarthropathy and arthritis mutilans.
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Results. Sixty-four patients changed pattern. Nail disease (67% of total) was more 
common in patients with DIP joint disease (27% of total), and was significantly 
associated with adjacent DIP joint disease.
Conclusions . The subgroup of onset did not remain constant with time, i.e. the 
mode of onset did not predict outcome in the majority of patients, and hypothesis (i) 
was disproven. The topographic association of nail and DIP joint disease suggests a 
common local inflammatory mechanism.
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INTRODUCTION
Psoriatic arthritis has been divided into subgroups by various authors according to 
the distribution and number of joints involved (Moll and Wright 1973, Kammer et al 
1979, Gladman et al 1986, Helliwell et al 1991). It is unclear whether these 
subgroups are homogeneous with time. Also, relatively few series of patients have 
been reported in which the relationship between the skin, nails and joints has been 
adequately studied. The topographic relationship between nail and DIP joint disease 
has long been recognised but not statistically analysed (Wright 1956).
In the present study I have investigated whether the mode of onset of joint disease 
predicts the ultimate pattern of disease expression. I have also assessed in detail the 
relationship between nail and DIP joint disease, and patterns of skin and nail 




A clinic has been established at the Royal National Hospital for Rheumatic 
Diseases, Bath to study joint disease in patients with psoriasis. This section presents 
a cross-sectional study of the first 100 patients to attend this clinic in whom the 
mode of onset was known. All patients had an inflammatory arthropathy and 
psoriasis (Moll and Wright 1973, Bennett 1979, Gladman 1992b). The presence of 
rheumatoid factor was not used as an absolute exclusion criterion because of its lack 
of specificity for rheumatoid arthritis and its low prevalence in the normal 
population. The majority of patients were referrals from other rheumatology clinics, 
some were new referrals from the general practitioner and a minority (less than 10%) 
were referrals from dermatology clinics. All patients were seen by a rheumatologist 
and data were accumulated using a form designed specifically for the study.
Assertainment Bias
The data from this study must be interpreted with knowledge of the inherent bias in 
the method of patient selection. This is a population of hospital outpatients, 
attending a clinic set up specifically for these patients, so does not represent a 
sample from the general practice population, and may not represent a population 
seen by other rheumatologists who do not have a specific interest in the condition. It 
is hoped that it may be representative of groups of patients attending other psoriatic 
arthritis clinics. In addition, patients with two diseases (arthritis and psoriasis) are 
more likely to attend hospital departments than patients with one disease, which has 
an impact on studies comparing these patients with those with one disease (eg 
rheumatoid arthritis, psoriasis alone), and in studies of mortality.
Females outnumbered males in this study by 57 to 43, whereas in the majority of 
studies of psoriatic arthritis, males have slightly outnumbered females or the sex
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distribution has been equal. Ankylosing spondylitis is a major research interest in the 
Royal National Hospital for Rheumatic Diseases, lead by Dr Andre Calin. Male 
patients with psoriasis and arthritis in whom spondyloarthropathy is predominant 
(psoriatic spondylitis or ankylosing spondylitis with coincident psoriasis) are seen in 
Dr Calin’s clinics. These patients may have been included in other series of psoriatic 
arthritis.
Demographic Data and Joint Involvement
The age of onset and the duration of psoriasis and arthritis, the family history, the 
mode and site of onset of joint disease and previous and current treatment were 
recorded.
The mode of onset referred to the joints involved within the first three months of 
symptoms; this information was usually well recalled by the patient and in most 
cases confirmed by documentation in the rheumatology case notes. However, I 
acknowledge that the absence of a complete record of objective clinical findings at 
onset may have resulted in an under estimate of the number and site of joints 
involved, particularly if some joints were significantly more severely involved than 
others. Conversely, some patients may have over estimated the number of involved 
joints if they experienced pain without objective clinical findings. The initial 
presentation was subdivided using three methods. Firstly five groups were identified; 
monoarthritis, DIP joint disease only, oligoarthritis (2 to 4 joints affected), 
polyarthritis (5 or more joints affected), and spinal disease. Secondly, the patients 
were divided by joint size into small joint (including hands and feet), large joints of 
the limbs, axial (including the spine and chest wall), and combinations of these. 
Thirdly, the patients were divided by anatomical region into upper limb, lower limb, 
spinal disease and combinations of these.
33
The number of involved or damaged joints was documented for each patient, using a 
method similar to that described by Gladman (Gladman et al 1987). The joint score 
ranged from 0-70 with one point scored for each involved joint. The joints included 
were the DIP joints, EP joints of the thumbs, PIP joints, MCP joints, wrists, elbows, 
shoulders, temporo-mandibular, stemo-clavicular and acromio-clavicular, hips, 
knees, ankles (mortice joint), talocalcaneal, midtarsal, metatarsal-phalangeal joints, 
inter-phalangeal joint of the first toe and the remaining toes. The spine was excluded 
from this score although involvement of the cervical and lumbar spine was noted and 
used to assign the subgroup. The subgroup of joint disease was assigned in a similar 
way to that described above for the mode of onset, with the addition of arthritis 
mutilans as a sixth subgroup.
The activity of the peripheral joints was also documented for each patient. The 
number of tender joints was determined by a method or examination described by 
Ritchie in rheumatoid arthritis, but modified to include the DIP joints (Ritchie 1967). 
The number of swollen joints was also noted. A joint was considered to be active if 
it was tender and/or swollen.
Indices of peripheral joint disease activity and severity were obtained by counting 
the numbers of active or damaged peripheral joints and assessed as mild (0 to 10 
joints), moderate (11-20 joints) or severe (>20 joints).
Although symmetry was not used to distinguish subgroups, symmetrical joint 
involvement was defined in two ways; firstly by at least one identical joint being 
involved on both sides of the body and secondly in a method devised by Helliwell et 
al (1991). In the latter method, the number of matched pairs of involved joints was 
related to the total number of matched and unmatched pairs and a ratio of 0.5 or 
greater defined symmetry. Functional assessment was made using the modified
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Stanford Health Assessment Questionnaire (HAQ) (Kirwan and Reedback 1986, 
Fries et al 1980).
Laboratory Data
A rheumatoid factor, full blood count, plasma viscosity, anti-nuclear antibodies and 
immunoglobulins were performed on all patients.
Skin and Nails
The skin and nails were examined using a predefined protocol and performed under 
the supervision of a dermatologist (CL). Psoriasis was classified as plaque (psoriasis 
vulgaris), discoid, guttate, localised pustular or a combination of these. The 
distribution of skin psoriasis was recorded and the current severity was graded 
according to the Psoriasis Area and Severity Index (PASI) score (range 0 to 72) 
(Camp 1992, Appendix A). A nail score was determined for each patient, and 
derived as follows. Each fingernail was assessed for pitting, onycholysis, 
hyperkeratosis and severe nail deformity with involvement of both sides of the nail 
("dystrophy"). Each of the listed features scored one with a possible maximum nail 
score of 40.
Radiology
Radiological evaluation was performed on clinically affected joints. The radiological 
protocol consisted of an anterior-posterior (AP) view of both hands and feet, lateral 
view of both heels, AP view of pelvis, AP view of lumbar spine (to include thoraco­
lumbar junction) and a lateral view of the cervical spine in flexion. All films were 
examined by a radiologist (GE) and by two rheumatologists (NJM and SMJ). The 
five year follow - up study of hand radiology is reported in Section 2b. The cervical 
spine radiology has been published (Jenkinson et al 1994).
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Statistical Analysis
All information was entered onto Excel Worksheets in a Workbook on an Apple 
Macintosh computer, creating a psoriatic arthritis database. Statistical analysis was 
performed using Multistat and Statworks software packages. A descriptive analysis 
was made because the study population was too small for epidemiological 
techniques such as cluster analysis to be performed. The chi-squared test and 
Fisher’s exact test was used for comparing discrete variables between subgroups, 
and in evaluating the observed and expected frequencies of nail involvement in 
relation to adjacent or distant DIP joint involvement. Student's t-test was used for 
comparing continuous variables for parametric data; the Mann Whitney U test for 
non-parametric data. Spearman's rank coefficient was used for correlation analysis. 




Age and Sex Distribution of Psoriasis and Arthritis
The general characteristics of the study group including the age and sex distribution 
are given in Table one. Females outnumbered males in this study by 57 to 43 (ratio 
1.32:1). The unusual preponderance of females in this series has been discussed in 
the methods, and may relate to a research interest in the spondyloarthropathies in the 
same hospital. Sixty-three per cent of patients presented with psoriasis before 
arthritis, with the remaining patients almost evenly divided between those whose 
skin disease was discovered incidentally on presentation with arthritis and those who 
developed skin disease later. Ninety-nine were sero-negative for rheumatoid factor 
(less than 80 i.u by nephelometry).
Mode o f Onset and Outcome of Disease Subsets
The outcome of disease in relation to the mode of onset is summarised in Table 2. 
Ninety per cent of 39 patients presenting with a monoarthritis, 79% of 24 patients 
with an oligoarthritis and 20% of 25 patients with a polyarthritis changed pattern. 
Six of ten patients presenting with spinal symptoms developed a 
spondyloarthropathy. In total, 64 patients changed pattern, 62 of whom had 
progression of their disease. Of the four patients who remained in the monoarthritis 
group three had involvement of one knee and one had disease confined to a single 
proximal interphalangeal joint. Two patients had apparent regression of their disease 
with a polyarthritis at onset and subsequently only evidence of an oligoarthritis. Four 
patients who presented with spinal symptoms developed a peripheral arthritis 
without spondyloarthropathy. Only one patient, included in the oligoarthritis group, 
had the synovitis acne pustulosis hyperostosis osteomyelitis syndrome (SAPHO) 
(Benhamou et al 1988).
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The distribution of the site and the type of joint disease at onset are shown in Table 
3. Fifty-three patients presented with small joint disease which was more frequent in 
females (p< 0.01) as was upper limb disease at onset (p<0.05). Thirty-one of these 
(24 females, seven males, p < 0.01) presented with hand disease which was the most 
common site of onset . Axial onset was more frequent in males (p<0.01) and those 
presenting with spinal disease were significantly younger (mean age 41.8 years, 
standard deviation 6.9) than the oligoarthritis (mean 47.9 +/_14.7) (p< 0.05) or 
polyarthritis (mean 50.5+/_ 15.0 years) (p<0.02) groups. The mean ages for the 
monoarthritis and mutilans groups were 48.2 +L 12.1 years and 59.0 +/_ 16.0 years 
respectively.
The relationship of Disease Duration to Functional Outcome and the Use of 
DMARDs
Table 4 shows the disease duration, HAQ scores and use of DMARDs of the 
subgroups. Not unexpectedly, the polyarthritis group had a significantly worse 
functional outcome defined by HAQ scores than the oligoarticular and monoarthritis 
groups combined (p<0.05). They had also used more disease modifying therapy 
(p<0.01), had a longer disease duration (p<0.01), and more erosions (p<0.001) than 
the oligoarticular group. Of those with peripheral arthritis, patients with more severe 
disease had longer disease durations. Those with arthritis mutilans had the longest 
disease duration followed by polyarthropathy, with the monoarthritis/DIP joint 
disease only and oligoarthropathy groups having the shortest disease durations.
Ninety-one patients were taking NSAIDs and 26 disease modifying antirheumatic 
drugs (DMARDs); a further 14 patients had taken DMARDs in the past. The 
distribution of the current and previous use of DMARDs is shown in Table 5. 
Intramuscular gold was most commonly used followed by methotrexate, 
sulphasalazine, auronofin, penicillamine, azathioprine, hydroxychloroquine. Six 
patients had also taken prednisolone (4 at the time of study) and one patient
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cyclophosphamide. Twenty-eight patients had taken two or more DMARDs and 13 
had had surgery for joint disease. Patients taking DMARDs had a significantly 
longer disease duration (17.2 v 8.8 years, p <0.001) and significantly greater 
functional disability (p<0.001) than those without.
Symmetry o f Peripheral Joint Disease
The frequency of symmetry depended on the method employed. When only one 
identical contralateral joint was required to define symmetry, all 63 of the 
polyarthritis group and six of 22 of the oligoarthritis group had symmetrical disease. 
When Helliwell's method was used, 51 of 63 patients in the polyarthritis group and 
4 of 22 patients in the oligoarthritis group had symmetrical disease.
Relationship between Joint Disease and Skin and Nail Involvement
The distribution of the specific types of skin and nail disease are shown in Table 6. 
This distribution is similar to that in the general psoriatic population (Camp 1992). 
There was no association between the type or distribution of skin involvement and 
arthritis subgroup, nor was there any relationship between the activity of psoriasis 
and joint severity, activity or functional status. The timing of onset of joint disease in 
relation to the pattern of onset and ontcome of joint disease is shown in Table 7. 
However, there was a significant correlation between the number of involved joints 
(joint score) and functional status (HAQ Score). There was a significant correlation 
between PASI and the nail scores (p<0.001) and nail disease increased with the 
duration of psoriasis (p<0.02) (Table 8).
Sixty-seven per cent of patients had psoriatic nail disease, which is a greater 
frequency than that found in psoriasis alone (c 40%) and reflects that found in 
previous studies (up to 80% (Roberts et al 1976)). All patients with hyperkeratosis or 
"dystrophy" had either pitting, onycholysis or both. The nail score was significantly 
greater in those who developed psoriasis before arthritis or simultaneously (p<0.05).
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Nail disease occurred in all subgroups (Table 3). There was no correlation between 
nail severity and the severity of arthritis. Males tended to have more severe skin and 
nail disease than females, but this was not significant.
Twenty seven per cent of patients had clinical and/or radiological evidence of DIP 
joint disease in their hands which is less than reported in other series (Potter and 
McEwan 1992). Those with DIP joint disease tended to have a longer disease 
duration than those without (means 15.6 years and 11.0 years respectively) but this 
was not significant. DIP joint disease occurred in all subgroups except 
spondyloarthropathy and monoarthritis, but only one patient had DIP joint disease 
exclusively (Table 3).
Nail disease was more common in patients with DIP joint involvement (85% with 
DIP joint involvement v 60% without) (p<0.02). The association of nail disease and 
adjacent DIP joint disease was analysed by calculating the observed and expected 
frequencies of DIP joint disease in relation to adjacent affected and unaffected nails. 
Fingers and thumbs if the hands were included and the IP joints of the thumbs were 
considered to be equivalent to the DIP joints of the fingers. For example, a single 
affected nail on one digit of one hand would have a one in ten chance of association 
with a single affected DIP joint. Chi-squared and Fisher’s exact tests were used, 
depending on the number of observations. The accumulated data revealed that 
patients with nail disease in a particular hand were significantly more likely to have 
DIP disease in this hand than on a hand without nail disease (p<0.05). The detailed 
analysis showed that patients with nail disease in a particular digit were significantly 
more likely to have DIP joint disease in the adjacent joint than patients without nail 
disease in that digit (p values for each of the ten digits analysed ranged from p<0.02 
to p <0.001). Accumulating the data for all the digits, DIP joint disease was 
significantly more likely to occur with nail disease in the adjacent joint than alone 
(pO.Ol).
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Patients with DIP joint disease also tended to have more severe nail disease, but this 
did not reach significance.
Conclusions.
To conclude, the pattern of joint disease, defined by joint number changed in sixty- 
four of the 100 patients studied, i.e. the subgroup of onset did not remain constant 
with time. Nail disease (67% of total) was more common in patients with DIP joint 
disease (27% of total), and was significantly associated with adjacent DIP joint 
disease.
However, the data from this study must be interpretated with an appreciation of its 
limitations. Fistly, the ascertainment bias has already been discussed in the methods. 
Secondly, the study was cross-sectional in design and data regarding the pattern of 
joint disease at onset was retrospective and not subject to a rigorous protocol. 
Thirdly, the patients had a large range of disease durations, with patients with the 
longest disease durations developing more extensive disease, hence the application 
of this data in assessing the prognosis of individual patients within a fixed timescale 
is limited. Finally, the subgroups were defined by the number of joints involved, 
which obscures the differing patterns of disease within the polyarticular group. Some 




Clinical Features in 100 Patients with Psoriatic Arthritis
Clinical Feature
Number of females 57
Number of males 43
Mean age (years) (range) 49.7 (16-80)
Mean age at onset of skin lesions (years) (range) 28.9 (3-70)
Mean age of onset of joint disease (years) (range) 37.6 (5-70)
Psoriasis before arthritis 63 (24M/39F)
Simultaneous onset 20 (12M/8F)
Arthritis before psoriasis 17 (7M/1 OF)
Mean duration of psoriasis (years) (range) 20.8(1-61)
Mean duration of arthritis (years) (range) 12.1 (1-53)




TABLE 2. Evolution of Disease Subsets The number of patients in 
each combination of subgroups at onset and at the time of the 
baseline assessment (outcome) in the psoriatic arthritis clinic is 
shown. The total number in each group at onset is shown in the final 
column, and the total for each group at outcome is shown in the final 
row. The mean age of onset by mode is also shown.
Outcome
Mode of O nset
Mean Age 
of Onset by 
Mode
Mono DIP Oligo Poly Spond Arthritis
Mutilans
Total
Monoarthritis (Mono) 37.5 4 0 13 22 0 0 39
DIP Joint Disease Only 41 0 1 1 0 0 0 2
Oligoarthropathy (Oligo) 38.1 0 0 5 18 0 1 24
Poly arthropathy (Poly) 41.1 0 0 2 20 0 3 25
Spondyloarthropathy(Spond) 28.2 0 0 1 3 6 0 10
Total 37.6 4 1 22 63 6 4 100
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TABLE 3
Type and Site of Joint Disease at Onset by Sex. The significance of 
the difference in the sex distribution for each mode of onset is shown
Joint Disease M F Significance Total
Small 18 35 (p<0.01) 53
Large 12 17 (NS) 29
Lower Limb 18 24 (NS) 42
Upper Limb 11 27 (p<0.05) 38
Axial 9 1 (p<0.01) 10
Small and Large 3 4 (NS) 7
Small and Axial 1 0 (NS) 1
Spinal and Peripheral Disease 1 0 (NS) 1
Upper and Lower Limb 6 3 (NS) 9
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TABLE 4 Pattern of joint disease by sex, age of onse t disease duration of arthritis and psoriasis. HAQ score, 
use of DMARDs. and the presence of nail and distal interphalanqeal joint disease Significant 
differences between subgroups are also indicated at the base of the table.
Subgroup No. of Patients Sex Mean age of Mean Duration Mean Duration Mean HAQ Use of DMARD Nail Disease DIP Disease




Monoarthritis (Mono) 4 1 3 51 6.8 24.8 0.41 0 3(75) 0
Distal Interphalangeal 1 1 0 45 10 10 0.125 0 1 (100) 4 (100)
Joint Disease Only (DIP) 
Olgoarthropathy (Oligo) 22 8 14 41.3 6.6 14.5 0.49 9.1 13(59) 3(9)
Polyarthropathy (Poly) 63 25 38 36.6 13.9 20.2 0.87 50.8 45 (71) 19(30)
Spondyloarthropathy 6 6 0 29.2 13.7 19.5 0.65 33 2(33) 0
(Spond)
Arthritis Mutilans (AM) 4 1 3 32.5 21.5 30 1.34 75 3(75) 4(100)
Total 100 43 57 37.6 12.5 20.6 0.77 40 67 27
Subgroup Comparisons
Duration of Psoriatic Arthritis: poly v oligo (t test), p=0.007; oligo v spond, p=0.038 
HAQ Score: poly v oligo + mono (t test), p<0.05;
Use of DMARDs: poly v oligo (chi-squared test), p<0.01
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TABLE 5
Distribution of Therapy The number of patients on each medication 
when first seen in the psoriatic arthritis clinic (baseline) and since onset 
(previous) is shown. The cumulative number of patients on each 
medication is shown in the first column.
Therapy Number of Patients Baseline Previous
NSAIDS 91 91 0
All DMARDs 40 26 14
Intramuscular Gold 19 9 10
Methotrexate 13 8 5
Sulphasalazine 11 5 6
Penicillamine 7 1 6
Azathioprine 7 1 6
Hydroxychloroquine 4 4 0
Oral Steroids (for joint disease) 6 4 2
Cyclosporin 2 1 1
Surgery 13 NA NA
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TABLE 6
Pattern of Psoriasis and Nail Disease The percentage of patients with 
a particular type of psoriasis and nail disease is shown.
Type of Psoriasis (%) Type of Nail Disease (%)
Plaque 79 Pitting 74
Scalp 70 Onycholysis 70
Discoid 10 Hyperkeratosis 34
Guttate 4 Severe nail deformity 5
Pustular 3 ("dystrophy")
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TABLE 7. Onset of skin disease in relation to onset of arthritis by the pattern of joint disease at onset
and at the baseline assessm ent in the clinic (outcome)
Mode of Onset Outcome
Total (M/F) Mono DIP Oligo Poly Spond Mono DIP Oligo Poly Spond Arthritis
Mutilans
Psoriasis before Arthritis 63 (24/39) 27 1 13 18 4 2 0 16 39 4 2
Simultaneous Onset 20(12/8) 2 1 8 5 4 1 1 2 14 1 1
Arthritis before Psoriasis 17(7/10) 10 0 3 2 2 1 0 4 10 1 1
Total 100 (43/57) 39 2 24 25 10 4 1 22 63 6 4
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TABLE 8.
Joint. Skin and Nail Correlations The significance of correlations 
between joint damage and activity, skin, nail and HAQ scores are 
shown.
Parameters Spearman Correlation Coefficient Significance
Jt Score v HAQ 0.458 <0.001
Jt Score v Nail Score 0.12 NS
Jt Score v PASI -0.029 NS
Jt Score v Jt Activity -0.033 NS
HAQ v Nail Score -0.103 NS
HAQ v PASI -0.022 NS
PASI v Nail 0.361 <0.001
PASI v Active Jts 0.053 NS
Nail v Active Jts 0.131 NS
HAQ v Active Jts -0.046 NS
Nail Score v Duration Psoriasis 0.26 0.013
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DISCUSSION
Attempts to classify psoriatic arthritis have been complicated by the overlap between 
subgroups, the importance given to extraosseus abnormalities, including the 
synovitis-acne-pustulosis-hyperostosis-osteomyelitis syndrome (SAPHO) 
(Benhamou et al 1988), the definition of symmetry, the relationship of DIP joint 
disease to the subgroups and the temporal change in the pattern of arthritis.
Moll and Wright, based on their own descriptive work (Wright 1956, Wright 1959, 
Wright 1961, Wright and Moll 1971) and radiological studies by Avila et al (Avila 
et al 1960) described five clinical patterns: (i) "classic" psoriatic arthritis confined to 
DIP joints of hands and feet (5%); (ii) arthritis mutilans with sacro-ileitis (5%); (iii) 
symmetric polyarthritis, indistinguishable from rheumatoid arthritis (15%); (iv) 
asymmetric oligoarthritis (70%); and (v) spondylo-arthropathy (5%)(24). Further 
studies and review articles reaffirmed these subgroups (Wright and Moll 1976, Moll 
and Wright 1973, Moll 1979, Little et al 1975, Leonard et al 1978, Molin 1978, 
Scarpa et al 1984, Moll 1984), although the overlap between subgroups and possible 
evolution from one subgroup to another was noted (McCormack and Barth 1985). A 
more recent study using radionucleotide scanning concluded that all patients with 
peripheral arthritis should be grouped together, the spondyloarthropathy group 
retained and a new group added, comprising rare patients with extra-articular 
osseous disease, including patients with SAPHO (Helliwell 1991). Applying this 
classification to our patients, 94 were grouped together, 6 remained in the 
spondylarthritis group and only one belonged to the extraarticular osseous group. 
Radionucleotide scanning may have revealed more patients with extra-articular 
osseous abnormalities, but this is not practical in a clinical setting. Whilst the extra- 
articular osseus group including SAPHO should be recognised, its relative rarity 
makes its separate classification difficult to justify, a point also made by Veale et al 
(1994). Other attempts at reclassification include that by Gladman et al (1986), who
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initially increased the number of groups to seven, but later in a review of 220 
patients, proposed a spectrum of disease patterns and severity (Gladman et al 1987). 
Most recently three groups have been suggested (Veale et al 1994), similar to those 
proposed by Kammer (Kammer et al 1979), with the spondyloarthropathy group 
retained and peripheral arthritis divided into two subgroups - asymmetric arthritis 
and symmetric polyarthritis. The groups are loosely defined in terms of the 
assessment of symmetry and the number of joints involved, but the classification 
may prove useful clinically.
I divided our patients into six subgroups - monoarthritis, DIP joint disease alone, 
oligoarthritis, polyarthritis, spondyloarthritis and arthritis mutilans. The three 
patients with monoarthritis would be included in Moll and Wright's asymmetrical 
oligoarticular subgroup, but the lack of progression of disease beyond one knee and 
the absence of DIP disease distinguished them from the rest of the subgroups. The 
mean disease duration for the monoarthritis subgroup was similar to that of the 
oligoarthritis subgroup but about half of the mean for all patients, so it is possible 
that the patients in these subgroups may have progression of their disease and 
change subgroup. It is striking that, for those with peripheral arthritis, those with 
more extensive and severe joint involvement (arthritis mutilans and poly arthropathy 
groups) had longer disease durations than the DIP joints disease only, oligoarthritis 
and monoarthritis groups. This raises the possibility that the number of joints 
involved is a function of disease duration. The homogeneity of the 
spondyloarthropathy group in this study, with all six patients presenting with spinal 
symptoms and the absence of DIP joint disease, supports the view that this subgroup 
should be retained (Helliwell et al 1991, Veale et al 1994).
The number of patients with oligoarthritis, which tends to be asymmetrical, and 
polyarthritis, which tends to be symmetrical, has varied considerably between 
studies largely because of differences in subgroup definitions. The subgroup
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frequencies initially reported by Moll and Wright, who found a majority of patients 
(70%) in the asymmetrical oligoarticular group only 15% in the symmetric 
polyarthritis group (Moll and Wright 1973) has not been confirmed in other series. 
In our study, the ratio of oligoarthritis (including monoarthritis patients to make 
studies comparable) to polyarthritis was 1 to 2.3. Gladman et al, in a study of 220 
patients, also found that oligoarthritis was far less common than polyarthritis with a 
ratio of 1: 2.2 (Gladman et al 1986 and 1987) and the preponderance of patients with 
polyarthritis has subsequently been confirmed by Wright et al, when a more rigid 
definition of the number of joints involved was used (Wright 1992). However, in a 
recent study of 100 patients, Veale et al (1994) clearly illustrate the difficulties in 
classifying the peripheral arthropathy of psoriatic arthritis by the use of two 
methods of classifying their patients. The text states that they found the 
asymmetrical oligoarthritis subgroup more common than symmetrical polyarthritis 
with a ratio of 1.3:1, although 11 patients with an asymmetrical polyarthritis were 
included in the oligoarticular group. They then applied strict definitions of symmetry 
and number of joints involved, as used by Helliwell et al (1991), and found 45% of 
patients in the asymmetrical oligoarticular group, 11% in an asymmetrical 
polyarticular group and 38% in the symmetrical polyarticular group. When these 
patients were included in the polyarthritis group, the ratio of polyarthritis to 
oligoarthritis of 1.1 to 1.0. Therefore, once again patients with polyarthritis 
outnumbered those with oligoarthritis.
The use of both the number of joints involved and symmetry to define the 
oligoarticular and polyarticular subgroups has proved difficult in other series 
(Kammer et al 1979, Barraclough et al 1977). Obviously, the fewer joints involved, 
the more likely the disease is to be asymmetrical but a small number of patients will 
inevitably have a symmetrical oligoarthritis or an asymmetrical polyarthritis. The 
difficulty is illustrated by the differing results of the two methods employed in this 
study and we therefore did not use symmetry to define our subgroups.
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The rarity of pure DIP joint involvement and its occurrence over the spectrum of 
disease patterns has been previously noted (Green et al 1981, Laurent 1985, Veale et 
al 1994, Torre Alonso et al 1991). In our series DIP joint disease occurred in all 
subgroups except spinal disease and the monoarthritis group, and three patients had 
DIP joint involvement exclusively. The association of DIP joint disease with nail 
disease in the same digit has long been recognised (Bauer et al, 1941), although 
detailed analysis has not been performed. This study confirms that there is a 
topographical association of nail disease with DIP joint disease when analysed for 
each digit and for each hand.
The evolution of disease patterns from the oligoarthritis to the polyarthritis group is 
a further matter of debate. Whereas Gladman has suggested that this is common 
(Gladman 1992c), Helliwell et al (1991) found that only 5% changed pattern. In the 
current study, 64% of patients presenting with monoarticular or oligoarticular 
disease developed polyarthritis. These patients may have changed pattern early in the 
course of their disease before reaching a plateau, although the significantly greater 
disease duration for the polyarthritis group suggests that the number of joints 
involved is a function of disease duration. To conclude, the subgroup of onset did 
not remain constant with time, i.e. the mode of onset did not predict outcome in the 
majority of patients, and hypothesis (i) was disproven. This is further studied in the 
prospective 5 year follow-up study of Chapter 2b.
Although the attempts to define clinical subgroups of joint disease have added 
greatly to our clinical perception of psoriatic arthritis, it has had limited impact on 
our understanding of the pathogenesis. The lack of any serological markers for the 
disease, adds to this difficulty. In addition, there are no clearcut HLA associations 
related to specific subgroups of joint or skin disease, although the association of the 
class II antigens HLA DR to peripheral disease and HLA-DR4 with erosive
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disease requires further elucidation (McHugh et al 1987, Chapter 2c). The 
association of nail disease and DIP joint disease is possibly the only clinical 
evidence that there is a peripheral biological link between events in the skin and the 
joint. Research into disease mechanisms at a genetic and cellular level is needed to 
elucidate the true relationship between psoriatic skin, nail and joint disease 
(Chapters 2c and d; Chapter 3)
Conclusions
To conclude, the major findings from this study are that the subgroup of onset did 
not remain constant with time, i.e. the mode of onset did not predict outcome in the 
majority of patients. Hypothesis (i) (see list of hypotheses and study aims and 
summary at the beginning of this chapter) is therefore disproven. The subgroup of 
disease is at least in part a function of disease duration. This finding is likely to 
apply to other classification systems in which the number of involved joints is used 
to define subgroups.
This is the first which statistically analyses the association between nail and adjacent 
DIP joint disease, although the observation was originally made by others earlier this 
century (Bauer, 1941, Wright 1956). The topographic association of nail and 
adjacent DIP joint disease provides clinical evidence for a local inflammatory 
mechanism that may link the two manifestations of the disease.
54
CHAPTER 2b
PROGRESSION OF PERIPHERAL JOINT DISEASE IN 
PSORIATIC ARTHRITIS: A FIVE YEAR CLINICAL AND 
RADIOLOGICAL FOLLOW-UP STUDY 
SUMMARY
Introduction. The progression of disease in psoriatic arthritis, the homogeneity of 
disease subgroups, and predictive factors for disease progression have been 
infrequently studied. Hypothesis. Psoriatic arthritis is a progressive disease, with 
increasing joint involvement in the majority. Study Aim. To perform a prospective 
clinical and radiological follow-up study of the patients included in Chapter 2a.
Study Design. Prospective.
Methods . The 100 patients described in Chapter 2a were followed up after a 
median of five years. Nine patients had died and five were unavailable for follow-up. 
A further patient on whom complete data was available was included. In total 87 (49 
females, 38 males) completed the proforma detailed in Chapter 2a. Seventy-five 
patients had serial hand radiographs scored using a modified Sharp’s Index. A 
bivariate analysis of initial factors versus rates of progression of joint and HAQ 
scores was performed.
Results . The clinical subgroups were as follows (cross-sectional study /follow up 
study): monoarthritis 4/1; DIP joint disease only 1/1; oligoarthritis 23/11, 
polyarthritis 51/59, mutilans 2/3 and predominant spondylitis 6/7. Five patients (2 
previously monoarthritis and 3 oligoarthritis) had no clinical evidence of joint 
involvement at follow-up. In total, 19 patients changed subgroup, 12 had an increase 
in the number of joints involved, six a decrease, and one changed from an 
oligoarticular pattern to predominant spondylitis. Within the polyarticular group 
37/51 patients had an increase in the number of joints involved. Four patients with 
predominant spondyloarthropathy also had peripheral joint disease. For the whole 
population, there were significant increases in the number of joints involved (median
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6 v 11, p<0.001 Wilcoxon signed rank), erosion and joint space narrowing scores in 
the hands and HAQ scores (median 0.375 v 0.5, p<0.001). There were no significant 
differences in skin and nail scores although 9 further patients had developed nail 
disease. There was a significant correlation between the initial viscosity and rate of 
progression of joint damage (Spearman correlation, p<0.011).
Conclusions. This study provides evidence that peripheral joint disease in psoriatic 
arthritis is progressive in the majority of patients and reinforces the need for 
effective monitoring and treatment.
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INTRODUCTION
The natural history of psoriatic arthritis, the homogeneity of disease subgroups, and 
predictive factors for disease progression have been infrequently studied (Gladman 
1994 and Gladman et al 1995b). A cross-sectional study of the first 100 patients to 
attend the psoriatic arthritis clinic in Bath is presented in Chapter 2a and has been 
published (Jones et al 1994). One of the major conclusions of this study was that the 
mode of onset did not predict outcome in the majority of patients. Forty patients 
progressed from a monoarticular or oligoarticular pattern of disease at onset to 
develop polyarthritis. However, the study had a number of limitations, which are 
described in the concluding paragraph of the discussion to Chapter 2a. Of particular 
importance are the ascertainment bias, cross-sectional and retrospective design and 
variable disease durations between disease onset and baseline evaluation. Some of 
these limitations have been addressed in the current prospective study which 
describes the clinical distribution of joints involvement and assesses progression 
within a fixed timescale.
Data on the pattern and rate of progression of radiological changes in the hands in 
patients with psoriatic arthritis is also limited (Roberts et al 1976, Gladman et al 
1990). Furthermore there is no data on the prevalence of distinctive radiographic 
features such as bony proliferation, DIP involvement, periostitis, joint space 
widening, bony ankylosis, osteolysis and tuftal changes in a cohort of patients. It has 
been previously reported that radiographic damage tends to occur early in the course 
of psoriatic arthritis and then reaches a plateau, although few studies have addressed 
this prospectively (Gladman et al 1990). The progression of radiological changes in 
the hands and the relationship between parameters of radiological severity and 
clinical joint scores is addressed in the current study.
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A prospective study of 87 psoriatic arthritis patients is now presented at a median 
follow-up interval of 65 months. The primary aims were to determine the clinical 
progression of peripheral joint disease, to further evaluate subgroup homogeneity, 
and to determine possible predictors for disease progression. The secondary aims 
were to determine and quantify the pattern and progression of radiological features 
in the hands and to relate the progression of radiographic joint damage to clinical 
parameters. The cross-sectional study (Chapter 2a) revealed no significant 
associations between the activity or severity of joint disease and the activity and 
severity of psoriasis or nail disease, but demonstrated a statistically significant 
topographic association between nail and DIP disease. This has been further 
evaluated in the current study. Hence, the third aim was to assess the evolution of 




Eighty six patients (48 females and 38 males) from the cross-sectional study 
(Chapter 2a) were available for follow-up and one additional patient (a female) on 
whom there was complete initial data was included, so the total number of patients 
was 87. A possible reason for the excess of females has been discussed in Chapter 
2a. Patients were followed at a median of 65 months (range 39 - 90). Fifty of these 
87 patients were still attending the psoriatic arthritis clinic or other general 
rheumatology clinics in Bath; the remaining thirty-seven patients were contacted by 
letter or telephone and asked to attend a follow-up appointment. Of the remaining 14 
patients, nine had died, two could not be traced and three declined follow-up; two of 
the latter were elderly, lived outside the region and were unable to travel; a further 
patient declined follow-up, preferring to attend practitioners of alternative medicine. 
The cause of death of the nine patients who died was ascertained by obtaining the 
contemporary medical records or general practitioner’s notes; where these were 
incomplete or unhelpful, the general practitioner was contacted by telephone.
Demographic Data and Joint Involvement
A proforma identical to that completed in the cross-sectional study was completed 
on all patients. This included a standardised examination of peripheral joint and axial 
involvement, skin psoriasis score using the PASI index, nail score 
(Appendix A) and functional assessment using a HAQ Score. Patients were divided 
into subgroups based on objective evidence of involvement on examination at 
follow-up. The subgroup distinctions employed in the cross sectional study were 
used as follows:- monoarthritis ; DIP joint disease only; oligoarthritis (<5 joints 
involved), polyarthritis (>4 joints involved), arthritis mutilans and predominant 
spondylitis. Arthritis mutilans was defined as a severe deforming polyarthritis 
causing widespread radiographic osteolysis and the ‘opera glass’ hand. The
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peripheral joint score ranged from 0 - 7 0  joints involved with one point scored for 
each involved joint. The joints included were DIP joints, EP joints of the thumbs, PEP 
joints, MCP joints, wrists, elbows, shoulders, temporo-mandibular, stemo-clavicular 
and acromio-clavicular, hips, knees, ankles (mortice joint), talocalcaneal, midtarsal, 
metatarsal-phalangeal joints, inter-phalangeal joint of the first toe and the remaining 
toes. The spine was excluded from this score although involvement of the cervical 
and lumbar spine was noted. A full blood count, rheumatoid factor and 
inflammatory markers including a viscosity, ESR and C-reactive protein were 
obtained.
Hand Radiology
Standard antero-posterior views of the hands were also performed with verbal 
consent, irrespective of hand symptoms or signs. The films were single emulsion on 
a mammographic plate. Ethical approval was obtained from the Bath and South 
West Ethical Committee
Seventy five pairs of films taken at baseline and follow-up were subsequently 
available for assessment (median interval 65 months, range 39 - 90). The scorer was 
blinded to the clinical details of the patients and the order at which the radiographs 
were taken. At least ten sets of radiographs were scored at one single reading by the 
same observer. A modified Sharp’s index was used to score the radiographs, which 
has been validated in the course of this study. A full description of the index and its 
modification is included in Appendix B. Briefly, the index scores the number and 
severity of erosions and joint space narrowing; the latter was modified for psoriatic 
arthritis and termed joint space abnormality to included apparent widening of the 
joint space.
The pattern of involvement and other radiological features of interest which have 
been reported as being characteristic of psoriatic arthritis were also documented.
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The following signs have been reported as differentiating psoriatic arthritis from 
rheumatoid arthritis:- phalangeal tufts, osteolysis, bony proliferation, periostitis, 
asymmetry, apparent joint space widening and bony ankylosis. Juxta-articular 
osteopenia, soft tissue swelling, DIP and wrist involvement were also noted and 
malalignment was graded as moderate (subluxation) or severe (dislocation).
Data Analysis
All data was stored in a Microsoft Excel database and analysed using Statworks and 
Multistat software packages on an Apple Macintosh Computer. The distribution of 
the various data sets was assessed first and a descriptive comparison of the data at 
baseline and follow up was made initially. A bivariate analysis of initial factors 
versus rates of progression of joint HAQ and radiographic data was performed. 
Correlations between data sets were assessed using Spearman’s non-parametric 
method.
Skin and Nails
The skin and nails were examined using a pre-defined protocol under the supervision 




Demographic Data and Mortality
The demographic data for the 87 patients is shown in Table 1. Nine patients had died 
since the original study. Five of the deaths were related to coronary artery disease, 
but one death was attributed to immobility and general debility associated with 
psoriatic arthritis mutilans. All of the patients who died were elderly.
Evolution of Joint Disease and Functional Outcome
The evolution of clinical subgroups used in Chapter 2a (Jones et al 1994) is shown in 
Table 2. In total, 19 patients (22%) changed pattern, 12 of whom had an increase in 
the number of joints involved, six had decreased joint involvement, one had no 
change in symptoms, and a further patient who initially had peripheral joint 
involvement with four joints involved developed predominant spondyloarthritis. One 
patient with polyarthritis evolved to arthritis mutilans. The number of joints involved 
in the patients with polyarthritis at baseline increased in 37 out of 51 patients. Joint 
involvement in the patients with polyarthritis at baseline increased in 37 out of 51 
patients. Four patients with predominant spondyloarthropathy also developed 
peripheral joint disease. Four patients (two with monoarthritis at baseline and two 
with oligoarthritis at baseline) had no clinical evidence of joint disease, although one 
of these had mild dactylitis of the toes. One male patient continued to have evidence 
of distal joint disease exclusively.
The distribution of joint involvement in the 87 patients at baseline and follow-up is 
shown in Tables 3 and 4.
For the whole group, the number of joints involved increased (median 6 v 11, p < 
0.001). .The HAQ scores also increased (median 0.375 v 0.5, p < 0.001).
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Extra-articular Features and Laboratory Parameters
One female (disease duration 40 years) developed cervical myelopathy secondary to 
a combination of psoriatic and osteoarthritic lower cervical spine disease. She 
presented insidiously with neck pain and a slowly evolving quadriplegia and made 
an excellent recovery from surgical decompression and stabilization. Prior to the 
development of the myelopathy, this patient was included in the paper describing 
cervical spine disease in this cohort of patients (Jenkinson et al 1994).
Only one patient was sero-positive for rheumatoid factor at baseline, but a further 
three further patients had become rheumatoid factor positive by follow-up (titre 
>1/80 by nephelemetry), all of whom had polyarthritis. Plasma viscosities were 
available for all patients at baseline and follow-up. ESR and C-reactive protein were 
only measured on all patients at follow-up. Fifty patients (57%) had elevated plasma 
viscosities at baseline compared with 45 (52%) patients at follow-up. However, the 
mean plasma viscosity at follow-up was greater than at baseline (1.77 versus 1.67, 
not significant). Only 20 patients at follow-up had C-reactive protein levels greater 
than 10 mg/1, the lower limit of estimation in our laboratory.
Hand Radiology
The cumulative scores for erosions and joint space abnormalities (see Appendix B) 
at baseline and at follow-up increased for all joints except for the joint space 
abnormality score for the proximal interphalangeal joint of the right hand (Table 5). 
(This may reflect the inclusion of joint space widening in the joint space abnormality 
score. For example, one patient with mutilating disease had radiographic ankylosis 
(score 4) followed by a reappearance of the joint space (score 0), although the latter 
represented an extension of the pathological process and should possibly have been 
scored as 4 for joint space widening). Both erosion and joint space abnormality 
scores were greatest at the wrist at both baseline and follow up. Of the finger joints, 
distal interphalangeal joints tended to be less affected in terms of erosions or joint
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space abnormalities than the proximal interphalangeal joints, which were most 
severely affected, or the metacarpo-phalangeal joints. The percentage increase in 
cumulative joint scores was greater for erosions than joint space abnormalities (59% 
v 35.5%).
Forty patients had erosions at baseline. Of these, 26 had more erosions, nine 
remained stable and five showed healing. Nine additional patients had developed 
erosions at follow-up. Thirty-eight patients had joint space abnormalities at baseline 
and 30 of these deteriorated, five remained stable and three improved. A further 11 
patients had developed joint space abnormalities at follow-up. The median erosion 
scores at follow-up were significantly greater than at baseline (0.0665 (range 0 - 2.6) 
versus 0.02190 (range 0 - 2.13), p < 0.01. The median rate of progression of 
erosions (change in erosion score per month) was 0.00195 (range 0.00014 - 0.033). 
Joint space abnormality scores were also significantly greater at follow up than at 
baseline (median 0.185 (range 0 - 3.24) versus 0.046 (range 0 - 3.52), p < 0.001 
Wilcoxon signed rank). The median rate of progression of joint space abnormality 
was 0.00089 (range 0.01 - 0.038).
Figure one shows the prevalence of the reported characteristic features of psoriatic 
arthritis at baseline and follow-up. All these features increased apart from tuftal 
changes, which decreased. Radiographic evidence of distal-interphalangeal joint 
disease increased and was present at follow-up in over one third of patients.
Evolution of Nail and Skin Disease
There were no significant differences between skin and nail scores at baseline and 
follow-up. The types of psoriasis did not change between baseline and follow-up and 
there was no association between subgroups of skin disease or type of psoriasis or 
severity of psoriasis based on the PASI score. Eleven further patients had developed 
nail disease, so a total of 68/87 (78%) had nail disease. Twenty-three of the eighty-
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seven patients reported simultaneous exacerbations of their skin and peripheral joint 
disease. The temporal relationship between joint, skin and nail disease has been 
studied prospectively in a cohort of twenty-four patients in Chapter 2c.
Correlations between Clinical and Radiographic Parameters and Predictive 
Factors for Disease Progression
There were significant positive correlations between the baseline erosion and joint 
space abnormality scores and the duration of arthritis (p<0.001 for both, Spearman 
correlation). Baseline clinical joint scores positively correlated with the rates of 
progression of erosions and joint space narrowing (Spearman, p < 0.001). Baseline 
erosion and joint space abnormality scores correlated with the rates of progression of 
erosions and joint space abnormalities respectively (Spearman, p < 0.001), implying 
that those with more severe disease at baseline had a greater capacity to undergo 
progressive joint damage.
There was an insignificant negative correlation between disease duration at baseline 
and the rates of progression of joint scores and erosions suggesting that the rates of 
progression may slow slightly with time. However, there was a slight positive trend 
in correlation between the rate of progression of joint space abnormality and disease 
duration, possibly reflecting the increase in incidence of osteoarthritis with time.
There was also a significant correlation between initial viscosity and the rate of 
progression of joint damage (Spearman, p<0.011).
Conclusions. In total, 19 patients changed subgroup, 12 had an increase in the 
number of joints involved, six a decrease, and one changed from an oligoarticular 
pattern to predominant spondylitis. The majority of patients within the polyarticular 
group (37/51) had an increase in the number of joints involved. Four patients with 
predominant spondyloarthropathy also developed peripheral joint disease. For the
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whole population, there were significant increases in the number of joints involved 
erosion and joint space narrowing scores in the hands and HAQ scores. There were 
no significant differences in skin and nail scores although 9 further patients had 
developed nail disease. There was a significant correlation between the initial 
viscosity and rate of progression of joint damage, which may be a predictive factor 
for disease progression.
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TABLE 1. Demographic Data and Mortality
No of patients followed up 
No. of patients lost to follow-up 
No. of deaths
Median age of death (range) 
Causes of death
Sex (female: male)
Median age in years (range)
Median disease duration at follow-up 
in years(range)




70.5 (63 - 83)
cardiac disease 5
bronchopneumonia and a perforated gastric ulcer 1
carcinoma of the breast 1
psoriatic arthritis mutilans 1
unknown 1
49:38 
53.5 (21 - 85) 
15.5 (5-58)
65 (39 - 90)
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TABLE 2. Evolution of disease subsets from baseline to follow-up (N=87) The rows and columns show the numbers of each 
combination of subgroups at baseline and follow-up. The final column shows the total number and percentage of patients in each 
subgroup at baseline, and the final row shows the total number and percentage of patients in each subgorup at follow-up.
Subgroup at
R a s e l in e
Mono DIP
Subgroup at Follow-up 
Oligo Poly Spond Arthritis
Mutilans
Nil Total in subgroup at baseline 
(% of total patients)
Nil N/A N/A N/A N/A N/A N/A N/A N/A
Monoarthritis (Mono) 1 0 0 0 0 0 3 4 (4.6)
DIP Joint Disease Only 0 1 0 0 0 0 0 1 (11)
Oligoarthropathy (Oligo) 1 0 10 10 1 0 2 23 (26.4)
Polyarthropathy (Poly) 0 0 1 49 0 1 0 51 (58.6)
Spondyloarthropathy(Spond) 0 0 0 0 6 0 0 6 (6.9)
Arthritis Mutilans 0 0 0 0 0 2 0 2 (2.3)
Total in subgroup at follow-up 
(% of total patients) 1 (1.1) 1(1-1) 11 (12.6) 59(67.8) 7 (8.0) 3 (3.4) 5 (5.7) 87(100)
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TABLE 3. Clinical distribution of joint involvement in the small joint of the 
hands and feet at baseline and follow-up. The number of patients with 
involvement of a particular joint is shown and the percentage increase in 
involvement from baseline to follow-up is indicated for both right and left sides




MCPs (total) 39 45 15 27 39 44
MCP1 23 31 35 23 34 48
MCP2 22 35 59 18 30 67
MCP3 19 31 63 18 • 28 56
MCP4 9 22 144 6 18 200
MCP5 10 22 120 8 20 150
PIPs (total) 30 43 43 30 39 30
IP(Thumb) 17 26 53 15 23 53
PIP2 14 26 86 16 25 56
PIP3 19 27 42 19 29 53
PIP4 9 21 133 12 25 108
PIP5 10 23 130 11 24 118
DIPs (total) 19 34 79 18 31 72
DIP2 14 22 57 12 24 100
DIP3 14 23 64 14 22 57
DIP4 7 19 171 10 21 110
DIP5 9 23 156 10 18 80
Hand (total) 
FEET
51 58 14 52 60 15
MTP Joints
MTP1 23 38 65 23 35 52
MTP2 27 35 30 26 30 15
MTP3 32 37 16 29 32 10
MTP4 25 29 16 22 28 27
MTP5 20 29 45 22 28 27
Toes
IP1 19 23 21 15 24 60
Toe2 17 28 65 22 31 41
Toe3 15 26 73 19 28 47
Toe4 18 28 56 14 25 79
Toe5 13 23 77 14 24 71
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TABLE 4. Clinical distribution of joint involvement in the large joints, 
tem poro-m andibular. sterno-clavicular and acrom ioclavicu lar joints at 
baseline and follow-up. The number of patients with involvement of a particular 
joint is shown and the percentage increase in the baseline number of patients from 
baseline to follow-up is indicated for both right and left sides.
Right Right % Increase Left Left % Increase
Temporo-mandibular 1 2 100 0 2 NA
Sterno-clavicular 0 2 NA 0 4 NA
Acromio-clavicular 0 1 NA 0 2 NA
Shoulder 12 27 125 15 28 87
Elbow 13 16 23 13 20 54
Wrist 13 16 23 13 20 54
Hip 5 11 120 2 8 300
Knee 22 31 41 28 29 4
Ankle 6 20 233 6 17 183
Talocalcaneal 11 14 27 12 12 0
Midtarsal 2 5 150 0 4 NA
NA - not applicable because no involvement at baseline
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TABLE 5. Total scores for erosions (ERO) and joint space abnormalities (JSA) for the joints of the 
hands and wrists at baseline and follow-up in 75 patients Left and right hands are shown separately an d 
the percentage increase in the scores from baseline to follow-up is indicated. All the scores increased except 
for the JSA score for the PIP joints of the right hand, which decreased, possibly reflected the inclusion of joint 
space widening in the scoring system.
Joints
Left hand 
ERO ERO % JSA JSA %
Right hand 
ERO ERO % JSA JSA %
(baseline) (follow-up) Increase (baseline) (follow-up) Increase (baseline) (follow-up) Increase (baseline) (follow-up) Increase
DIP 107 148 38 123 177 44 94 142 51 103 140 36
PIP 124 216 74 168 178 6 130 191 47 169 154 -9
MCP 98 164 67 121 224 85 139 214 54 146 254 74
CMC 68 115 69 112 167 49 78 107 37 153 233 52
Carpal 151 274 81 199 252 27 157 271 73 219 281 28
Rc+Ru 56 88 57 59 69 17 59 75 27 59 84 42
Total 604 1005 66 782 1064 36 657 849 29 849 1146 35
Rc = radio-carpal 
Rc = radio-ulnar
71
FIGURE 1. Distribution of radiological features of psoriatic arthritis at baseline and follow-up
■  Baseline ■Follow-up
Bony DIP Deformity Periostitis Joint Space Bony Asymmetry Osteolysis Tuftal
Proliferation Involvement Widening Ankylosis Changes
DISCUSSION
Mortality in Psoriatic Arthritis
There have been few studies of mortality in psoriatic arthritis. The data from the 
study by Roberts et al (1976) is similar to the current study. In this study 168 
patients were followed up from 1 to 10 years. There were 18 deaths, nine of which 
were from complications of atherosclerosis, 3 from infections, 2 from malignancies, 
2 from haemorrhages and 2 were unknown. One patient died under the age of 50 
with a myocardial infarction. Brubaker et al (1992) had 20 deaths in a follow-up 
study of 304 patients over 11 years, none of which were directly attributed to 
psoriatic arthritis. The studies and numbers of deaths are all too small to make 
definite conclusions.
The largest mortality has recently been published (Wong et al 1997). This study 
evaluated the causes of deaths and standardised mortality ratios (SMR) of 53 deaths 
in patients attending a single out-patient clinic in Canada. There was a significantly 
increased mortality compared with the general population in both men and women 
(SMR 1.65 and 1.59 respectively). The proportions of the various causes of death 
were similar to that in the general population, with the exception of respiratory 
disease which was increased, although no cause could be identified. Thirty-six per 
cent of deaths were from circulatory causes; although this was slightly greater than 
occurred in the general population, it did not reach statistical significance. Psoriatic 
arthritis was considered a contributory factor in only one death, as in the current 
study.
Evolution o f Joint Disease
To date, there have been few studies in which patients with psoriatic arthritis have
been assessed over a period. Roberts et al (1976) reported that 94 of 168 patients
with psoriatic arthritis had been followed for more than 10 years, 15 for 5 - 10
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years, 32 for 2-4 years and 15 were seen once. Their follow-up suggested that 
patients who presented with a distal arthritis often proceeded to have multiple joints 
involved. Those who presented with a polyarthritis or deforming arthritis continued 
to further deteriorate, with data similar to our study. The percentage who 
deteriorated was less than in our study, possibly reflecting the diverse range of 
follow-up times.
This prospective follow-up study further emphasizes the preponderance of 
polyarthritis in established disease which tends to be symmetrical, as opposed to the 
asymmetry of mono or oligoarthritis. This progression of joint involvement has 
been reported in the small number of previous prospective studies (Gladman et al 
1994 and 1995b). In the current study, the percentage of patients with oligoarthritis 
based on involvement of five or less joints was only 13.7% at follow-up, closer to 
the figure from a study from Southern Italy (Della Valle et al), than studies from the 
United Kingdom or the USA (Moll and Wright 1973, Bennett 1985).
Only one patient in our series continued to have distal joints involved exclusively. 
This has not been found as an exclusive feature of arthritis in some series (Kammer 
et al 1979, Torre Alonso 1991, Helliwell et al 1991) but has been found exclusively 
in others (Gladman et al 1987). The presence of exclusive distal interphalangeal 
(DIP) joint disease has been debated (Helliwell and Wright 1992, Scarpa et al 1992, 
Veale and Fitzgerald 1992) and the presence of isolated DIP joint disease remains 
controversial. Only four patients from the original cohort of 100 developed arthritis 
mutilans, one of whom died prior to the follow-up study, confirming the rarity of 
this condition even in hospital attendees with psoriatic arthritis.
Hanly et al (1988) assessed 52 patients with psoriatic spondyloarthritis over 30 
months and showed that, whereas there was no clinical evidence of a significant 
increase in spinal disease, peripheral joint disease progressed. However, neck disease
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is a common feature of psoriatic arthritis (Jenkinson et al 1994) and caused cervical 
myelopathy in one patient. This complication is recognised in psoriatic arthritis and 
has been recently reported (Agaki et al 1996).
It has been recognised that some patients may have a benign cause with an initial 
presentation which subsides never to recur. Gladman has also reported complete 
resolution in 7 patients. This was the case in 4% of our patients , who had no 
evidence of joint involvement at follow-up. However one of these had non-tender 
mild dactylitis of the toes, which is interesting in the light of the recent suggestion 
that enthesopathy and dactylitis may represent a separate subgroup of joint disease 
(Salvarani et al 1997)
In general, psoriatic arthritis has been considered to be a milder form of arthritis than 
rheumatoid arthritis. The pattern of involvement of the small joints of the hands is 
similar to rheumatoid arthritis. Even when the distribution of joint involvement and 
synovitis is similar, patients with psoriatic arthritis may appear to have less pain and 
disability than rheumatoid arthritis (Oriente 1994). This may be related in part to the 
characteristic lack of joint tenderness in psoriatic arthritis compared with 
rheumatoid arthritis (Buskila et al 1992). Charcot’s joints have recently been 
reported in association with arthritis mutilans. The lack of joint tenderness may 
result in underestimating the extent of the disease, so it is important to review 
appropriate radiographs. Some patients with radiographic joint abnormalities may 
not be appreciated clinically in routine circumstances. This is a critical part of the 
evaluation and may influence therapeutic decisions.
Scarpa et al (1989) described 57 patients with psoriatic arthritis treated with 
auronofin. At 12 months there was improvement in the inflammatory activity in 64% 
of patients. However, there was no clinical information after 12 months, or 
radiological data to support the statement that psoriatic arthritis is a mild articular
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disease. Gladman et al (1995b) assessed patients who had been followed up 
prospectively for at least five years. There was clear evidence of alleviation of joint 
inflammation. However more patients developed both clinical and radiological 
evidence of damage, as in the current study. It was noted in Gladman’s study that the 
rate of progression of joint damage at follow-up was lower than at the initial visit, 
indicating that more damage occurred early in the course of disease.
Functional Assessment
The HAQ has been validated in rheumatoid arthritis and modified for use in 
spondyloarthritis (Daltry et al 1990). It has been recently modified to include 
limitations due to skin disease (Husted et al 1995). In the current study, which 
focused on peripheral joint disease, and used objective measures of skin 
involvement, we have used the standard HAQ, so that the data directly measures 
peripheral joint dysfunction and can be compared with studies of rheumatoid 
arthritis.
The HAQ socre deteriorated with time (median 0.35 to 0.5), but much less than has 
been found in studies of rheumatoid arthritis. In a study of 1,274 patients with 
rheumatoid arthritis, 50% had a HAQ score of >1 at 2 years, 50% had a HAQ score 
of > 2 at six years and 50% had a HAQ score of > 2.5 at 10 years (Wolfe and Cathay 
1991; Wolfe et al, 1991). Gladman found the HAQ to correlate with pain and 
fibrositic tender points rather than joint damage. The low HAQ scores are consistent 
with the low joint tenderness observed in the disease (Buskila et al 1992).
Laboratory Features
IgM rheumatoid factor was positive in one patient at baseline and follow up and a 
further three patients at follow-up. In a previous long-term follow-up study, 16% of 
131 PsA patients were consistently sero-positive and 10% fluctuated between 
positive and negative results (Roberts et al 1976).
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Gladman et al (1995) assessed patients who had been followed up prospectively for 
at least five years. There was a clear evidence of alleviation of joint inflammation 
demonstrated by a reduction in the number of actively inflamed joints and a 
reduction in the ESR. This was accompanied by higher use of non-steroidal anti- 
imflammatory drugs and disease-modifying anti-rheumatic drugs at the follow-up 
visit. Despite the fact that inflammation appeared to subside, deformity and damage 
progressed, suggesting, perhaps, that treatment may not have been provided early 
enough in the course of the diseases. In the current study, a high initial viscosity at 
baseline is associated with a greater rate of progression of clinical joint involvement 
and may be a predictive factor for its progression. This has also been shown by 
Gladman (Gladman et al, 1995).
Hand Radiology
Erosive disease in the hands was common. In our population, which were not 
selected on the basis of hand symptoms, 46% had erosions at baseline which 
increased to 56% at follow-up. Nissila et al (1983) followed 14 patients with 
psoriatic arthritis for at least three years. The number of patients with erosive disease 
increased from 8 to 11, although the number with inflamed joints reduced. The 
authors concluded that patients with psoriatic arthritis had a similar progression to 
rheumatoid arthritis. Hence radiological damage in the hand is progressive in the 
majority of patients with psoriatic arthritis, especially those with widespread damage 
at baseline.
The prevalence of the specific radiographic features or psoriatic arthritis increase 
with time but overall are present in a minority of patients. A comparison between 
polyarticular psoriatic arthritis and disease duration-matched, gender-matched 
controls with rheumatoid arthritis and osteoarthritis would be useful to determine
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differences in the pattern and severity of damage and the specificity of the reported 
features of psoriatic arthritis.
One of the largest percentage increases in the specific features of psoriatic arthritis is 
in bony ankylosis, which may cause particular disability in the hand (Gladman et al 
1990), particularly when it affects the wrist or MCP joints, rather than the distal 
joints. Fibrosis precedes ankylosis, which may be related to the release of specific 
cytokines. Loosening of the joint due to the pencil-in-cup deformity also increased 
although it remained uncommon. It is also a disabling deformity, even if isolated to 
distal joints, because of their importance in fine movement such as unbuttoning a 
shirt.
Skin and Nail Involvement
There was a remarkable similarity in the PASI and nail scores at baseline and 
follow-up. Nail disease has been consistently found to be increased in patients with 
psoriatic arthritis versus those with psoriasis alone (Camp 1992). It is on interest that 
eleven further patients had evidence of nail disease at follow-up, with a total 
percentage of 78%.
Conclusions
Psoriatic arthritis is a heterogeneous disease in onset, expression and outcome. The 
arthritis may vary considerably in its pattern and has been divided into several 
subgroups (Moll and Wright 1973, Chapters 2a). This current study provides 
evidence that psoriatic arthritis is not the benign disease once considered; 
polyarthritis is most common in patients referred to rheumatologists (Wright 1992, 
Jones et al 1994), and the majority of patients have progressive peripheral joint 
disease. This is consistent with Gladman’s work, based on the largest existing 
database of psoriatic arthritis (Gladman et al 1995b). However, it must be 
remembered that there are a small number of patients (five in this study, seven
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reported by Gladman (Gladman 1994) who have isolated or infrequent episodes of 
joint inflammation and who do not develop clinical evidence of joint damage. In the 
current study radiological damage in the hand was also progressive, especially those 
with widespread damage at baseline. Hence overall the study provides evidence that 
peripheral joint disease in psoriatic arthritis is progressive in the majority of 
patients and reinforces the need for effective monitoring and treatment.
However, the unpredictability of the course of peripheral disease and response to 
therapy is of major concern to both patient and rheumatologist. Good prognostic 
indicators are essential in justifying early intervention. The strongest known clinical 
prognostic indicator to date is the inflammatory marker -  the viscosity was measured 
in the current study, and the ESR in Gladman’ s work (Gladman et al 1995a) both of 
which are associated with an increase rate of progression of disease.
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CHAPTER 2c
THE TEMPORAL RELATIONSHIP BETWEEN JOINT, SKIN 
AND NAIL DISEASE - A PROSPECTIVE 2 YEAR STUDY 
SUMMARY
Introduction. It has been estimated from cross-sectional work that the activity of 
skin and peripheral joint disease in psoriatic arthritis may fluctuate concurrently in 
one quarter to one third of patients (Chapter 2b, Gladman 1987).
Hypothesis. Patients with simultaneous exacerbations or remissions of skin and joint 
disease may represent a distinct subset of psoriatic arthritis.
Study Design. Prospective.
Methods. Twenty-four patients with psoriatic arthritis were evaluated for the 
severity and activity of skin, nail and joint disease at approximately three monthly 
intervals over a minimum period of two years. All patients had peripheral joint 
involvement and evidence of active joint disease at baseline.
Results. Twelve patients considered that they had periodic exacerbations of joint 
and skin activity at baseline, but this was not substantiated by prospective study. 
Only four patients always had simultaneous flares or remissions of skin and joint 
disease and a further nine sometimes had simultaneous flares or remissions; the 
remaining eleven patents had no relationship between skin or joint exacerbations or 
an inverse relationship. The four patients in whom simultaneous flares or remissions 
occurred throughout the study and the nine patients in whom simultaneous flares or 
remissions sometimes occurred were not distinguished by any specific feature of 
their joint disease.
Conclusions . Simultaneous flares or remissions of peripheral joint and skin 
disease occur invariably in a minority of patients with psoriatic arthritis. This
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characteristic is independent of the timing of onset of joint disease in relation to skin 
disease and does not define a distinct subset of joint disease.
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INTRODUCTION
Clinical descriptive and epidemiological studies have conclusively established a link 
between psoriasis, nail disease and arthritis. However, the precise relationship 
between these three manifestations of the disease remains uncertain. It has also been 
reported that psoriasis tends to be more severe in patients with psoriatic arthritis and 
nail disease tends to be more common, although this data has been disputed (Camp 
1992). It is unclear whether the severity of skin disease may be an independent 
prognostic factor for psoriatic arthritis. Some individuals, 20% in most studies, 
present with joint symptoms before skin lesions appear whereas, in the majority, up 
to 80%, skin problems manifest themselves first. It would therefore appear that a 
separate triggering event is required for the initiation of the three manifestations of 
disease. Once these three manifestations are established, the temporal relationship 
between the activity and severity of joint disease and the activity and extent of skin 
disease and nail disease may be important to patients and rheumatologists in 
determining disability and in devising treatment strategies. This has never previously 
been assessed prospectively.
Gladman reported that 35% of patients have simultaneous exacerbations of skin and 
peripheral joint disease (Gladman et al 1987), but no relationship was reported by 
patients with predominant spondyloarthropathy. The data was not obtained 
prospectively, although the figure has often been quoted in reviews (Gladman 1994). 
In Chapter 2b, 23 of 87 patients (26.4%) reported simultaneous exacerbations of skin 
and joint disease. Hence, it is possible that there may be a subset of patients with 
psoriatic arthritis, distinguished by simultaneous exacerbations of their disease that 
share a common immunogenetic profile.
The aim of the current study was to prospectively evaluate the temporal association 
of skin and joint involvement. The frequency of simultaneous exacerbations of
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joint, skin and nail disease was assessed in patients attending the psoriatic arthritis 




Patients attending the psoriatic arthritis clinic in Bath were recruited for the study. 
Patients were entered into the study based on the following criteria - established 
psoriatic arthritis and stable medication for joint and skin disease at baseline. All 
patients verbally consented to the study and committed themselves to attending eight 
further appointments at approximately three monthly intervals over a minimum of 
two years. Recruitment occurred over a nine month period and a total of 29 patients 
entered the study, 5 of whom were withdrawn because of missing data after baseline 
(e.g. failure to keep the study appointment; inflammatory markers not available). 
Data was accumulated using a specially designed form.
Methods
All patients were seen by the same investigator (SJ) at approximately three monthly 
intervals. Data was entered on the psoriatic arthritis database after each clinic visit. 
At the baseline visit, information was taken including a detailed history of skin joint 
and nail disease using the proforma described in Chapters 2a and b. Patients 
completed a self-assessment questionnaire at baseline which included a question 
about simultaneous exacerbations of skin and joint disease. The joints, skin and nails 
were examined at each assessment. The activity of a joint disease was assessed using 
a modified Ritchie index for tender joints and a joint swelling score (Eular 1993; 
Appendix C). The pattern and number of joints involved was also evaluated by 
counting the number of active and damaged joints, so that the subgroup of joint 
disease could be determined. Functional assessment was made using the modified 
Stanford Health Assessment Questionnaire disability index (Kirwan et al 1986). A 
skin (PASI score) and nail scoring system was used to assess the severity and extent 
of skin and nail disease using methods previously described (Appendix A). At each 
visit changes to the medication for joint or skin disease, other interventions such as
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inpatient therapy for psoriasis, PUVA, UVB, joint injections, or admissions for skin 
or joint disease were noted. Radiological examination was performed where 
clinically indicated. All patients were managed according to guidelines established 
in the psoriatic arthritis clinic.
Haematological and biochemical markers of disease severity including a full blood 
count and differential, erythrocyte sedimentation rate, C-reactive protein and plasma 
viscosity were taken at each visit. The ESR, CRP and viscosity are all process 
markers of activity of joint disease activity, but not skin psoriasis (Brahn and 
Scoville 1988; Sitton et al 1987, Laurent et al 1981, Oriente et al 1984). A 
rheumatoid factor was performed at the baseline assessment.
The ESR, modified Ritchie index and joint swelling score were used to calculate a 
modified disease activity score which has been validated in rheumatoid arthritis and 
early synovitis (Eular, 1993; Appendix C). Global assessment of disease activity was 
not used as this may be influenced by the activity of psoriasis. The ESR was 
preferred to the CRP and viscosity because it has been validated for use in this 
index, there was no missing data after baseline in any patient, and because it covers 
the full range. The laboratory minimum for the CRP is 10mg/l, although it is 
recognised that values below this may be abnormal.
Descriptive Analysis.
Joint, skin and nail scores were entered onto an Excel database and plotted so that 
the tendency for joint, skin or nail scores to change simultaneously or otherwise 
from one time-point to the next could be readily described. The data graphs for each 
patient are shown in Appendix D. Exacerbations or remissions or joint and skin 
disease, joint and nail disease and nail and skin disease were deemed to have an 
equal chance of occurring simultaneously or inversely. To determine whether
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exacerbations or remissions of the three manifestations of disease occur sequentially, 




The demographic data for the patients included in this study is shown in Table 1. By 
chance more women were recruited, reflecting both the slight sex predominance in 
the clinic and the greater commitment of the women to attend follow-up 
appointments. All patients were sero-negative for rheumatoid factor. Only ten 
patients (40%) had the rheumatoid arthritis ‘shared epitope’, which is less than the 
percentages found in control populations (Chapter 2d) and reflects the fact that our 
population was sero-negative for rheumatoid factor and distinct from rheumatoid 
arthritis. Twelve patients were taking either sulphasalazine or methotrexate at 
baseline.
Nineteen patients developed psoriasis before arthritis, in three patients psoriasis was 
discovered when the arthritis presented, and in six the arthritis presented first. The 
duration of nail disease was not remembered reliably in most patients so the data is 
not included. Nine patients said that they had simultaneous flares of their joint and 
skin disease on questioning at baseline.
Sixteen of the twenty-four patients had nail disease at baseline and a further five 
patients (numbers 3, 5, 8, 18, 19 and 23) developed nail disease during the course of 
the study. Two further patients developed nail disease after the study was completed 
(patients 7 and 23).
The scores for joint, skin and nail disease for all twenty-four patients have been 
plotted and are shown for each patient in Appendix D. The tendency for 
simultaneous flares or remissions of joint, skin and nail disease to occur is 
summarised in Table 2, and plotted for skin and joint disease, joint and nail disease 
and nail and skin disease in Figures la to c.
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Temporal Relationship of Joint and Skin Disease
Only five patients always had simultaneous flares or remissions of skin and joint 
disease and a further nine sometimes had simultaneous flares or remissions; the 
remaining ten patents had no relationship between skin or joint exacerbations or an 
inverse relationship (Table 2). The tendency for simultaneous flares or remissions 
was unrelated to patient perception of a relationship at baseline. Of the nine patients 
who considered that they had periodic exacerbations of joint and skin activity at 
baseline, simultaneous flares or remissions occurred in only five, with no consistent 
relationship or an inverse relationship in the remaining four patients. In total, joint 
and skin disease flared simultaneously in 61% of 117 episodes in which significant 
changes in both joint and skin scored occurred, with an inverse relationship in the 
remaining 40%, which is only slightly more that would be expected by chance. The 
thirteen patients in whom simultaneous exacerbations or remissions occurred were 
not distinguished by the timing of onset of arthritis in relation to psoriasis or any 
other features of their joint or skin disease.
No consistent time-lag between exacerbations or remissions of skin and joint disease 
was observed.
Temporal Relationship of Joint and Nail Disease
Three patients had simultaneous flares of joint and nail disease, a further six tended 
to have simultaneous flares; five had no tendency, eight had a tendency for an 
inverse relationship and two always had an inverse relationship (Table 2). In total, 
joint and nail disease flared simultaneously in only 35 of 75 time-points in which 
significant changes in joint and skin scores occurred; at the remaining 40 time-points 
the changes were in opposite directions.
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No consistent time-lag between exacerbations or remissions of skin and joint disease 
was observed.
Temporal Relationship of Nail and Skin Disease
Four patients had simultaneous flares of skin and nail disease, a further six had 
simultaneous flares most of the time; in seven there appeared to be no relationship, 
in five there was a tendency for an inverse relationship and in two there was always 
an inverse relationship. In total, nail and skin disease flared simultaneously at 38 of 
61 time-points in which significant changes in both nail and skin scores occurred, 
with an inverse relationship at the remaining 23 time-points.
No consistent time-lag between exacerbations or remissions of skin and joint disease 
was observed.
Effect o f Treatment
The possible effects of modification of treatment for either skin or joint disease are 
complex, and the analysis in this study has been performed using the raw data 
without speculating on the possible differential confounding effect of treatment. 
Examples of possible effects are as follows. In patient three sulphasalazine was 
stopped and then restarted between time-point 6 and 7 (Appendix D), coinciding 
with a flare and remission of both joint and skin disease; the same pattern was seen 
in patient 17 between time-points one and 2 (Appendix D); in patient 7, UVB was 
given prior to appointment 7 - and improvement in the PASI score was noted and the 
joint score also improved (Appendix D); in patient 5 the dose of methotrexate was 
increased from 12.5mg per week to 15mg per week between appointments four and 




In summary, 12 patients considered that they had periodic exacerbations of joint and 
skin activity at baseline, but this was not substantiated by prospective study. Only 
four patients always had simultaneous flares or remissions of skin and joint disease 
and a further nine sometimes had simultaneous flares or remissions; the remaining 
eleven patents had no relationship between skin or joint exacerbations or an inverse 
relationship. The four patients in whom simultaneous flares or remissions occurred 
throughout the study and the nine patients in whom simultaneous flares or 
remissions sometimes occurred were not distinguished by any specific feature of 
their joint disease.
Hence, simultaneous flares or remissions of peripheral joint and skin disease occur 
invariably in a minority of patients with psoriatic arthritis. This characteristic is 
independent of the timing of onset of joint disease in relation to skin disease and 
does not define a distinct subset of joint disease.
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TABLE 1. Baseline characteristics of the 24 patients The patients are numbered as in Table 2 and Appendix D.
Patient Age Duration Duration Age Age Family Subgroup Pattern of Nail DIP Effusions Dactlylitis Spondylitis Erosions Use of Shared
Number Psoriasis Arthritis Psoriasis Arthritis History Arthritis Psoriasis Disease Joint DMARDS Epitope
Disease
1 54 36 24 18 30 y SP P y y n n y y y y
2 36 23 16 13 20 n AO PS y n n y n n n y
3 29 6 5 23 24 y AO PS n y n y n y y n
4 34 13 5 13 29 n SP PS y y n n n y n n
5 21 5 5 16 16 y AP PS n y y y n y y n
6 54 42 4 12 50 y SP P y y y y n y n y
7 30 8 5 22 5 n SP PS y n y n y n y y
8 62 10 17 53 45 y SP PSG n n y n n n y n
9 33 9 5 24 28 y AO NIL y n n y n n n n
10 39 9 8 30 31 n AO PS y n y n y n y n
11 28 7 2 21 26 n SP P y n y y n y n n
12 57 9 5 48 52 n AO GS y y n y n n n y
13 30 4 3 26 27 n AO PS y y n y n n n y
14 31 13 4 18 27 y SP PS y y n n n y y n
15 47 11 5 35 41 n AO P n n n n n n n y
16 32 25 16 7 16 y AP S y y n y n y n y
17 19 6 4 13 15 y AO PS y y y n n n y y
18 47 41 6 6 41 n SP PS n y n n n n n y
19 40 14 10 20 24 y SP PGS n y n y n y y n
20 38 16 16 22 22 y SP Nil y y n n n y n n
21 40 20 17 20 23 n AO PS y y n n n n n n
22 48 0 1 47 46 n AP P n y n y n n y n
23 25 1 1 24 24 n AO PG n y y y n n y n
24 62 12 5 50 57 y SP PGS y y n n n y y n
or Total 39 14.2 7.8 24.2 30 12 NA NA 16 17 8 12 3 11 12
AO = asymmetrical oligoarthritis 
SP = symmetrical polyarthritis
P = plaque psoriasis; G = guttate psoriasis; S = scalp psoriasis
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TABLE 2. The temporal relationship between joint, skin and nail disease.
Patient Simultaneous Flares Patients Reporting Simultaneous Flares Simultaneous Flares or
Number or Remissions of Joint Simultaneous Flares or Remissions of Joint Remissions of Skin
and Skin Disease of Joint and Skin Disease and Nail Disease and Nail Disease
1 Always Yes Inverse relationship always Inverse relationship always
2 Sometimes Yes Inverse relationship sometimes Inverse relationship sometimes
3 Sometimes No Inverse relationship sometimes Sometimes
4 Inverse relationship always No No relationship Sometimes
5 No relationship Yes Always No relationship
6 Sometimes No Sometimes Always
7 Always No No relationship No relationship
8 Sometimes No Always Always
9 No relationship No Always No relationship
10 Inverse relationship sometimes Yes No relationship Sometimes
11 Sometimes No Inverse relationship sometimes Inverse relationship sometimes
12 Inverse relationship sometimes Yes Inverse relationship sometimes Sometimes
13 Sometimes Yes Inverse relationship sometimes Inverse relationship sometimes
14 Sometimes No Sometimes Sometimes
15 No relationship Yes No relationship No relationship
16 Always Yes Inverse relationship sometimes No relationship
17 Always Yes Sometimes Sometimes
18 Inverse relationship sometimes No Sometimes Inverse relationship sometimes
19 Inverse relationship sometimes No Inverse relationship sometimes Always
20 Inverse relationship sometimes No Inverse relationship sometimes Inverse relationship always
21 Always No Sometimes Always
22 Sometimes No No relationship No relationship
23 Inverse relationship sometimes No Inverse relationship always Inverse relationship sometimes
24 Sometimes No Sometimes No relationship
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FIGURE la. The temporal relationship between joint and skin disease in 24
patients over 2 years.
Always Usually No relationship Usually inverse Always inverse
together together relationship relationship
FIGURE lb .  The temporal relationship between joint and nail disease in 24 
patients over 2 years.
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together





FIGURE lc . The temporal relationship between skin and nail disease in 24









The patients included in this study were typical psoriatic arthritis patients. It is of 
note that the majority of patients had nail disease (87% by the end of the study) and 
half the patients had dactylitis at baseline. Nail lesions remain the only clinical 
feature that identifies patients with psoriasis that are at risk of developing arthritis 
(Gladman et al, 1986) and evidence from the prospective follow-up study (Chapter 
2b) and the current study indicates that this characteristic increases with time.
The absolute scores obtained for skin activity and severity and joint activity also 
require some discussion. It has been suggested that patients with severe psoriasis 
tend to develop arthritis and that their arthritis may be more severe, although the 
evidence for this is flawed (Little et al 1975; Leonard et al 1978). A higher 
frequency of arthritis has been reported among hospital inpatients with psoriasis; 
these patients have severe psoriasis necessitating admission, and their arthritis is 
more likely to be noticed that the general population with psoriasis. In the current 
study the severity of psoriasis never reached a psoriasis area and severity index 
(PASI) score of 20, so was remarkably mild; however, some patients received 
treatment for their psoriasis between appointments which may have influenced the 
PASI scores and indeed the periodicity of skin activity compared with joint activity. 
It has been previously noted that the joints of patients with psoriatic arthritis are less 
tender that those with rheumatoid arthritis (Buskila et al 1992), both over tender 
fibrositic points and over actively inflamed joints. This may cause difficulty when 
measuring the extent of the arthritis, and may account for the low modified Ritchie
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scores recorded in this study on patients who had clear evidence of joint activity and 
progression.
Previous cross-sectional data has suggested that there is a clear relationship between 
a flare in skin disease and peripheral joint disease in approximately one third of 
patients (Gladman et al 1986). This data was quoted in a later review, where it was 
acknowledged that it was not obtained prospectively (Gladman 1994). In Chapter 
2b, the prospective follow-up study, 23 of 87 patients claimed to have simultaneous 
exacerbations of their skin and joint disease, and in the current study, nine patients 
claimed to have simultaneous exacerbations at baseline. However, this was not 
substantiated by prospective study. Cross-sectional data, based on patient 
perception, is likely to be unreliable because it is dependent on the most recent 
recall of the patient, which will by chance include simultaneous exacerbations or 
remissions in approximately a third of cases.
In all large series of psoriatic arthritis, including my own, some patients have 
developed arthritis before the appearance of skin lesions (Roberts et al 1976, 
Kammer et al 1979, Gladman et al 1987. Torre Alonso et al 1991, Chapter 2a; Jones 
et al 1994), some develop arthritis and psoriasis simultaneously and in the majority 
psoriasis develops first. A temporal relationship may be considered to be more likely 
in those who develop the manifestations simultaneously, but the three patients in 
whom this occurred had an inverse relationship between skin and joint activity.
Conclusions
The current study is unique. The activity of joint, skin and nail disease has never
96
been previously documented prospectively by a single observer. It may represent a 
window of opportunity to do the work, because the increasing use of cyclosporin 
and combination therapies in psoriatic arthritis may obscure the true temporal 
relationship between the manifestations of disease.
To conclude, in patients with psoriatic arthritis managed by standard therapies in the 
clinic, concurrent flares of skin and joint disease occur consistently in only a 
minority of patients. This finding is in keeping with other well-known clinical 
features of psoriatic arthritis - the arthritis may follow psoriasis by many years or 
vice-versa and severe arthritis may be accompanied by mild psoriasis or vice-versa. 
Whether the severity of skin disease is increased overall in patients with arthritis 
remains uncertain. There are also distinct differences in the cellular immunology of 
the skin and joints (Barker 1994, Panayi 1994). Although some features of immune 
dysregulation may be shared by both skin and synovium, other features such as the 
surface markers of the T lymphocyte populations differ (see Chapter 3). Both 
manifestations of the disease may respond to methotrexate, cyclosporin and 
possibly, sulphasalazine, but these non-specific immuno-suppressive agents are used 
to treat immunologically-mediated conditions affecting many systems (Cuellar et al 
1994, Abu-shakra et al 1995, Clegg et al 1996, Goupille and Valat 1996, Mahle et al 
1996, Griffiths 1996). Their mechanisms of action are diverse, and do not in 
themselves provide evidence of a close relationship between skin and joint disease. 
However, when individuals do notice a relationship between their skin and joint 
flares, and in particular when both manifestations of the disease are troublesome, it 
is sensible to choose a therapeutic agent or combinations of agents with evidence of 
efficacy in both joint and skin disease.
CHAPTER 2d
PREVALENCE OF THE RHEUMATOID ARTHRITIS HLA 
DRB1 “ SHARED EPITOPE” IN 76 PATIENTS WITH 
PSORIATIC ARTHRITIS 
SUMMARY
Introduction Genetic factors may influence susceptibility and severity in psoriatic 
arthritis. An epitope encoded by the third, hypervariable region of the DRB1 gene is 
a major susceptibility factor for rheumatoid arthritis. Nevertheless its association 
with peripheral disease in psoriatic arthritis has not been determined.
Hypothesis. The rheumatoid arthritis ‘shared epitope’ may influence susceptibility 
for and severity of psoriatic arthritis, and may have implications for its pathogenesis. 
Study Aim. To determine the prevalence of the ‘shared epitope’ in patients 
followed prospectively for 5 years (Chapters 2a and b) and its relationship to clinical 
subgroups, erosive disease and disease progression.
Methods HLA DRB1 alleles and HLA DR1 and DR4 subtypes were determined by 
PCR-SSO and PCR-SSP respectively in 76 patients with psoriatic arthritis and 104 
normal healthy blood doners. Clinical data was collected on all psoriatic arthritis 
patients including disease subgroup, joint scores and presence of erosions on hand 
radiographs.
Results The prevalence of the ‘shared epitope’ in patients and controls was similar 
and equal in all subgroups (35/ 76 patients versus 51/104 controls). The “ shared 
epitope” was distributed within subgroups at follow-up as follows (number with 
epitope/ number in subgroup): distal interphalangeal joint disease only 1/1 ; 
oligoarthritis 7/15 ; polyarthritis 21/49; predominant spondylitis 4/7; arthritis 
mutilans 1/3. There was no significant association between the presence of the 
‘shared epitope’ and erosions in the hands, or on the rate of progression of joint
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scores or erosions. The *0401 subtype was significantly reduced in psoriatic arthritis 
patients compared with controls.
Conclusions The ‘shared epitope’ is present in psoriatic arthritis in a similar 
proportion to the general population and is present in all subgroups of the disease. 
The *0401 subtype is under-represented in psoriatic arthritis compared with controls, 




It has been established for over 20 years that certain HLA DR4 and DR1 serotypes 
are associated with the presence of rheumatoid arthritis in different populations. The 
further definition of DR4 and DR1 subtypes and the discovery that not all subtypes 
are associated with rheumatoid arthritis has lead to the’shared epitope hypothesis’ 
(Gregarson 1987). This provides an explanation for the population association 
between rheumatoid arthritis and difference serologically-defined class II antigens at 
teh DR locus on the basis of the shared possession of a short sequence of amino 
acids in the third, hypervariable region of the DRB1 gene. In rheumatoid arthritis, 
several authors have reported a hierarchy of disease susceptibility with a more 
pronounced association with 0401 (Dw4) and 0404 (Dwl4). Also there is good 
evidence that HLA-DR4 is associated with disease severity, with increased 
representation in hospital RA (van Zeben 1991). Homozygosity for the ‘shared 
epitope’ or compound heterozygosity, in which two different alleles containing the 
‘shared epitope’ has been found to be linked to severe erosive disease (McDonagh et 
al 1997).
Genetic susceptibility is likely to be of major importance in the development of 
psoriatic arthritis. The associations of the MHC Class I molecules are well 
established. B13, B17, B27 and Cw6 occur with increased frequency in both 
psoriasis and psoriatic arthritis (Al-Jarallah et al 1993, Eastmond and Woodrow 
1977 and Eastmond 1994) and HLA B16 and its splits B38 and B39 are associated 
with psoriatic arthritis (McHugh et al 1987, Gladman et al 1995a). In psoriasis it has 
been established that HLA Cw6 is the primary association and that the other HLA 
Class 1 associations are in linkage disequilibrium with this (Green et al 1988). Of 
the HLA Class II molecules, DR7 has been found consistently to be increased in 
both psoriasis and psoriatic arthritis (Armstrong et al 1983, McHugh et al 1987, 
Gladman et al 1995a). In psoriatic arthritis DR4 has been found to be associated with
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peripheral arthritis resembling rheumatoid arthritis by some (Gerber et al 1982, 
Gladman et al 1986) but not others (Salvarani et al 1989). It has also been associated 
with erosive disease (McHugh et al 1987). DR1 has also been found to be increased 
in some studies (Armstrong et al 1983). All these studies used immunocytotoxicity 
techniques; they did not examine the ‘shared epitope’ itself.
Psoriatic arthritis is a heterogeneous disease in onset, expression and outcome. The 
arthritis may vary considerably in its pattern and has been divided into several 
subgroups (Moll and Wright 1973, Chapters 2a and b). It is not the benign disease 
once considered; polyarthritis is most common in patients referred to 
rheumatologists (Jones et al 1994) and significant number of patients have 
progressive joint disease (Gladman 1995a, Chapter 2b). The unpredictability of the 
course of peripheral disease and response to therapy is of major concern to both 
patient and rheumatologist. Good prognostic indicators would be useful in justifying 
early intervention.
The objectives of this study were therefore to (i) determine to prevalence of HLA 
DRB1 alleles and the ‘shared epitope’ in hospital outpatients with psoriatic arthritis 
compared with healthy controls; and (ii) to determine the association of the “ shared 
epitope” with subgroups of disease and erosive disease, and the progression of joint 
scores and erosions over five years.
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PATIENTS AND METHODS
Seventy-six patients were included in the study, all of whom were included in the 5 
year prospective follow-up study of psoriatic arthritis described in Chapters 2a and 
b. Peripheral blood was taken during the follow-up visit and subtyping for the 
‘shared epitope’ and other DRB1 alleles performed. The patients were caucasion, 
had psoriasis, an inflammatory arthropathy and were sero-negative for rheumatoid 
factor at baseline. A standard clinical and radiological proforma was completed in all 
patients at baseline and follow-up. Hand radiographs were examined for the presence 
of erosions.
The control population consisted of 104 healthy Caucasian blood donors. All of these 
were subjected to the screening procedure for blood donors, but mild psoriasis, 
which has a population prevalence of approximately 2% may have been present.
Immunogenetics
DNA was separated from peripheral blood leucocytes using a standard salting out 
method.
Examination of the HLA-DR locus was performed by two polymerase chain 
reaction (PCR) based techniques, PCR-SSO (sequence specific oligonucletides) and 
PCR-SSP (sequence specific primers), which overcome the problems of serological 
typing, i.e. equivocal results and cross-reactivity (Olerup and Zetterquist 1991, 1992 
and 1994 and Zetterquist and Olerup 1992). In PCR-SSO, nucleotide sequence 
variation in the HLA-DRp genes is detected using gene amplification of the whole 
HLA region by the polymerase chain reaction and hybridisation with sequence 
specific oligonucleotide probes using a dot-blot apparatus. PCR-SSP works on the 
principle that a perfectly matched primer pair is used in a reaction more sufficietly 
than a mismatched pair. Two reactions are required both containing an allelic
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specific primer whcih leads to the production of a allelic specific product. 
Genotyping is perfomed by resolving the product on agarose gel.
Nomenclature
The alleles encoding the ‘shared epitope’ contain a consensus sequence of amino 
acids at positions 70-74 in the third hypervariable region (HVR3) carrying the 
QKRAA or QRRAA pentapeptide motif. The subtypes encoding this epitope and 
current and serological nomenclature are shown in Table 1.
Statisical Analysis
Genotyping data was entered onto the psoriatic arthritis EXCEL database and the 
frequency distributions of the various alleles were determined. Chi-squared tests 
were used to determine differences in the prevalence of the ‘shared epitope’ and its 
constitutive alleles between the psoriatic arthritis and control populations. Student’s 
t test was used for comparison of continuous variables for parametric data.
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RESULTS
Relationship o f the Shared Epitope (SE) to Demographic Data
The characteristics of the patient population is described in detail in Chapters 2a and
b and summarised in Table 2.
The ratio of females to males in the psoriatic arthritis patients was 1.53:1. The 
ascertainment bias that may have contributed to the excess of females in this study 
has been discussed in Chapter 2a. The ‘shared epitope’ (SE) was most prevalent in 
the male population (18/30 (60%) versus 17/46 (37%); test, p <0.05). The age of 
onset of arthritis was similar in patients with and without the SE and there was no 
difference in the time difference between the onset of psoriasis and arthritis. Hence 
the SE was not associated with either an earlier onset of arthritis or a earlier 
triggering of arthritis in patients with psoriasis. The duration of arthritis was also 
similar in those with and without the shared epitope, so the clinical comparisons 
between the two groups are independent of disease duration (Table 2).
Prevalence of HLADRB1 subtypes and the Shared Epitope
Thirty-five of the 76 patients (46%) in whom full subtyping data was available had 
the ‘shared epitope’ compared with 51 out of 104 controls (49%) (Table 3)
The prevalence of homozygosity and compound heterozygosity were also similar 
(Table 3).
When combined for analysis, the prevalence of the *04 subtypes (DR4), was 
significantly less in the patients with psoriatic arthritis compared with controls 
(Table 2). There was a reduction in the prevalence of *0101 in patients compared 
with controls, but this did not reach statistical significance (p=0.067) (Table 2).
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Relationship o f the Shared Epitope to Clinical Patterns o f Disease 
The patients were divided into subgroups as described in Chapters 2a and b. 
Oligoarthritis was strictly defined as involving four or less joints, and polyarthritis as 
involving five or more joints; one patient still had monoarthritis after a disease 
duration of five years. The ‘shared epitope’ was present in all patterns of disease, 
with no significant differences between subgroups.
Forty-one of the 76 patients had erosive disease in their hands at baseline which 
increased to 49 at follow-up. The ‘shared epitope’ was distributed equally among 
patients with erosions and those without both at baseline and follow up (19/41 
(46.3%) of those with erosions compared with 16/35 (45.7) of those without erosions 
at baseline and 23/49 (46.9%) of those with erosions and 12/27 (44.4%) of those 
without erosions at follow-up)(see Table 3). The mean disease durations of psoriatic 
arthritis was significantly greater for patients with erosions and those without 
erosions at both baseline (means 17.4 versus 7.22, p=0.001 (t test)) and follow-up 
(means 19.36 versus 13.6, p=0.027), indicating that the development of erosions is 
time-dependent. There were no significant differences in the rate of progression of 
joint scores or erosions in patients with and without the ‘shared epitope’.
There was a slight trend for more of the HLA-DR4 positive patients to have erosive 
disease. Eleven of the sixteen (68.8%) DRB1*04 positive patients had erosive 
disease compared with 30 of 60 (50%) of the DRB1*04 negative patients, which was 
not statistically significant.
Conclusions
The prevalence of the ‘shared epitope’ in patients and controls was similar and equal 
in all subgroups. There was no significant association between the presence of the 
‘shared epitope’ and erosions in the hands, or on the rate of progression of joint
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scores or erosions. The *0401 subtype was significantly reduced in psoriatic arthritis 
patients compared with controls.
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TABLE 1. Nom enclature for HLADRB1 sub types encoding the 'shared  epitope'







DRB1*1001 DR10 Not Known
DRB1*1402 DR6, DR14 Dw16
HLA-DRB1*0103 (Dw'BON), DRB1*0104 (Dw20) and the remaining DR4 specificities are excluded
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TABLE 2.
Distribution of HLADRB1 sub types encoding the Shared
Epitope (SE) and Remaining *01 and *04 Subtypes in Patients
SUBTYPE
and Controls
Number of Patients 
with Subtype (%) 
(N= 76)
Number of Controls 
with Subtype (%) 
(N= 104)
DRB1 *0101 21 (27.6) 17(16.3)
*0102 1 (1.3) 4(3.8)
*0103 3 (3.9) 2 ( 1.9)
*0101/0103 1(1.3) 0
TOTAL *01 24 (31.6) 23 (22.1)
DRB1 *0401 11 (14.5)A 29 (27.9)A
*0402 0 1 (0.96)
*0403 2 (2.6) 1 (0.96)
*0404 3 (3.9) 8 (7.7)
*0405 1 (1-3) 0
*0407 0 3 (2.9)
*0408 0 0
TOTAL *04 16 (17)A 38 (36.5)A




DRB1*0101/0101 1 (1-3) 0
*0401/0401 2 (2.6) 3
*0401/0404 1 (1-3) 1 (0.96)
*0101/0404 1 (1-3) 3 (2.9)
*0101/0401 1 (13) 2(1.9)
*0401/0102 0 1 (0.96)
*0102/0102 0 1 (0.96)
TOTAL 6 (7.9) 11 (10.6)
TOTAL SE 35(46.1) 48 (46.2)
*04 and *01 alleles not encoding the "shared epitope" are shown in italics. 
A p<0.05
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TABLE 3. Demographic Data and Clinical Features in Relation to the Shared
Epitope (SE)
Feature SE p resen t SE ab sen t
Sex of Patients
Female (N=46) 17(37%)* 29 (63%)*
Male (N= 30) 18(60%)* 12 (40%)*
Age at Follow-up 53.5 (21-85) 54.6 (31-85)
Duration of Arthritis at Follow-up
(Years; Mean (range))
18.2 (5 -5 9 ) 18.2 (5 -4 7 )
Age of Onset of Arthritis
(Years; Mean (range))
36.3 (5 -7 1 ) 35.6 (10-71)
Onset of Arthritis in Relation to Psoriasis 
(Years; Mean (range))
9.5 (-20 - 52) 8.8 (-19-55)
Erosive Disease at Baseline (N=41)(Number/%) 19(46.3) 22 (53.7)
Erosive Disease at Follow-up (N=49)(Number/%) 23 (46.9) 26 (53.1)
Number of Involved Joints (Range) 17.5(0-62) 15.4(0-57)
Subgroup Number(% subgroup) Number(% subgroup)
Distal Interphalangeal Joint Disease only (N=1) 1 (100) 0
Psoriatic Arthritis Mutilans (N=3) 1 (33) 2(66)
Oligoarthritis (N=16) 8(50) 8(50)
Polyarthritis (N=49) 21 (43) 28 (57)
Spondyloarthritis (n=7) 4(57) 3(43)




HLA DRB1 genotypes, the Shared Epitope and disease susceptibility 
In rheumatoid arthritis, the ‘shared epitope’ (SE) is well recognised as a 
susceptibility factor for the development of the disease. In the current study, the 
prevalence of the SE. in psoriatic arthritis was equal to that seen in the control 
population, so does not appear to confer any susceptibility to the development of 
psoriatic arthritis overall. However the proportion of DR4 and DR1 alleles was 
different. Patients with psoriatic arthritis had significantly decreased total HLA 
DRB 1*04 and HLA DRB 1*0401 and a trend for an increase in HLA DRB1*01 and 
HLA DRB 1*0101 compared with normal controls; this pattern has been previously 
reported (Armstrong et al 1983).
HLA DRB1 Genotypes and the Shared Epitope and Clinical Patterns o f Disease 
In RA several authors have looked specifically at radiological progression as a 
measure of disease severity, some reporting an association of DR4 with erosive 
change on X-ray (Young et al 1984) and some not (Walton et al 1995). A 
prospective study in RA failed to find a relationship between the severity or the rate 
of X-ray progression and DR4 (Stockman 1991). The association is not seen in 
population-based studies where milder disease is more prevalent (Thomson et al 
1993). HLA-DRB1 genotyping in patients attending an early synovitis clinic has 
been shown to predict erosive disease (Gough et al 1994), but medium term 
prospective studies have since reported that, although genomic HLA typing is useful 
to predict the development of persistent RA, there is no clinically useful correlation 
between the HLA DRB1 type and disease severity (Eberhardt et al 1996). Hence, 
even in rheumatoid arthritis where the prevalence of the ‘shared epitope’ is 80% and 
DR4 is strongly associated in British and North American populations, the 
relationship to disease severity and progression is not clear cut.
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Early studies of HLA DR typing in psoriatic arthritis may have been misleading 
because of the small numbers of patients reported and the inclusion of rheumatoid 
factor positive patients who had a pattern of arthritis resembling rheumatoid arthritis, 
and may have had coincident psoriasis and arthritis. Gerber et al found HLA DR4 in 
10 of 12 patients with a pattern of arthritis resembling rheumatoid arthritis, 
compared with 36% of controls (Gerber et al 1982). In early data from Giadman’s 
group (1986), 7 of 12 patients were HLA DR4 positive compared with 30% of 
controls, although two of these HLA DR4 +ve patients were IgM rheumatoid factor 
positive. In a larger Italian population, which has a low population prevalence of 
HLA DR4, Salvarani (1989) failed to find any association between HLA DR4 and 
any pattern of psoriatic arthritis. Gladman (1995) has recently failed to find any over 
-representation of HLA DR4 compared with controls (30% in both) or any 
association between HLA DR4 and disease progression .
The current study was part of a 5 year prospective follow-up study and the 
prospective nature allowed for greater certainty of disease classification, stability of 
diagnosis as well as assessment of disease course and severity. The ‘shared epitope’ 
was present in all subgroups of disease, and the proportions of patients in each 
subgroup did not change with the change in subgroup due to disease progression 
over five years. In addition there was no relationship between the presence of the 
shared epitope and the presence of erosions in the hands, which may represent more 
severe peripheral joint disease, or the rates of progression of joint scores or erosions. 
However, there was a slight trend for those patients with DR4 to have more erosive 
disease and a more rapid rate of progression.
Conclusions
The HLA DRB1 ‘shared epitope’ does not significantly influence the susceptibility 
to PsA or the severity of disease in sero-negative patients. The under-representation 
of DR4 and specifically the HLA DRB 1*0401 allele compared with controls
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suggests that other HLA DRB1 alleles may have greater importance, such as DR7, 
although this allele is also over-represented in psoriasis alone (Gladman 1995b). 
Other non-HLA genotypes may also have relevance to the aetiopathogenesis, but 
genetic linkage studies involving large populations of psoriatic arthritis patients or 
multicase families may be required to discover true associations. The lack of 
association with the SE and psoriatic arthritis is further evidence of its separate 
identity from rheumatoid arthritis.
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CHAPTER 2e
THE EFFECT OF HORMONAL FACTORS ON THE ONSET AND 
COURSE OF PSORIATIC ARTHRITIS. 
SUMMARY
Introduction . The relationship of hormone-associated events to disease expression is 
of particular importance to female patients. The likely effects of hormonal factors have 
been established in patients with rheumatoid arthritis and it has been suggested that 
these hormonal events may also be important triggers and modifiers of psoriatic 
arthritis.
Hypothesis. Hormonal factors may influence the onset of joint and skin disease in 
psoriatic arthritis.
Study Aim . To determine the relationship between pregnancy and other hormonal 
factors in
influencing the onset and expression of skin and joint disease in psoriatic arthritis. 
Methods . The relationship between hormonal factors and the onset and expression of 
arthritis and psoriasis in 88 women with psoriatic arthritis (including 64 mothers) is 
assessed. A proforma was completed on all patients, including age of onset of psoriasis 
and arthritis, pattern of joint disease and relationship of pregnancy, menses and the 
perimenopausal period to arthritis and psoriasis. Seventy-seven male patients were 
used as a control population.
Results . The age of onset of arthritis in the females was similar to that of the males . 
There was also no significant difference in the age of onset of the 64 mothers. Psoriasis 
preceded arthritis by a mean of 10.5 years in the mothers, and 6.2 years in the men. 
There were 134 pregnancies including seven miscarriages and 2 terminations. Ten 
mothers developed arthritis prior to the first pregnancy. Of these, 4 had pregnancy- 
related remissions and post-partum flares and a further 3 had post-partum flares of
113
peripheral joint disease. One patient with arthritis mutilans developed arthritis during 
the second trimester of the first pregnancy which deteriorated post-partum. Six patients 
developed arthritis in association with the post-partum period of the first pregnancy. 
The mean age of onset of arthritis in these seven patients was 24.4 years, a mean of 
eight years after the onset of psoriasis. Of the four who had subsequent pregnancies all 
had a pattern of pregnancy-associated remissions and post-partum flares; this pattern 
has been confirmed by prospective data in four patients. Eleven patients developed 
arthritis and 7 had flares of joint symptoms during the perimenopausal period; 13 had 
pre-menstrual exacerbations.
Conclusions . Pregnancy and other hormonal factors may trigger or modify psoriatic 
arthritis in a minority of women. In those who develop arthritis prior to or in 
association with the first pregnancy, a pattern of remissions and post-partum flares of 
peripheral joint disease is likely in subsequent pregnancies.
114
INTRODUCTION
Hormonal factors may also have a role in determining outcome in psoriatic arthritis. 
There is a growing awareness of the role of pregnancy and other hormone-associated 
events in mediating the onset, expression and outcome of rheumatic diseases, 
particularly systemic lupus erythematosus and rheumatoid arthritis which both have 
a marked female predominance (Petri 1997, Buyan et al 1993, 0stensen and Lee 
Nelson, 1995). Onset of RA closely related to pregnancy has been described and a 
greater than five-fold increase in risk of RA onset during the first 3 months post­
partum has been reported, particularly in the first pregnancy (Silman et al 1992). In 
rheumatoid arthritis post-partum onset is positively associated with breast feeding, 
possibly related to hyperprolactinaemia.
There have been fewer studies in the sero-negative spondyloarthropathies, including 
psoriatic arthritis, but it has been suggested that hormone-associated events may also 
be important modifiers of the disease (0stensen 1992). A preliminary study of 15 
mothers with psoriatic arthritis suggested that pregnancy may trigger an earlier onset 
of psoriatic arthritis in the post partum period (McHugh and Laurent 1989). Both 
retrospective and prospective work by Ostensen, found that the pregnancy related 
remissions and post-partum flares of peripheral joint disease occurred in psoriatic 
arthritis (0stensen 1992).
The aim of the current study was to assess the relationship between hormonal- 
associated events including pregnancy and breastfeeding, menstruation and the 




All patients attended the psoriatic arthritis clinic at the Royal National Hospital for 
Rheumatic Diseases. Eighty-seven women including 64 mothers completed the 
study. Seventy-seven males were used as a control population. All patients had 
psoriasis, an inflammatory arthropathy and were sero-negative for rheumatoid 
arthritis.
The study design was retrospective in 60 mothers and prospective in four mothers. All 
patients were included on the psoriatic arthritis database containing information 
regarding the duration of joint and skin disease and the mode of onset and pattern of 
joint disease. A specific proforma relating to hormonal factors proforma was 
completed on all female patients at interview. The retrospective data was corroborated 
where possible by case-note review. Data collected included the number and age of 
pregnancies, the outcome of the pregnancies, and the age of menarche and the 
menopause. The pattern and severity of joint and skin disease and relationship to 
exacerbations or remissions of pregnancy, menstruation and the perimenopausal period 
was also recorded.
Four patients became pregnant during the study. Objective evaluation of the activity of 
joint and skin disease was made prior to pregnancy, during pregnancy and post-partum 
using the following measures. The distribution of joint involvement was noted, activity 
was assessed modified Ritchie, PASI and nail scores and the biochemical markers 
viscosity and ESR.
Statistical Analysis
The data was entered onto an Excel database and analysed using Excel and Statworks 
software packages. For the evaluation of the timing of pregnancy on the time of onset 
of psoriatic arthritis, three groups were identified for statistical comparison - mothers,
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non-mothers and men. The age of onset of arthritis and psoriasis was compared using 
Student’s t test after normality testing.
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RESULTS
The demographic data and subgroup of joint disease data on the females and males 
in this study is shown in Table 1. All patients had an inflammatory arthritis 
associated with psoriasis and all but one were sero-negative for rheumatoid factor.
All the women had peripheral joint disease. Thirty had oligoarthritis, fifty-three had 
polyarthritis and five had arthritis mutilans. No female had distal joint disease 
exclusively or predominant spondyloarthropathy. The distribution of subgroups in 
the males was as follows: Distal interphalangeal joint disease only in one; arthritis 
mutilans in one; polyarthritis in forty; oligoarthritis in twenty-eight; predominant 
spondyloarthropathy in seven. The age of onset of arthritis in the females (mean 38.4 
yrs, range 13-70) was similar to that of the males (mean 36.6 yrs, range 5 - 71 ) and 
there was also no significant difference in the age of onset of the 63 mothers (mean 
39.1, range 13 - 70) (Table 1). Psoriasis preceded arthritis by a mean of 10.5 years in 
the mothers, 11.8 years in the non-mothers and 6.2 years in the men with no 
significant differences between the three groups.
The 63 mothers had 133 pregnancies including seven miscarriages and 2 terminations. 
Four of the miscarriages were in one patient, the cause of which was uncertain (Anti- 
cardiolipin antibodies were absent). Nine mothers developed arthritis prior to the first 
pregnancy. Of these, 3 had pregnancy-related remissions and post-partum flares and a 
further 3 had post-partum flares of peripheral joint disease. There was no apparent 
association between the disease duration, patient age or timing of arthritis in relation to 
psoriasis and the tendency for pregnancy to affect the expression of psoriasis in these 
six women.
One patient with arthritis mutilans developed arthritis during the second trimester of 
the first pregnancy which deteriorated post-partum. Six patients developed arthritis in
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association with the post-partum period of the first pregnancy. The mean age of onset 
of arthritis in these 7 patients was 24.4 years, a mean of 8.3 years after the onset of 
psoriasis. Of the four who had subsequent pregnancies all had a pattern of pregnancy- 
associated remissions and post-partum flares. This pattern has been confirmed by 
prospective data in four patients, three of whom were first time mothers and the fourth 
in her third pregnancy (see Table 3).
Eleven patients developed arthritis and 7 had flares of joint symptoms during the 
perimenopausal period and within two years of the cessation of menstruation. 
Thirteen patients had pre-menstrual exacerbations.
No relationship between hormone-associated events and the onset or activity of 
psoriasis was reported in any patient.
Conclusions
Pregnancy did not appear accelerate the onset of arthritis in relation to psoriasis. Ten 
mothers developed arthritis prior to the first pregnancy, 4 of whom had pregnancy- 
related remissions and post-partum flares and a further 3 had post-partum flares of 
peripheral joint disease. One patient developed arthritis during the second trimester of 
the first pregnancy which deteriorated post-partum. Six patients developed arthritis 
during the post-partum period of the first pregnancy. Of the four who had subsequent 
pregnancies all had a pattern of pregnancy-associated remissions and post-partum 
flares.
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TABLE 1. Age of onset of psoriasis and arthritis in mothers, non-mothers and males. The mean difference in the 
age of onset of arthritis and psoriasis, and the timing of psoriasis in relation to arthritis for each group is shown
Mean age of onset 
of psoriasis
(years)
Mean age of onset 
of arthritis
(years)
Mean difference in age of 















Mothers (N=63) 29.1 39.1 10.5 40 11 12
Non-Mothers (N=24) 24.8 36.5 11.8 18 4 2
TOTAL (N=87) 27.9 38.4 11 58 15 14
MALES
TOTAL (N=77) 30.6 36.6 6.2 47 18 12
TOTAL 29.1 37.6 8.5 105 33 26
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TABLE 2. Onset and exacerbations of psoriatic arthritis in relation to hormonal events for 
mothers, all post menopausal women and all women. Thirtv-two mothers were post-menopausal 
at the time of the study.
Subgroup of 
patients
Time of onset or 
modification 
of psoriatic arthritis
Number of patients (%)
Onset of Flare of 
arthritis arthritis 




Mothers (N=64) Before first pregnancy 10 (15.9) NA NA
During 1st pregnancy 0 0 4(6 .3 )
Post-partum pregnancy one 6 (9.5) 7(11.1) 0
During second pregnancy 1 (1.6) 0 4(6 .3 )
Post-partum pregnancy two 0 4 (6.3) 0
After all pregnancies 47(74.6) NA NA
All post-menopausal Before menopause 23(41.8) NA NA
women (N=55)
Perimenopausal 11(20) 7 (12.7) 0
Post-menopausal 21 (38.2) NA NA
All women (N=87) Before menopause 55 (63.2) NA NA
Pre-menstrual NA 13(15) 0
NA = Not applicable
Post- partum = 0 to 4 months following birth 
Perimenopausal = within 2 years of cessation of periods
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TABLE 3. Clinical characteristics and activity of joint and skin disease before, during and after pregnancy in the four patients studied prospectivelv
Patient Age before Subgroup Medication
Number pregnancy arthritis




No of active No of active Plasma Plasma Plasma DAS DAS DAS Timing of Flare
joints joints Viscosity Viscosity Viscosity Before During After Post partum
during after Before During After Pregnancy Pregnancy Pregnancy
pregnancy pregnancy Pregnancy Pregnancy Pregnancy
31 AO Sulphasalazine
stopped pre-conception
1.63 1.54 1.73 1.76 1.04 1.73 3 months
34 A P  Oruvail 12 1.64 1.54 1.72 2.03 2.17 3.89 3 months




1.63 ND 1.75 ND ND ND Immediate




1.62 1.56 1.53 ND ND ND 3 months
Notes
DAS = disease activity score (Appendix C)
Patient three had w idespread pain and tenderness and dactylitis of her toes, but no synovitis 
ND = not done
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DISCUSSION
The effect of pregnancy and other hormonal factors on risk and modification of 
rheumatoid arthritis is complex. Amelioration of the symptoms and signs of 
rheumatoid arthritis during pregnancy was initially described by Hench in 1938, who 
found 90% had relief of symptoms. Other retrospective studies have shown 
amelioration to occur in about three quarters of pregnancies and prospective studies 
have confirmed this. Most women who improve experience initial relief in the first 
trimester and rheumatoid arthritis recurs within three to four months of delivery (Lee 
Nelson and Ostensen 1997). This data compares with three out of nine of the patients 
in the current study who had onset of psoriatic arthritis before the first pregnancy, 
six or whom had a post-partum flare. In rheumatoid arthritis, seropositivity for 
rheumatoid factor, patient age, degree of disability and disease duration have not 
been found to predict the expression of disease during pregnancy . The lack of 
association with sero-positivity is consistent with our findings in this sero-negative 
population with psoriatic arthritis. In rheumatoid arthritis, it has been shown that if a 
women improves during one pregnancy, improvement is likely to occur in 
subsequent pregnancies as well, which is also suggested in our study.
Amelioration of rheumatoid arthritis occurs early in pregnancy (Hench 1938). 
0stensen and Husby (1983) compared activity during pregnancy with preconception 
disease and found initial arthritis relief usually occurred in the first trimester, with 
further improvement in the second and third trimesters. Once improvement occurred, 
it persisted, becoming more complete as gestation progressed.
Epidemiological studies have also shown that, although initial onset of rheumatoid 
arthritis can occur during pregnancy, overall the chance of this occurring is 
significantly reduced, but increases in the first year post-partum and decreases 
thereafter. One patient in our study developed onset of psoriatic arthritis during
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pregnancy, which deteriorated following the pregnancy. Studies in rheumatoid 
arthritis have also indicated that there is no indication of any adverse effects of 
rheumatoid arthritis on pregnancy outcome, which is also suggested by our data in 
psoriatic arthritis.
Conclusions
This data does not support the notion that pregnancy commonly triggers an earlier 
onset of arthritis in mothers in comparison with non-mothers and men. However, in 
a minority of susceptible women, it may trigger or modify psoriatic arthritis. In those 
who develop arthritis prior to or in association with the first pregnancy, a pattern of 




EXPRESSION OF THE CUTANEOUS LYMPHOCYTE 
ANTIGEN (CLA) AND ITS COUNTER-RECEPTOR 
E-SELECTIN IN THE SKIN AND JOINTS OF PATIENTS WITH 
PSORIATIC ARTHRITIS
SUMMARY
Introduction The second part of this thesis focuses on immunological mechanisms 
that may explain the link between joint and skin disease in psoriatic arthritis. 
Hypothesis. Selective T cell recruitment to skin and joint tissue and subsequent 
activation may explain the observed relationship between skin and joint disease in 
psoriatic arthritis. Study Aim. To investigate whether skin-homing T lymphocytes 
identified by the cutaneous lymphocyte antigen (CLA) are increased in the synovial 
membrane of patients with psoriatic arthritis.
Methods Twenty - six synovial samples (13 psoriatic arthritis, 7 rheumatoid 
arthritis, 6 osteoarthritis) were obtained from involved knees. Lesional skin biopsies 
were taken from 9 of the patients with psoriatic arthritis and 6 patients with psoriasis 
alone. All samples were single and dual-stained for CLA and CD3 (to identify T 
lymphocytes) using HECA-452 (anti-CLA) and anti-CD3 monoclonal antibodies. E- 
selectin expression was also determined.
Results The percentage of dual-stained lymphocytes was significantly greater in 
psoriatic skin than in synovium (p < 0.001) and similar between psoriatic and 
rheumatoid synovium. There was no significant difference in the percentages of 
CLA-positive cells in psoriatic skin in patients with psoriatic arthritis compared with 
psoriasis alone. The intensity of endothelial E-selectin expression was significantly 
greater in skin psoriasis than in synovium (p < 2 x 10"^), and rheumatoid synovium 
had significantly greater expression than psoriatic synovium (p < 0.05). However,
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there was no significant correlation between E-selectin expression and the 
percentages of CLA-positive lymphocytes.
Conclusion This study provides further evidence that the CLA antigen is enriched 
on skin-homing lymphocytes. Conversely, the link between skin and joint 
inflammation in psoriatic arthritis does not seem to be explained by increased 
trafficking of CLA positive T cells to psoriatic synovium.
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INTRODUCTION
The epidemiological and clinical basis for the distinction of psoriatic arthritis other 
forms of arthritis is well established. The topographic relationship between nail and 
distal interphalangeal joint disease is well establihsed (Jones et al 1994 and Chapter 
2a, Wright 1956, Kay 1997). Espinoza postulated that “ noxious substances” may 
traffic between the sites, linking their involvement (Gerber and Espinoza 1985). 
Although the inflammatory processes which link skin, nail and joint disease remain 
elusive, an immune-mediated pathology is implicated.
Immunopathogenic mechanisms involving T lymphocytes in psoriasis and arthritis 
appear similar. Both the skin and synovium are infiltrated with activated 
T lymphocytes (Barker 1994, Panayi 1994), with a preponderance of CD4RO+ 
cells, known to migrate preferentially to peripheral tissues (Panayi 1994). There are 
known associations with major histocompatibility haplotypes (McHugh 1987, 
Eastmond 1994). Both psoriasis and arthritis increase in severity with the depletion 
of T helper lymphocytes secondary to HIV infection (Espinoza et al 1992, Arnett et 
al 1991), and both improve in response to immunotherapy such as cyclosporin A.
The skin is a functionally unique immune site with apparently a specific homing 
mechanism for T cells. The cutaneous lymphocyte antigen (CLA), defined by the 
monoclonal antibody HECA-452 identifies a population of skin-homing memory T 
cells (Picker et al 1990). The receptor for CLA on dermal endothelium is the 
inducible cell adhesion molecule E-selectin (Picker et al 1991), a protein which also 
acts to tether neutrophils during their initial rolling interaction with the blood vessel 
wall at the onset of an inflammatory response (Berg et al 1991, Bevilacqua et al 
1994). It has been proposed that E-selectin on venules at sites of acute inflammation 
supports neutrophil recruitment, whereas in sites of chronic inflammation in the skin 
mediates accumulation of CLA-positive T cells (Picker et al 1991).
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The principal aim of the current study was to determine whether skin and joint 
disease in psoriatic arthritis may be linked through the inappropriate expression of 
CLA molecules, E selectin or both. We have therefore investigated the percentages 
and distribution of skin-homing (CLA-positive) T lymphocytes and their counter­
receptor E-selectin in the skin, synovium and peripheral blood of patients with 




The study was approved by the Bath and South West Ethical Committee. Written 
consent was obtained for biopsies.
PATIENTS
Thirteen patients with psoriatic arthritis and synovitis of a knee were recruited from 
a psoriatic arthritis clinic. Clinical information including the age, sex, duration of 
psoriasis and arthritis, subgroup of joint disease, presence of erosions, degree of 
knee synovitis, skin severity, periodicity of skin and joint disease and the presence of 
nail disease was recorded. All patients had active psoriasis, and were sero-negative 
for rheumatoid factor.
Controls included samples from 7 patients with sero-positive rheumatoid arthritis 
defined by the American College of Rheumatology (Arnett et al 1988), six patients 
with osteoarthritis and six patients with psoriasis alone. No patient or control had 





Biopsies were taken from knee joints by a standard blind needle biopsy technique 
using a Polley’s needle after local anaesthesia. At least six samples of synovial 
membrane were obtained from different regions of the suprapatellar pouch. Paraffin
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sections were obtained for descriptive histology. Samples from two of the patients 
with RA and three of the six patients with osteoarthritis were obtained at the time of 
arthroscopy or joint replacement.
2. Skin
Elliptical skin samples were obtained from 9 patients with psoriatic arthritis, 8 of 
whom had concurrent synovial biopsies, and 6 patients with psoriasis alone, 
recruited from a dermatology clinic. A musculoskeletal history and joint 
examination was performed to confirm the absence of arthritis in the latter patients. 
Biopsies were taken from lesional edges of the most active accessible plaques. In 
one patient the skin biopsy was taken from a plaque directly on the involved knee.
Further control tissue included three samples of normal skin from healthy 
volunteers, one sample of lesional skin from a patient with severe eczema, and a 
sample of normal tonsil.
Preparation of sections
Tissue sections of skin and synovium were mounted on cork with 5% polyvinyl 
alcohol (PVA), snap frozen in liquid nitrogen and stored at -70°C- The cork was 
mounted on to a metal chuck with PVA, and 8pm sections were cut on a cryostat at - 
25°C. Sections were mounted serially on 4-well glass slides, air-dried for one hour 
and fixed in acetone at room temperature for 10 minutes, wrapped in tin-foil and 
stored at -20 prior to use. Histology was checked every 10 sections using a rapid 
staining technique (Diffquick). Synovial specimens without clearly defined synovial 




The antibodies and other reagents used are listed in Table 1. The monoclonal 
antibody HECA-452 was provided by Dr Louis Picker, University of Texas, USA.
Single-staining for CD3 and CLA
CD3 populations were quantified using anti-CD3 supernatant (undiluted) or control 
mouse IgG (dilution 1 in 500) and alkaline phosphatase/ monoclonal anti-alkaline 
phosphatase (APAAP) complexes using a standard method described by the 
manufacturer (Dakopatts.)
Sections were stained for CLA using HECA-452 (rat IgM) and a standard 
biotin/streptavidin-alkaline phosphatase technique:- (l)blocking step for 20 minutes 
with human AB serum in 5% solution with Tris-buffered saline (TBS); (2) one hour 
incubation with HECA-452 monoclonal antibody (rat IgM) at 1/30 dilution or 
control rat IgM (1/100 dilution); (3) 30 minute incubation with biotinylated species- 
specific anti-rat immunoglobulins at 1/50 dilution ; (4) 30 minute incubation with 
streptavidin-alkaline phosphatase at 1/50 dilution ; (5) Fast red/substrate for 15 to 20 
minutes at room temperature. All reagents were diluted in TBS and lOOpl of diluent 
used for each section. Each stage was followed by washing for 1-2 minutes in TBS. 
Finally the sections were lightly counterstained with haematoxylin and mounted.
Double fluorescence staining was used to estimate the percentage of 
CLA-positive T lymphocytes because the HECA-452 monoclonal antibody is not T- 
cell specific, also identifying related E-selectin ligands on high endothelial venules 
(HEVs), neutrophils and monocytes.
Fluorescence Double-Staining
Sections were double-stained for CLA and CD3 using HECA-452 and anti-CD3 
supernatant and fluorescein isothiocyanate (FITC) and tetramethylrhodamine
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isothiocyanate (TRITC) conjugates respectively and appropriate non-reactive control 
monoclonal antibodies. Each serial 4 well slide had a control section, single-stained 
sections for CLA and CD3 and a double-stained section. The incubation steps for 
double-staining were:- (1) 20 minute blocking step with human AB serum in 5% 
solution with PBS (2) 45 minute incubations with anti-CD3 supernatant (undiluted) 
and goat TRITC anti-mouse IgG (1 in 50) ; (3) 20 minute blocking step with 5% 
normal mouse serum (NMS) (4) HECA-452 monoclonal antibody (1/30 dilution) (5) 
45 minute incubation with rabbit biotinylated species-specific anti-rat 
immunoglobulins (1/50); (6) FITC-streptavidin (1/50) . All antibodies were diluted 
in phosphate-buffered saline (PBS) and each stage was followed by washing for 1-2 
minutes with PBS. The sections were mounted using 1,4-diazabicyclo (2, 2, 2) 
octane (DABCO) as an interface.
Three psoriatic synovial sections were similarly double-stained for macrophages 
using anti-CD68 instead of anti-CD3.
Sections were stained in duplicate or triplicate, blinded to the diagnosis and scored 
by two investigators (the author and Jonathon Dixey). The number of single and 
double-stained T lymphocytes were assessed in the dermis of the skin and sublining 
layer of the synovium. Sequential fields were studied using an eyepiece orientated 
along the dermo-epidermal junction or synovial lining layer. A section was only 
scored if the singly stained section was of equivalent intensity to the dual stained 
section. Inter observer variability was within 10%.
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Determination and Quantification of E-Selectin Expression
The anti-E-selectin monoclonal antibody was used, followed by the APAAP 
complex according to the protocol described by the manufacturers (Dakopatts), 
followed by haematoxylin counterstaining. Endothelial morphology was confirmed 
in longitudinally cut vessels by the endothelial cell marker anti-CD34. Anti-E 
selectin was used at a dilution of 1/200, anti-CD34 and APAAP at 1/50. Vessels in 
the dermis of the skin and synovial sublining were scored in sequential fields. The 
number of vessels, the proportion of E-selectin positive vessels and the intensity of 
staining was determined on an arbitrary scale as follows:- 0 = no staining detected; 1 
= minimal staining; 2 = moderate staining; 3 = strong staining. The mean intensity 
was computed for each section. The density of the surrounding inflammatory 
infiltrate was also determined using the following scale:- 0 = no inflammatory 
infiltrate; 1 = small inflammatory infiltrate; 2 = moderate inflammatory infiltrate; 3 
= dense inflammatory infiltrate.
FLOW CYTOMETRY
Sample Collection
Ten mis of venous blood was taken from 12 patients with psoriatic arthritis, 6 with 
rheumatoid arthritis and 6 normal controls. All the psoriatic arthritis and rheumatoid 
arthritis patients had clinical evidence of active synovitis. Three of the psoriatic 
arthritis patients were included in the immunohistological study (Table 2, patients 3, 
4 and 7).
Materials
The reagents used are listed in Table 1. The FITC-conjugated HECA-452 
monoclonal antibody and a control FITC-conjugated rat IgM with unspecified 
reactivity were donated by Dr Picker and used undiluted.
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Methods
Mononuclear cells (MNC) were separated from lOmls heparinised whole blood 
using a standard lymphoprep gradient. Ten mis of heparinised blood was taken from 
each patient. The separated MNCs were washed with medium, counted and re­
suspended in RPMI and 10% foetal calf serum and preincubated with 50pl 
undiluted normal human serum. Five x 10^ cells were used per test. The following 
reagents were added:- (1) anti-CD3, (2) phycoerythrin (PE)-conjugated anti-mouse 
immunoglobulins (1/50) and (3) FITC-conjugated HECA-452 monoclonal antibody 
(undiluted) with appropriate controls minus one or more reagents. After 30 minutes 
incubation, the cells were resuspended in PBS containing 1% paraformaldehyde.
Flow cytometry was performed using a Becton-Dickinson FACStar Plus with 
air-cooled argon laser and Consort 32 computer. Gating was performed by setting 
the threshold with reference to the relevant negative control. The percentages of 
CLA positive circulating T lymphocytes in peripheral blood of patients with 
psoriatic arthritis, rheumatoid arthritis and normal controls were determined.
DATA ANALYSIS
Data were analysed using a Hewlett Packard personal computer with software 
packages including Microsoft Excel and Statmost. Normality testing was performed 
prior to analysis. Duncan’s test for multiple comparisons was used for the various 
patient groups. The Mann Whitney U test was used to compare all the psoriatic skin 
versus the synovial samples. The Wilcoxon signed rank test was used for paired 





The patients represented a spectrum of disease severity for both joint and skin 
disease (Table 2). There were 6 females and 7 males, mean age 44 (range 20 to 62 
years). The mean duration of arthritis 15 years (range 6 - 27) and psoriasis 18 years 
(range 0 - 36). One patient (patient 13) had trivial psoriasis only that at the time of 
synovial biopsy and did not reach the criteria for a PASI score. The 
immunohistological data were assessed in relation to clinical parameters.
Immunohistology 
T lymphocyte populations
The distribution of T lymphocytes in each sample was quantified prior to double- 
staining (Table 3). Eight synovial samples (6 osteoarthritis, 2 psoriatic arthritis) did 
not have sufficient lymphocytic infiltration to accurately determine the percentages 
of CLA positive T cells. The two psoriatic arthritis patients had mild synovitis only 
at the time of biopsy. For the 6 osteoarthritis patients, only isolated lymphocytes 
were present, with an occasional double-stained cell. Apart from the osteoarthritis 
group, the mean numbers of T cells per field (T cell density) were similar in the 
other four patient groups. There was a weak negative correlation between the T cell 
density in synovium and the duration of arthritis but this was not significant. There 
was also a weak positive correlation between the degree of synovitis clinically in 
psoriatic arthritis and the T cell density, but this was not statistically significant.
Immunohistological distribution of the CLA antigen
The CLA antigen was present on many cell types within the synovium, including T 
cells, vascular endothelium, neutrophils and macrophages. Its presence on 
macrophages was also confirmed by double-labelling with an anti-CD68 monoclonal 
antibody. In the skin, CLA-positive lymphocytes were observed in all lymphocytic
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areas; this included perivascular lymphoid aggregates around superficial dermal 
vessels, immediately below the stratum basale, and in the more diffuse cellular 
infiltrate. Other skin cell types also stained for HECA-452 including macrophages, 
polymorphonuclear leucocytes, vascular endothelial cells and Langerhans cells.
CLA/CD3 double -staining
The percentages of CLA/CD3 double-stained lymphocytes in patient groups and 
control tissue are shown in Table 3 and Figure 1. Representative results of 
fluorescence double- staining of CD3 and CLA for psoriatic skin and synovium are 
shown in Figures 2a-d. There was a significant correlation between the density of the 
inflammatory infiltrate and the percentages of CLA positive T cells (p<0.05).
The following comparisons between disease groups were made: (a) all skin (N=19) 
and all synovial samples (N=18); (b) psoriasis (N=15) and psoriatic arthritis
synovium (N=ll); (c) psoriatic arthritis synovium (N=9) and rheumatoid arthritis 
synovium (N=7); (d) paired psoriatic arthritis synovial membrane and skin samples 
(N=7) and (e) psoriasis in patients with arthritis (N=8) and those without arthritis 
(N=6).
The percentages of lymphocytes double-stained for CLA and CD3 were significantly 
greater in (a) skin than in synovium ( p<10"6 ) and (b) psoriasis than in psoriatic 
arthritis synovium (p=0.01). For paired skin and synovial samples from psoriatic 
arthritis patients, the percentages of double-stained lymphocytes were also 
significantly greater in skin than in synovium (p< 0.02). In one paired sample of 
psoriatic skin and synovium (Patient 8) the percentage expression was 48.5% and 
34% respectively.
There were no significant differences between the percentages of double-stained 
lymphocytes in psoriatic arthritis synovium compared with rheumatoid arthritis
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synovium. In skin psoriasis there were no significant differences in the percentages 
of CLA positive lymphocytes in patients who had arthritis compared with those 
with psoriasis alone. The percentages in the three samples of normal skin and from 
one sample of eczematous skin were similar (all 60%), but much less in tonsil (2.5 
%).
There were no significant associations between any clinical parameter and the 
percentages of double-stained lymphocytes in synovial tissue. There were no 
significant associations between the degree of synovitis clinically and the percentage 
of double-stained lymphocytes. In particular, there were no significant differences 
between the percentages of double-stained lymphocytes in the four patients who had 
coincident exacerbations of their skin and joint disease and those in whom there was 
no apparent temporal association. The patient with the greatest percentage of double­
stained lymphocytes in synovium (34%) did have simultaneous exacerbations of his 
skin and joint disease.
E selectin expression
The mean number of blood vessels per field, the percentage of positively stained 
vessels, the E-selectin intensity and the density of the perivascular infiltrate are 
shown in Table 4. Comparisons between the percentages of positive vessels, E- 
selectin intensities, numbers of vessels and perivascular infiltrates were made in the 
following groups - (a) all skin (N=18) and all synovial samples (N=16); (b) all 
psoriasis (N=15) and psoriatic arthritis synovium (N=10); (c) psoriatic arthritis 
synovium (N=10) and rheumatoid arthritis synovium (N=6); (d) paired psoriatic 
arthritis synovial membrane and skin samples (N=6) and (e) psoriasis in patients 
with arthritis (N=8) and those without arthritis (N=6).
The results for the disease group comparisons for the intensity of E-selectin 
expression were as follows: (a) E-selectin expression was significantly greater in
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skin than synovium (p < 2 x 10"6) and (b) in skin psoriasis compared with psoriatic 
synovium (p < 2 x 10'^); (c) E-selectin expression was significantly greater in 
rheumatoid arthritis synovium compared with psoriatic arthritis synovium (p < 
0.05); (d) E-selectin expression was significantly greater in skin than synovium (p < 
0.018) in paired skin and synovial samples from patients with psoriatic arthritis; (e) 
there was no significant difference in E-selectin expression in the skin of patients 
with arthritis compared with those without arthritis. The results of these comparisons 
were similar when the numbers of positive vessels was used instead of E selectin 
intensity. No E-selectin expression was seen in 3 of 10 psoriatic arthritis synovial 
samples and 1 of 7 rheumatoid arthritis synovial samples. Minute quantities only of 
E-selectin were detected in osteoarthritis synovial membrane. In skin E-selectin was 
expressed in all samples throughout the dermal vessels, including the deep dermal 
vasculature, and was present in all samples. E-selectin expression in skin and 
synovium is shown in Figure 3.
The numbers of vessels per field were significantly greater in synovium than all the 
skin samples, including the three samples of exzema and normal skin ( p < 0.03). 
Furthermore the difference remained significant when only psoriatic skin was 
analysed ( p < 0.04). However, there were no significant differences between the 
numbers of vessels per field between any of the remaining disease groups.
There were no significant differences in the density of the perivascular infiltrates 
between the patient groups. For psoriatic arthritis synovium there was a significant 
correlation between E-selectin expression and the density of the inflammatory 
infiltrate (p < 0.005). For all the disease groups combined, there was a weak positive 
correlation between E-selectin expression and the density of the inflammatory 
infiltrate, but this was not significant. There were no significant correlations between 
E-selectin intensity and any clinical parameter or the percentages of CLA positive T 
cells.
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CLA positive T cells in Peripheral Blood
Flow cytometry results for T lymphocytes double-stained for CD3 and CLA are 
shown in Figure 4. Patients with rheumatoid arthritis had slightly greater percentages 
of double-stained cells (median 4.8, range 2.6 - 8.4 %) than those with psoriatic 
arthritis (median 2.9, range 1.4 - 5.8%) and four normal control patients (median 2.0, 
range 1.1 - 5.7% ). The differences between the disease and normal control groups 
were not significant.
Conclusions
The major findings are summarised as follows. The percentage of dual-stained 
lymphocytes was significantly greater in psoriatic skin than in synovium and similar 
between psoriatic and rheumatoid synovium. There was no significant difference in 
the percentages of CLA-positive cells in psoriatic skin in patients with psoriatic 
arthritis compared with psoriasis alone. The intensity of endothelial E-selectin 
expression was significantly greater in skin psoriasis than in synovium, and 
rheumatoid synovium had significantly greater expression than psoriatic synovium. 
However, there was no significant correlation between E-selectin expression and the 
percentages of CLA-positive lymphocytes.
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TABLE 2. Clinical characteristics of psoriatic arthritis patients.
Duration Duration Historical PASI Simultaneous
Patient Age Sex Arthritis/ Psoriasis/ Subgroup Erosions Knee Skin Score Nail Nail Score Skin and Joint
___________________ years_____years____________________________ Synovitis Severity (0-72) Disease (0-40)_______Exacerbations
1 59 F 27 28 Mutilans y 2 3 4.2 n 0 n
2 62 F 18 10 Polyarthritis y 3 3 4.8 n 0 n
3 53 M 24 36 Polyarthritis y 1 2 4.2 y 4 y
4 40 M 6 16 Polyarthritis y 2 2 4.4 y 17 n
5 38 M 7 8 Oligoarthritis n 1 2 2.1 y 6 n
6 20 F 6 8 Oligoarthritis n 3 1 2.7 y 7 y
7 30 M 26 9 Polyarthritis n 1 3 4.1 y 0 y
8 62 M 22 22 Polyarthritis y 3 3 1.2 y 5 n
9 42 F 7 20 Oligoarthritis n 1 1 0.6 y 0 n
10 40 M 12 12 Oligoarthritis n 2 2 2.1 n 0 n
11 48 M 20 33 Polyarthritis y 2 2 2.4 y 18 n
12 46 F 15 30 Polyarthritis y 2 2 0.5 y 7 y
13 34 F 6 <1 Polyarthritis y 3 Trivial 0 y 3 n
Patients 3 and 7 had insufficient synovial lymphocytes for quantitative assessment.
Paired skin samples were available on patients 1-8
Historical skin severity and knee synovitis are graded on a three point scale -1 = mild, 2 = moderate and 3 = severe
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TABLE 3: T Lymphocyte densities and percentages of CLA positive
cells in psoriatic arthritis, rheumatoid arthritis synovium and psoriatic skin
Sample
Number
Number of T cells 
per h p f (X40) 
Mean(range)






1 18(11-32) 107 11.2
2 20(13-26) 101 4
3 <1 ND ND
4 92 (32-231) 369 3.8
5 1 0 (8 - 1 1 ) 39 15
6 38(16-55) 269 3.3
7 8 (1-39) 631 7.1
8 4(1-13) 159 34
9 <1 ND ND
10 25(12-40) 253 7.5
11 11(1-53) 310 4.2
12 11(3-21) 157 5.7
13 9(5-13) 53 11
Mean (SD) 22 (25) 307 (173) 9.7 (8.9)
RA Synovium
1 (surgical) 1 (0-45) 362 14
2 44 (33-52) 261 2.7
3 16(9-25) 197 10
4 7(3-11) 51 3.9
5 41(19-67) 285 4.9
6  (surgical) 27(11-65) 348 14.4
7 30 (21-38) 180 2 .2




1 10(5-14) 52 51.9
2 11 (6-16) 56 46.4
3 17(7-34) 121 41.3
4 21 (13-26) 170 50.6
5 23 (3 - 58) 132 56.1
6 35 (19-66) 283 57.6
7 12 (6-24) 167 32.3
8 25 (11-40) 197 48.2
9 35(13-47) 21 2 42.9
Mean (SD) 19(9.6) 147 (74) 47.5 (7.9)
Psoriasis
1 26 (6-15) 104 43.3
2 36 (24-39) 254 57.8
3 11 (8 -2 0 ) 100 38
4 20(9-28) 256 39.5
5 6 (2-11) 51 60.8
6 24 (17-39) 166 75.3
Mean (SD) 21 (1 0 .1) 155 (85.5) 52.4 (14.7)
*Psoriatic synovial samples 1 - 8  are paired with psoriatic arthritis skin 
samples 1 - 8 .
ND = not done
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TABLE 4. Number of vessels per field, expression of E selectin and density of perivascular
infiltrate in psoriatic arthritis, rheumatoid arthritis synovium and all skin samples.
Number Number of Vessels 
















1 10 30 33 1 1.93
2 4.3 18 50 0.65 1.35
3 ND ND ND ND ND
4 4.3 13 0 0 0.85
5 ND ND ND ND ND
6 4.2 25 16 0.2 0.76
7 7.1 50 0 0 1.2
8 8.75 70 13 0.65 1.35
9 ND ND ND ND ND
10 6.5 65 35 0.54 1.37
11 4.5 18 22 0.22 1.22
12 10 10 0 0 0.2
13 10 10 20 0.2 1.3




1 (surgical) ND ND ND ND ND
2 5 10 50 0.7 0.7
3 5.5 11 9 0.09 0.36
4 ND ND ND ND ND
5 15.3 92 64 1.38 1.63
6 (surgical) 5.9 142 48 0.77 0.77
7 2.3 7 0 0 2.86
8 6.9 104 62 1.31 1.14




1 3 9 100 2.44 1.56
2 5 45 100 2.06 0.66
3 8.3 33 100 1.82 1.39
4 3.9 27 100 2.44 1.19
5 6 30 100 2.67 1.8
6 6.6 39 87 1.66 1.27
7 4.8 43 100 1.95 1.02
8 11.3 102 84 1.95 1.22
9 5 15 100 2.87 2.13
Mean (SD) 6 (2.5) 40.3 (27.7) 96.8(6.4) 2.21 (0.41) 1.36 (0.43)
Psoriasis
1 2.5 10 100 1.6 1.7
2 2.8 14 100 1.29 1.86
3 1.5 12 100 2.5 1.25
4 4 16 94 1.81 1.44
5 4.2 21 100 2.48 1.29
6 3.7 46 100 1.6 1.33
Mean (SD) 3.7 (1.0) 28.8(13.3) 99(2.4) 2.09 (0.5) 1.53 (0.25)
Eczema 1 5.4 27 89 2.3 1.78
Normal 1 3.7 11 18 0.18 0.73
2 2 10 80 0.9 0.6
Mean (SD) 2.9 (1.2) 10.5(0.71) 49(43.8) 0.54(0.51) 0.67 (0.09)
•Psoriatic synovial samples 1 - 8 are paired with psoriatic arthritis skin samples 1 - 8 .  
All sam ples correspond to those in Table 3.
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FIGURE 1
Percentages of T lymphocytes that are CLA positive in psoriasis with and without 




















Photomicrographs of fluorescence dual staining of psoriatic skin and psoriatic 
arthritis synovium, (a) TRITC anti-CD3 labelled lymphocytes in skin psoriasis 
(stained red; green filter) (original magnification X 20); (b) FITC HECA-452 
labelled cells in psoriasis (original magnification X 20). The majority of T 
lymphocytes in the aggregate are CLA positive, (c) TRITC anti-CD3 labelled 
lymphocytes in psoriatic arthritis synovium (stained red; green filter) (original 
magnification X 40) ; (d) FITC HECA-452 labelled cells in psoriatic arthritis 
synovium (stained green; red filter) (original magnification X 40). Almost all the 
lymphocytes are CLA negative. A rare pair of dual-stained lymphocytes are shown 
(long arrows). A non-lymphocytic cell labelled with the HECA-452 monoclonal 
antibody is also shown (short arrow).
The bar represents 100pm.
FIGURE 3a - c
Differing intensities of E-selectin expression on vascular endothelium in (a) 
psoriasis, (b) rheumatoid arthritis synovium and (c) psoriatic arthritis synovium. A 
typical vessel in each section is indicated by the arrows.







A representative two-dimensional flow cytometric profile of lymphocytes from the 
peripheral blood of a patient with rheumatoid arthritis. The upper left quadrant 
shows CD3 positive /HECA-452 negative lymphocytes; the upper right quadrant 
shows dual-stained CD3 positive/ HECA-452 positive lymphocytes and the lower 
right quadrant shows single-stained CD3 negative/HECA-452 positive lymphocytes. 





Patients with psoriatic arthritis provide a unique opportunity for studying tissue 
specific homing mechanisms that contribute to chronic inflammation. I have 
obtained paired samples of chronically inflamed skin and synovium from such 
patients, which span all the patterns and severities of peripheral joint disease with 
the common features of knee synovitis and active skin disease. Our major finding is 
that there is a significantly greater percentage of CLA positive lymphocytes in 
psoriatic skin compared with synovium in psoriatic arthritis, and that this difference 
is independent of the clinical characteristics. The data confirms previous evidence 
that the CLA molecule is enriched only on skin-homing T lymphocytes (Picker et 
al,1990) and is similar to the results reported in another recent study of psoriatic 
arthritis (Pitzalis et al 1996). Differential expression of the CLA antigen represents 
the single most prominent difference between the T lymphocyte infiltrate in psoriatic 
skin and synovium. Furthermore there was no significant difference in the numbers 
of CLA positive T lymphocytes in peripheral blood between psoriatic arthritis, 
rheumatoid arthritis and normal healthy control patients. I conclude that there does 
not appear to be any circulating clonal expansion of CLA positive lymphocytes in 
patients with psoriatic arthritis.
The lack of association between the expression of the CLA molecule in psoriatic 
skin and synovium may be consistent with existing observations regarding the link 
between psoriasis and arthritis. For instance there is no association between the type 
or distribution of skin involvement and arthritis subgroup (Jones et al 1994 and 
Chapter 2a). Also a pattern of joint disease typical of mutilating psoriatic arthritis 
may occur without skin disease or with nail disease only (O’Neill et al 1992). In the 
majority of patients the skin disease presents first and although up to 35% of patients 
report exacerbations of both skin and peripheral joint disease joint disease, this 
temporal relationship only occurs slightly more often than would be expected by
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chance (Gladman et al 1987, Chapters 2b and c). The prospective study of Chapter 
2c shows that a temporal relationship is only found consistently in a small minority 
of patients. In the current study, I have included two patients who reported 
simultaneous exacerbations of skin and joint disease, one of whom had a higher 
percentage of CLA positive lymphocytes than any other synovial sample; however 
the intensity of expression was noted to be less than in skin psoriasis. In previous 
work one sample of liver was found to have 40% CLA positive T lymphocytes 
(Picker et al 1990). Our patient had a severe active synovitis in his knee suggesting 
that during acute inflammation general mechanisms might overide specific homing 
mechanisms.
E-selectin is up-regulated on the vascular endothelium of inflammatory skin lesions 
(Groves et al 1991) as well as other inflammatory sites (Bevilacqua et al 1994). The 
increased intensity of its expression in psoriatic skin compared with synovium found 
in the present study is similar to that previously reported by some (Veale et al 1995), 
but not others (Pitzalis et al 1996). Although the increased expression of E-selectin 
in skin may have a bearing on the greater expression of CLA on lymphocytes in 
skin, there was no significant correlation between E-selectin expression and the 
percentage of CLA positive lymphocytes. E selectin also binds neutrophils via the 
Sialyl Lewis X moiety, so its expression could reflect neutrophil diapedesis 
prominent in psoriatic skin but not synovium. In addition the reduction in mean 
vascular E-selectin intensity in psoriatic arthritis compared with rheumatoid arthritis 
was similar to that found previously (Veale D et al 1993). We have also studied E - 
selectin expression in osteoarthritis and found small quantities, similar to that found 
in the normal synovium of amputees (Fairbum et al 1993).
The CLA antigen is not specific to psoriasis but occurs in high percentage in normal 
and all inflammatory skin conditions (as we have found by studying normal skin and 
eczema). The remarkable similarity in the percentages of CLA positive lymphocytes
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in all our patients also suggests that the molecule is not specific to psoriasis but is 
globally present on the majority of T lymphocytes in all skin, independent of the 
lymphocyte density. CLA is not present on virgin T cells but is up-regulated on a 
subset of T cells undergoing the virgin to memory transition in secondary lymphoid 
tissues (Picker et al 1993). Upregulation of CLA occurs in a highly regulated tissue- 
selective manner . For example, CLA is upregulated on over half of the T cells 
undergoing the virgin to memory transition in skin-associated peripheral lymph 
nodes but on fewer than 10% of transitional T cells in the mucosa of the small 
bowel. In addition CLA expression seems to be further up-regulated when memory- 
effector T cells are reactivated in skin, indicating that the local microenvironment at 
the time of T-cell activation acts to influence the homing receptor repertoire of the 
resultant memory-effector cells.
Conclusions
I conclude that the study supports the hypothesis that the CLA population of 
lymphocytes is essentially specific to skin, even when skin and an extra-cutaneous 
site of inflammation occur simultaneously in the same patient, as in psoriatic 
arthritis. Therefore there is no evidence to suggest that skin psoriasis and arthritis are 
linked through a common mechanism involving CLA T lymphocyte interactions 
with E-selectin. It remains possible that skin and joint disease in psoriatic arthritis 
could be linked through an undiscovered adhesion receptor for a particular T 
lymphocyte subset, or by a common T cell antigen. The topographic association of 
nail disease and distal interphalangeal joint disease still requires explanation, and 
examination of the distal interphalangeal joint and nailbed tissue itself may be the 
only way of determining related immunopathology. As skin disease usually 
precedes joint disease, knowledge of genetic susceptibility factors and mechanisms 




LIPOPROTEINS AND THEIR SUBFRACTIONS IN PSORIATIC 
ARTHRITIS : IDENTIFICATION OF AN ATHEROGENIC 
PROFILE WITH ACTIVE JOINT DISEASE 
SUMMARY
Introduction. Dyslipoproteinaemia may be relevant in the management and 
ultimate outcome of patients with psoriatic arthritis.
Hypothesis. Dislipoproteinaemia occurs in psoriatic arthritis and may be related to 
disease activity and atherogenic potential.
Study Aims, (i) To characterise the lipid profile in psoriatic arthritis and investigate 
whether there are similarities to the dyslipoproteinaemia reported in rheumatoid 
arthritis and other inflammatory forms of joint disease, (ii) to investigate whether 
there is an atherogenic lipid profile in psoriatic arthritis, which may have a bearing 
on mortality.
Study Design. Cross-sectional.
Methods. Fasting lipids, lipoproteins and their subfractions were measured in 50 
patients with psoriatic arthritis and their age and gender matched controls.
Results. High density lipoprotein-cholesterol (HDL-cholesterol) and, specifically, 
its third subfraction, HDL-3-cholesterol, were significantly reduced in the 
psoriatic arthritis patients. The most dense subfraction of low density lipoprotein 
(LDL), LDL-3, was significantly increased in the psoriatic arthritis patients. Twenty 
patients with active synovitis had significantly lower total cholesterol, LDL- 
cholesterol and HDL-3-cholesterol than their controls. Twenty-five % of the 
psoriatic arthritis patients had elevated Lipoprotein (a) (Lp(a)) levels (> 300mg/l) 
compared with 19% of controls, athough this did not reach statistical significance.
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Conclusion. Elevated levels of LDL-3 combined with low levels of HDL- 
cholesterol are associated with coronary artery disease. We report such an 
atherogenic profile in a chronic inflammatory form of arthritis, which may be 
associated with accelerated mortality.
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INTRODUCTION
Metabolic factors may be of significance in the management and ultimate outcome 
of psoriatic arthritis patients. Patients with rheumatoid arthritis have an accelerated 
mortality compared with the general population, which may be attributed in part to 
an increased risk of cardiovascular disease (Pincus 1995). Active rheumatoid 
arthritis is associated with an abnormal lipid profile (dyslipidaemia). Altered 
concentrations of serum (London et al 1963, Rossner and Lofmark 1977, Lorber et al 
1985, Lazarevic et al 1992, Svenson et al 1987), and synovial lipids (Winyard et al
1993) and lipoproteins may occur including a reduced serum cholesterol (London et 
al 1963), decreased serum triglycerides (Rossner and Lofmark 1977, Lorber et al 
1985, Lazarevic et al 1992, Svenson et al 1987) and altered apoprotein 
concentrations (Rossner and Lofmark 1977). In addition decreased cholesterol in 
LDL, and cholesterol in HDL have been found, especially in association with active 
disease (Lorber et al 1985). The causes of mortality in psoriatic arthritis patients is 
less well documented, although there is evidence that psoriatic arthritis may be 
associated with an increased risk (Wong et al 1997). A pattern of 
dyslipoproteinaemia similar to that seen in rheumatoid arthritis has previously been 
reported in psoriatic arthritis, which normalises with a reduction in disease activity 
(Lazarevic et al 1992).
Routine plasma lipid measurement, which does not take account of lipoprotein 
composition may not identify patients with risk factors for atherosclerosis. Increased 
knowledge of lipoprotein composition and the identification of lipoprotein 
subtractions has added to our understanding of the mechanisms of metabolic 
disturbance in lipid disorders (Lindgren et al 1972). Detailed lipoprotein 
composition has not been previously measured in studies of arthritis. In population 
studies, a low HDL-cholesterol associated with a high LDL-cholesterol has been 
associated with an increased risk of atherosclerosis (Castelli et al 1986). The
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smallest, most dense component of LDL, ( LDL-3), is the most important factor in 
contributing to atheroma (Austin et al 1988). Lipoprotein (a) (Lp(a)) has also 
emerged as an independent contributing factor to the risk of arteriosclerosis 
(Rosengren et al 1990, Terres et al 1995, Maher and Brown 1995). Increased levels 
of Lp(a) have been found in rheumatoid arthritis, but have not previously been 
measured in psoriatic arthritis (Rantapaa-Dahlqvist et al 1991).
The objectives of this study were firstly to characterise in detail lipoprotein 
composition, including Lp(a), in psoriatic arthritis and investigate whether there are 
similarities to the dyslipoproteinaemia reported in rheumatoid arthritis and other 
inflammatory forms of joint disease; secondly to investigate whether there is an 





Fifty patients attending the psoriatic arthritis clinic at the Royal National Hospital 
for Rheumatic Diseases were studied. All patients had psoriasis, an inflammatory 
arthropathy and were sero-negative for rheumatoid factor. Age and gender matched 
controls were obtained from a concurrent local population survey and demographic 
details for both patients and controls are shown in Table 1. The exclusion criteria for 
patients and controls were diabetes, hypothyroidism, renal disease, alcoholism, 
current treatment with a lipid lowering agent, admission to hospital with a severe 
illness within the previous three months, pregnancy and breast feeding. Any other 
concurrent or previous illness known to affect the lipid profile (infection, 
malignancy, gout, ischaemic heart disease or liver disease) was recorded. Present 
and previous medication were noted for all patients with particular reference to oral 
corticosteroids, retinoids, thiazides, beta-blockers, oral contraceptives and hormone 
replacement therapy. Four patients in the control group had a history of gout but 
were not hyperuricaemic at the time of the study. All patients and controls were 
eating a normal Western diet. Body mass indices (kg/m^) were calculated on all 
patients. Blood samples were taken from all patients after a 14 hour fast, centrifuged 
within two hours of collection and kept at -20^C until analysis. Samples for 
ultracentrifugation were analysed immediately.
Assessment o f Disease Activity
The inflammatory markers plasma viscosity, ESR and C-reactive protein (CRP) 
were measured in all patients. Active disease were defined as at least one clinically 
inflamed joint which was both swollen and tender. All of these patients had either an 
elevated ESR (>20 mm/hr) and/ or viscosity (>1.72mpas) and/or CRP (>0.01g/l) 
although this was not used to determine disease activity. The psoriasis area and
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severity index (PASI) was used to document the severity and activity of skin disease 
(Camp 1992).
Measurement o f Lipoproteins
Automated measurements were performed using an Abbott VP supersystem 
autoanalyser (Abbott Diagnostic Division, Maidenhead, UK). Lipids and 
lipoproteins were measured by standard precipitation techniques. Briefly, very low 
density lipoprotein (VLDL), total high density lipoprotein (HDL) and its third, most 
dense subtraction (HDL-3) were prepared by precipitation with sodium dodecyl 
suphate, Heparin-Manganese Chloride (MnCl2) and dextran sulphate respectively.
Cholesterol and triglyceride were measured in these subfractions by cholesterol 
oxidase para-amino-antipyrene (CHOD-PAP) and glycerol phosphate oxidase para- 
amino-antipyrene (GPO-PAP) enzymatic colorimetric methods (Boehringer , 
Mannheim, Germany) (inter-assay coefficients of variation (CV) 4% and 5%, and 
intra-assay CV 3% and 2% respectively). HDL-2 (density = 1.063-1.125g/ml) was 
calculated by subtraction of HDL-3 (density = 1.125-1.210g/ml) from total HDL. 
LDL- cholesterol and LDL- triglyceride were calculated by subtraction of the 
directly measured HDL and VLDL fractions from total serum cholesterol and 
triglyceride.
Apolipoprotein Al and apolipoprotein B were measured by electro-immunodiffusion 
in agarose gel (Sebia, Issy-les-Moulineaux, France). Lp(a) was measured in 45 
patients by ELISA (TintElize Lp(a), Biopool, Sweden: Box 1454, S-901 24 Umea) 
(assay range 0-800 mg/1).
Measurement o f Lipoprotein Subfractions
In 13 patients with active psoriatic arthritis from the total patient group and 13 age 
and gender-matched healthy volunteers, blood samples were fractionated by 
cumulative flotation ultracentrifugation based on the methodology described by
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Lindgren et al (1972). Briefly, plasma was adjusted to a density of 1.118g/ml by 
adding solid sodium chloride (NaCl). Two mis of density adjusted plasma was 
layered onto the surface of 0.5 ml of a 1.182g/ml NaCl/sodium bromide density 
solution in an ultracentrifuge tube. The following density solutions were layered on 
the surface of the plasma: 1ml of 1.0988g/ml followed by 1ml of 1.086g/ml, 2ml of 
1.079g/ml, 2ml of 1.0722g/ml, 1.5ml of 1.0641g/ml and finally 1.5ml of 
1.0588g/ml, Ultracentrifugation was carried out in a SW41 Ti rotor at 23°C. Seven 
consecutive runs were performed, calculated to float lipoproteins of the following 
flotation rates (Sf = Svedberg flotation units) to the top of the tube:- Chylomicrons 
(S£>400), three subtractions of very low density lipoprotein (VLDL) VLDL-1: Sf 
100-400, VLDL-2: Sf 60-100, VLDL-3: Sf 20-60, and three subfractions of low 
density lipoprotein (LDL):- LDL-1: sf 12-20, LDL-2: sf 6-12, LDL-3: sf 3-6. After 
each run, chylomicrons, VLDL-1, 2 and 3 were aspirated from the top 0.5mls of the 
tube and LDL-1, 2 and 3 were aspirated from the top 1.0ml of the tube, and the tube 
refilled with the same amount of density solution (1.0588/ml). The cholesterol and 
triglyceride components of these subfractions were measured by the enzymatic 
colorimetric methods described above and automated measurements were made 
using the Abbott supersystem VP autoanalyser.
Data analysis
Data was entered onto an Apple Macintosh computer and analysed using Excel, 
Statworks and Multistat statistical packages. Paired t tests were used for continuous 
variables following normality testing and the X2 test for comparing proportions. 
Prior to the analysis the non-normally distributed data including all triglyceride 
fractions and ratios and the VLDL-cholesteral: apolipoprotein B ratio, were 
logarithmically transformed for data analysis, and are given in the text and tables as 
antilogs. Values are presented as m e a n + / -  standard error of the mean for normally 
distributed data or as antilogs (mean +/- standard error of the mean) for non- 
normally distributed data. The Mann-Whitney U test was used for the non-
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Fifty patients with psoriatic arthritis were recruited, 20 of whom met the criteria for 
clinically active peripheral joint disease. The patients spanned a spectrum of disease 
subgroups. All patients had mild skin disease only at the time of the study, and no 
patient had a PASI score greater than 10 (Table 1). The major difference in therapy 
between patients and controls was in the use of NSAIDs in all but two of the 
patients, which are not reported to affect lipid or lipoprotein levels. Psoriasis alone 
may affect serum lipid levels, although usually only when severe (Seishima et al
1994). There were no significant correlations between PASI scores and any lipid 
parameter.
Lipid and lipoprotein concentrations
The lipid and lipoprotein results for 50 patients with psoriatic arthritis, including 20 
patients with active joint disease, and their age and gender-matched controls are 
shown in Table 2. HDL-cholesterol was significantly reduced in the psoriatic 
arthritis patients and the difference was related to cholesterol in HDL-3. Reduced 
cholesterol levels were even more pronounced in the twenty patients with active 
synovitis who were analysed separately. Patients with active arthritis had 
significantly lower total cholesterol, LDL- cholesterol and HDL-3 - cholesterol than 
their controls. The relative overall influence of LDL - cholesterol and HDL - 
cholesterol was expressed by calculating the ratio of serum total cholesterol 
concentration to that of HDL- cholesterol (Table 2). The ratio tended to be higher for 
patients than controls in both the total patient group and those with active disease, 
but did not reach statistical significance.
To assess any proportional changes in cholesterol and triglyceride in patients versus 
controls, the ratios of total cholesterol to triglyceride and their relative proportions in
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each lipoprotein were analysed (Table 2). For the total group of 50 patients, the 
cholesterol: triglyceride ratio in LDL was significantly less than in the control 
subjects, indicating a relative depletion of cholesterol compared with triglyceride in 
this lipopoprotein. There was a similar trend in patients with active arthritis although 
the difference did not reach sifnificance. The total cholesterol: total triglycerid ratio 
and proportions of cholesterol and triglyceride in HDL tended to be lower in the 
patient group, but the differences were not significant. The VLDL- 
cholesterol: VLDL-triglyceride ratio was similar for patients and controls.
Apolipoproteins
There were no significant differences in the apolipoproteins Al and B in the 
psoriatic arthritis patients compared with controls for the total group (Table 2). In 
the 20 patients with active disease, both apolipoproteins tended to slightly lower but 
this was not significant. Apolipoprotein Al is the predominant protein in HDL and 
apolipoprotein B the predominant protein in LDL. Therefore the apolipoprotein 
Al:HDL-cholesterol and apolipoprotein B:LDL-cholesterol ratios were calculated 
and compared for patients and controls. Both ratios tended to be greater for patients 
than controls, but in no case was this significant.
Lipoprotein subfraction composition
Thirteen patients with active joint disease were further studied for lipoprotein 
subfraction composition. Their initial profiles were similar to the 20 patients with 
active disease (data not shown). HDL-cholesterol was again significantly reduced 
compared with controls (1.09 v 1.41 mmol/1; p<0.005).
On analysing LDL sub fraction constituents (Table 3) the major difference between 
psoriatic arthritis patients and controls was an increase in all components of LDL-3. 
There were significantly greater concentrations of total cholestererol, in both its free 
and esterified forms, triglyceride, phospholipid and protein in LDL-3. Thus the total
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mass of LDL (lipid + protein) and LDL-3 :total LDL mass ratio was significantly 
greater in psoriatic arthritis compared with controls (Table 3) and there was a greater 
percentage of LDL -3 in total LDL in psoriatic arthritis (24.8%) compared with 
controls (15.5%)(t-test, p <0.001).
We next analysed the proportions of the various components making up the LDL 
lipoprotein subfractions (Figure 1). All components within LDL-3 were uniformly 
increased with no disproportion compared to controls, apart from an increase in 
phospholipids. However, there was significantly less cholesterol in LDL-1 and LDL- 
2 in patients compared with controls and a concomitant greater percentage of 
triglyceride in LDL-2 (Figure 1).
There were no significant differences between patients and controls in the total mass 
of VLDL-1, VLDL-2 or VLDL-3 subfractions or in the concentration of their 
constituents, but there are some significant differences in the percentage composition 
of the various constituents (Figure 2). There was a trend for the triglyceride, 
cholesterol and phospholipid concentrations in VLDL-1 and its total mass to be 
increased compared with controls (Table 3). The mean proportion of VLDL-1 in 
total VLDL was 22.3% versus 16.5% for controls . Also, the percentage of 
triglyceride in VLDL-3 was significantly reduced in the patients compared with 
controls and there was a trend for an increase in the percentage of triglyceride in 
VLDL-1 (Figure 2).
The chylomicron phospholipid concentration was significantly less in psoriatic 
arthritis compared with controls (Table 3) which was reflected in a significant 
decrease in the percentage composition of phospholipid in chlyomicrons (Figure 2).
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Lipoprotein (a)
There were no significant differences in Lp(a) levels in patients with psoriatic 
arthritis and controls (median 174 mg/1 (range 10 - 800) v 157mg/l (range 10 - 
800)). When the patients with active synovitis were analysed separately, Lp(a) levels 
was found to be increased (median 187 mg/1 v 88 mg/1) but this did not reach 
statistical significance (Mann Whitney U test). Also, 25% of psoriatic arthritis 
patients had Lp(a) levels greater than 300mg/l compared with 19% of the controls 
although the difference in the proportion was not significantly different. A power 
calculation indicates that 360 patients and controls would be required to gain a 
significant difference in the proportion of patients and controls with an Lp(a) of 
greater than 300mg/l. There were weak positive correlations between Lp(a) levels 
and ESR (Pearson's r=0.27, p=0.098), plasma viscosity (r=0.27) and CRP (r=0.18).
Conclusions.
The major findings of this study are as follows. High density lipoprotein-cholesterol 
(HDL-cholesterol) and, specifically, its third sub fraction, HDL-3-cholesterol, were 
significantly reduced in the psoriatic arthritis patients. The most dense 
subfraction of low density lipoprotein (LDL), LDL-3, was significantly increased in 
the psoriatic arthritis patients. Twenty patients with active synovitis had 
significantly lower total cholesterol, LDL-cholesterol and HDL-3-cholesterol than 
their controls. Twenty-five % of the psoriatic arthritis patients had elevated 
Lipoprotein (a) (Lp(a)) levels (> 300mg/l) compared with 19% of controls, athough 
this did not reach statistical significance.
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TABLE 1. Clinical Details of 50 patients and controls with specific 
reference to factors known to affect lipids.
Factor Patient Control
Mean Age (years/range) 44.8 (20-72) 44.8 (20-72)
Sex (M/F) 21/29 21/29
Mean Body Mass Index (SD) 25.8 (5.6) 24.6 (4.7)
PASI Score (Mean/range)






History of Gout 0 4
Topical dovanex 1 0
NSAIDs 48 0
Oral Contraceptive 0 5





No patient or control had concurrent infection, malignancy, ischaemic heart 
disease, liver disease or was taking corticosteroids or retinoids.
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TABLE 2. Lipid and lipoprotein concentrations in 50 psoriatic arthritis patients and 20 
patients with active diseases and their age and sex matched controls.





Patients with Active 
Disease (N=20) Controls
Mean Aqe/vears (range) 44.8 (20-72) 44.8 (20-72) 42.5 (20-72) 42.5 (20-72)
Total Cholesterol (mmol/L) 5.43 (0.2) 5.82 (0.13) 4.99 (0.24)*** 6.08 (0 .2 2 )***
VLDL-Cholesterol (mmol/L) 0.51 (0.05) 0.49 (0.04) 0.44 (0.05) 0.51 (0.04)
LDL-Cholesterol (mmol/L) 3.67 (0.19) 4.0 (0.1) 3.3 (0.25)* 4.12(0.25)*
HDL-Cholesterol (mmol/L) 1.12(0.05)* 1.29 (0.1)* 1.09 (0.05) 1.33 (0.1)
HDL-3 Cholesterol (mmol/L) 0.62 (0.04)*** 0.75 (0 .02)*** 0.62 (0 .1)* 0.77 (0.09)*
HDL-2 Cholesterol (mmol/L) 0.52 (0.03) 0.57 (0.04) 0.49 (0.18) 0.56 (0.17)
Total Cholesterol: HDL Cholesterol 5.40 (0.34) 5.14(0.47) 5.30 (0.65) 4.86 (0.33)
Total Triglyceride (mmol/L) 1.15(1.09) 1.13(1.07) 0.99(1.14) 1.35(1.1)
VLDL-Triglyceride (mmol/L) 0.30 (1.15) 0.32 (1.13) 0.25 (1.22) 0.35(1.27)
LDL-Triglyceride (mmol/L 0.63 (1.1) 0.52 (1.1) 0.53(1.16) 0.59(1.13)
HDL-Triglyceride (mmol/L) 0.23 (1.04) 0.25 (1.15) 0 .2 1  (1.06) 0.24 (1.11)
Total Cholesterol: 
Total Triglyceride
4.57 (1.07) 5.00 (1.07) 4.95(1.65) 4.44(1.51)
VLDL-Cholesterol:
VLDL-Triglyceride
1.35(1.07) 1.36 (1.07) 1.36(1.65) 1.23(1.84)
LDL-Cholesterol:
LDL-Triglyceride
5.47 (2.23)** 7.40 (1.07)** 5.75 (1.86) 6.69(1.49)
HDL-Cholesterol:
HDL-Triglyceride
4.76 (1.05) 4.95 (1.20) 4.71 (1.54) 5.26 (1.55)
Apolipoprotein A1 (mg/dl) 137 (4.22) 137 (4.88) 134(4.22) 145 (4.88)
Apolipoprotein B (mg/dl) 80 (3.68) 78 (5.86) 71 (3.68) 83 (5.86)
Apolipoprotein A1 : HDL-C 132(6.8) 115(6.2) 138(16.7) 111 (4.16)
Apolipoprotein B : LDL-C 24 (2.2) 19.9(0 .92) 25 (4.68) 21  (1 .1 2 )
Significant results for psoriatic arthritis patients versus controls: 
* p<0.05; ** p<0.01; *** p<0.005.
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TABLE 3. Concentration of cholesterol, triglyceride, phospoholipid and protein of each lipoprotein subfraction 
and their total mass for patients with psoriatic arthritis and controls (N=13).




Triglyceride Phospholipid Protein Total m ass
Patient Control Patient Control Patient Control Patient Control Patient Control
Chylomicrons 0.12(0.03) 0 .1 1 (0 .0 2 ) 0.36 (0.13) 0.45 (0.14) 0.05 (0.01)* 0.37 (0.15)* 0.18(0.03) 0.35 (0.18) 0.65 (0.16) 1.28 (0.29)
VLDL-1 1.82 (0.59) 1.05 (0.27) 14.5 (4 .4 4 ) 7.62(1.48) 2.8 (0.9) 1.06 (0 .2 ) 1.81 (0.59) 1.19(0.32) 20.94 (6.49) 10.92 (1.99)
VLDL- 2 3.09 (1.05) 2.08 (0.41) 15.5(4.48) 11.62 (2.09) 4.2 (1.3) 2.46 (0.33) 2.99 (0.89) 2.1 (0.34) 30.65 (18.35) 12.38 (3.03)
VLDL- 3 ‘ 9.67 (2.66) 7.79 (1.43) 20.88 (4.83) 16.38 (1.94) 9.89 (2.37) 7.03 (1.05) 7.0(1.88) 6.0(0.85) 45.22 (12.04) 35.52 (3.96)
LDL-1 13.95 (1.85) 15.24 (1.86) 9.49 (1.15) 7.68 (0.81) 9.99 (1.12) 9.12(1.25) 9.56 (0.9) 9.03 (0.97) 42.99(4.51) 41 (4.51)
LDL- 2 55.92 (2.99) 65.96 (4.92) 10.77 (1.33) 8.48 (1.03) 34.49 (3.17) 37.59 (2.95) 39.95(1.96) 40.99 (2.66) 142.8 (9.46) 153.6 (9.97)
LD L-3 25.59 (3.81)** 14.53 (0.79)** 4.02 (0.67)** 1.92 (0.23)** 13.98 (3.39)* 7.28 (0.72)* 20.74 (3.42)* 11.92 (0.91)* 61.9 (10.61)* 35.65 (2.18V
Significant results for psoriatic arthritis patients v controls: 
* p< 0.05; ** p<0.01
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LDL-1 Patients LDL-1 Controls
■ Cholesterol 
Triglyceride
■  Phospholipid 
a  Protein
LDL-2 Patients LDL‘ 2 C ontrols
LDL-3 P atien ts LDL-3 C ontrols
Figure 1. Percentage composition of cholesterol, triglyceride, phospholipid and protein 
in LDL for patients with psoriatic arthritis and controls.
Results given as mean (SEM); * denotes significant result.
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Figure 2. Percentage composition of cholesterol, triglyceride, phospholipid and protein in 
chylomicrons and VLDL for patients with psoriatic arthritis and controls.
Results given as mean (SEM); * denotes significant result.
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DISCUSSION
A pattern of dyslipidaemia similar to that found in rheumatoid arthritis has been 
reported in patients with psoriatic arthritis. Lazarevic et al (1992) studied 40 patients 
with psoriatic arthritis and found decreased concentrations of total lipids, total 
cholesterol, cholesterol in LDL, and cholesterol in HDL which normalized with a 
reduction in disease activity. In our current study, we have also found significantly 
reduced total cholesterol, LDL- cholesterol and HDL- cholesterol and the 
generalised supression of total cholesterol, LDL and HDL cholesterol was most 
apparent in those patients with active joint disease. In addition there was a 
significant elevation of LDL-3 total mass and its cholesterol and triglyceride 
components, and a tendency for Lp(a) to be increased. Neither of the lipid particles 
LDL-3 or Lp(a) have been previously studied in psoriatic arthritis.
A decrease in total LDL-cholesterol observed in our study group may imply 
protection from atherosclerosis. However, patients with active psoriatic arthritis had 
a significant shift in distribution towards the smallest, most dense particles of LDL 
(LDL-3), with normal or low levels of LDL-1 and LDL-2. LDL-3 constituted 24.8% 
of total LDL compared with 15% of controls. These findings have clinical relevance 
because high levels of LDL-3 in relation to LDL-1 and LDL-2 are strongly 
associated with atherosclerosis in population studies (Austin et al 1988). A similar 
pattern has been reported in non-insulin dependent diabetes mellitis in which LDL- 
cholesterol may be normal or reduced in association with excess small dense LDL-3 
and low HDL-cholesterol (James et al 1994, Barrett-Connor et al 1983). The shift in 
LDL composition is much more marked in diabetes mellitis where the percentage of 
LDL-3 in total LDL may reach 40%. In diabetes the shift is associated with 
hypertriglyceridaemia and increased VLDL-1. High levels of VLDL-1 may be more 
slowly catabolised, particularly if there is reduced lipoprotein lipase activity. High 
levels of VLDL-1 encourages increased neutral lipid transfer of cholesterol ester
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from HDL and LDL to VLDL, in exchange for triglyceride, leading to small dense 
LDL (LDL-3). In the current study, there were no significant differences in the total 
triglyceride levels or the concentration of VLDL subfractions compared with 
controls; however there was a trend for a slightly greater proportion of VLDL-1 in 
relation to VLDL-2 and 3 which suggests that the postulated mechanism in diabetes 
may be operating to some extent in active psoriatic arthritis.
The combination of a low HDL-cholesterol and a high LDL-3 found in the current 
study is strongly associated with an increased risk of atherosclerosis in population 
studies (Regnstron et al 1992). There are a number of mechanisms whereby 
increased LDL-3 may cause atherosclerosis. LDL-3 becomes rapidly oxidised and 
has an enhanced ability to cross cell surfaces where it may be directly toxic to 
endothelium. The clearance of LDL-3 from the circulation by the LDL receptor 
mechanism may also be impaired making more LDL available for removal by the 
atherogenic scavenger pathway (Nigon et al 1992). In the arterial wall, the resulting 
lipid-rich macrophages become foam cells that accumulate in early atheromatous 
lesions. An association between the susceptibility of low-density lipoproteins to 
oxidation in vitro and the extent of atherosclerosis of coronary vessels has been 
demonstrated (Campos et al 1992).
Lp(a) is an independent risk factor for atherosclerosis and thrombosis with values 
above 300mg/l associated with a twofold increased risk of myocardial infarction 
(Rosengren et al 1990) and an accelerated progression of coronary atheroma (Terres 
et al 1995). Its mode of action is thought to be related to homology with 
plasminogen resulting in inhibition of fibrinolytic activity and increasing the 
likelihood of thrombosis. Increased levels of Lp(a) have been reported in rheumatoid 
arthritis, where it may behave as an an acute phase protein (Maher and Browm 
1995). Our results show a similar pattern with a slight increase in Lp(a) levels and
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weak positive correlations with inflammatory markers, although none of the 
differences reached statistical significance.
Lipoproteins exist as packages containing predominantly cholesterol, triglyceride 
and apolipoproteins. The synthesis and catabolism of each constituent can proceed 
independently of the other contents of the package, although a certain amount of 
covariance exists. LDL cholesterol and triglyceride may be high or low, without any 
change or with an opposing change in apolipoprotein concentration. Apolipoprotein 
Al is the predominant apolipoprotein in HDL, constituting 60% of the protein mass, 
and apolipoprotein B the predominant apolipoprotein in LDL and VLDL, 
constituting 90% of the protein mass of LDL. LDL and VLDL have one 
apolipoprotein per lipoprotein package, so apolipoprotein concentration is an 
indication of the number of particles present. Lower apolipoprotein Al and high 
apolipoprotein B have been found in association with coronary artery disease. The 
apolipoproteins apo Al and apo B in the psoriatic arthritis patients were not 
significantly different from controls, although they tended to be lower in the active 
group, perhaps partly reflecting the generalized reduction in cholesterol and 
cholesterol-associated lipids. This notion is supported by the apolipoprotein Al: 
HDL-cholesterol and apolipoprotein B: LDL-cholesterol ratios which tended to be 
greater in the patients than controls, reflecting a greater relative suppression of 
HDL-cholesterol than apolipoprotein Al and LDL-cholesterol than apolipoprotein 
B.
There are a number of reasons why dyslipidaemia may be associated with an active 
inflammatory arthritis. An increased production of acute-phase proteins by the liver 
in inflammation may occur at the expense of lipoprotein production, thereby tending 
to reduce lipoprotein levels (London et al 1963). Enhanced reticulo-endothelial 
system uptake of lipoproteins in chronic inflammation may occur, which is 
compatible with an accelerated atherosclerotic process at the vessel wall (Svenson et
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al 1987). Mediators of inflammation, such as the interferons (a,p,%) , C-reactive 
protein and the pro-inflammatory cytokines interleukin 1 and TNFa produced by 
macrophages have been shown to suppress lipoprotein lipase activity and increase 
oxidative metabolism (Ilowite et al 1988, Ogawa et al 1989, Spriggs et al 1988, 
Fried et al 1989, Beutler and Cerami 1985, Rosenzweig et al 1987, Rowe et al 1984). 
Reduced levels of the anti-oxidant selenium has also been found in psoriatic arthritis 
(Azzini et al 1995).
The increased suppression of HDL-3 in relation to HDL-2 and total HDL also 
requires explanation. The triglyceride-rich HDL-2 is converted to the smaller 
lipoprotein HDL-3 by hepatic triglyceride lipase in the endothelium of hepatic 
sinusoids. Hepatic lipase may be suppressed, possibly by the effects of pro- 
inflammatory cytokines, in active psoriatic arthritis. It is likely that a combination of 
factors related to the systemic inflammatory response may operate in psoriatic 
arthritis to produce the observed pattern of dyspipoproteinaemia.
A reported increase in occlusive vascular disease in psoriasis has lead to various 
studies of lipids and lipoproteins, with conflicting results (Seishima et al 1994). 
Hypercholesterolaemia and/or hypertriglyceridaemia may occur which contrasts 
with the findings in psoriatic arthropathy. Apoliopoprotein B has been reported to be 
low, unchanged or increased in different studies (Seishima et al 1994, Brustein et al 
1976). However an increased prevalence of hypertension, diabetes mellitis, 
impaired glucose tolerance and hyperuricaemia, all of which are known to be 
associated with dyslipoproteinaemia, are associated with psoriasis and may not have 
been adequately controlled in some studies. In addition the severity of psoriasis may 
affect the results (Seishima et al 1994). None of our patients had severe skin disease 
(defined as a PASI score of greater than 30) at the time of the study, making it 
unlikely that psoriasis per se contributed to our findings.
173
Conclusions
To conclude, this is the first report documenting high levels of LDL-3 in relation to 
total LDL in a chronic inflammatory form of arthritis. Lipoprotein composition 
warrants further investigation in rheumatoid arthritis where the increased mortality 
from atherosclerosis is more clearly established. In patients with the pattern of low 
HDL, high LDL-3 and high Lp(a), long term follow up is needed to determine the 




Classification of disease should differentiate and completely describe the spectrum 
of all clinical patterns. None may be universally satisfactory, because every proposal 
derives from studies in locally selected populations. The natural history of the 
disease (eg genetic, environmental, geographic) are dissimilar in different 
populations. The recognition of new subsets should be supported by their different 
genetic or clinical features or by their distinctive prognosis. The perplexities of 
subgroup classification in psoriatic arthritis was discussed in detail in Chapters 2a 
and b and is well recognised in a recent review (Oriente, Biondi Oriente and Scarpa 
1994). The debate regarding the most appropriate method to use continues (Scarpa et 
al 1997).
I divided our patients into six subgroups, based on Moll and Wright’s original 
classification. This remains widely used by clinicians, and continues to be taught to 
students, despite many attempts to gain universal agreement on more homogeneous 
subgroups (Veale et al 1994). The subgroups used in Chapters 2a and b were as 
follows - monoarthritis, DIP joint disease alone, oligoarthritis, polyarthritis, 
spondyloarthritis and arthritis mutilans. The following criticisms can be directed at 
this classification. Firstly, monoarthritis and oligoarthritis, when strictly defined by 
the number of joints involved, may represent an earlier point in the time-course of 
disease than polyarthritis, and may evolve to polyarthritis (Chapters 2a and b). To 
increase subgroup homogeneity, ‘oligoarthritis’ could be loosely defined as ‘fewer 
joint involved than would be expected in rheumatoid arthritis’ in association with 
typical features of psoriatic arthritis such as dactylitis and enthesopathies. 
Polyarthritis should be interpreted as involving many joints, either in association 
with ‘typical features of psoriatic arthritis’ or in a pattern indistinguishable from
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rheumatoid arthritis. Secondly, both distal interphalangeal joint disease and 
spondyloarthritis may occur in the other subgroups of peripheral joint disease 
(Chapter 2a, Veale et al 1994). Thirdly, arthritis mutilans is also a severe form of 
polyarthritis and the key radiographic and pathological finding in this condition, 
osteolysis, may occur in more limited disease involving single joints or a few joints 
only. Lastly, the full spectrum of disease in psoriatic arthritis and in particular the 
associated extra-articular abnormalities may not be covered by these subgroups of 
joint disease. Extra-articular osseous abnormalities were found to be sufficiently 
common by radionucleotide scanning to justify a separate subgroup by Helliwell et 
al (1991) and osteoperiostitis of the great toe has recently been described (Goupille 
et al 1996).
The definition of psoriatic arthritis is important when considering recent proposals 
for further subgroups. Isolated peripheral enthesitis and /or dactylitis has been 
described as a subset of psoriatic arthritis (Salvarani et al 1997). However, the 
patients were seen over a six month period only, and longer follow-up would be 
required to assess whether joint involvement ultimately occurred. One of our 
patients had isolated dactlyitis of the toes at five year follow-up which begs the 
question of whether she was correctly included in the oligoarthritis subgroup when 
first seen in the clinic, ie were the joints or just soft tissue structures involved. 
Strictly speaking, patients with isolated dactylitis do not have an inflammatory 
arthropathy, so would not meet the Moll and Wright criteria for diagnosis, although 
many clinicians would make the diagnosis of psoriatic arthritis in such patients .
It may be difficult to determine whether joints underlying severe dactlylitis are 
involved as the whole digit may be painful and joint movement may be painful and 
restricted. The structures involved in dactylitis in psoriatic arthritis and other 
spondyloarthropathies has been recently assessed by two groups using magnetic 
resonance imaging and ultrasonography with conflicting results (Olivieri et al 1997;
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Kane et al 1997). Olivieri et al assessed toe dactylitis in seven patients and found 
flexor, and less frequently, extensor tenosynovitis. Capsular distension of the joints 
was used as a marker of joint involvement and was uncommon. It occurred in two 
MTP joints only. In a similar study, Kane et al found articular involvement to be 
common, occurring in 56% of patients (Kane et al 1997).
Another recent study has distinguished the arthritis associated with pustular psoriasis 
and psoriatic arthritis (Mejjad O et al 1996) and found anterior chest wall 
involvement to be common, and fewer joints involved. This particular pattern of skin 
disease was rare, occurring in only three of the patients (Chapter 2a and b). One of 
these had chest wall involvement, oligoarthritis and SAPHO (Benhamou et al 1988). 
No other association between the type or severity of psoriasis and a specific pattern 
of joint disease was observed in the studies presented (Chapters 2a, b to c)
Other extra-articular sequelae may occur in psoriatic arthritis. One of the patients 
reported in Chapter 2a and b developed a myelopathy related to neck disease, a 
complication recognised in psoriatic arthritis and recently reported (Agaki et al 1996, 
Sosner et al 1996). Other potentially serious extra-articular complications that have 
been reported, but were not diagnosed in our series include pyoderma gangrenosum 
and secondary amyloid, which has been reported as causing the death of a patient 
with arthritis mutilans (Tsuda et al 1996; Ahmed et al 1996, Smith and White 1994; 
Klunemann et al 1994).
Subgroups should, if possible, be homogeneous with time. The studies presented in 
Chapters 2a and b clearly indicate that subgroups strictly defined on the basis of the 
number of joints involved (oligoarthritis and polyarthritis) evolve from mono- or 
oligoarthritis to polyarthritis, and polyarthritis to mutilans as the disease progresses. 
This evolution of disease subgroups, with deterioration of joint disease over time is 
gaining wider acceptance (Espinoza and Cuellar, 1998). It has also been recognised
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that some patients may have a benign cause with an initial presentation which 
subsides never to recur. Gladman has also reported complete resolution in 7 
patients. This was the case in 4% of our patients , who had no evidence of joint 
involvement at follow-up. A set of prognostic indicators is required, so that patients 
most likely to progress are identified and appropriately treated. This issue has been 
evaluated in detail by Gladman et al (1995) who devised a univariate and 
multivariate risk model for disease progression. One of the most striking clinical 
features in both models is that a low sedimentation rate protects against disease 
progression. The correlation of the baseline viscosity with the rate of progression of 
joint disease in Chapter 2b supports this finding, and suggests that attempts should 
be made to suppress inflammation early in the course of the disease.
The presence of elevated inflammatory markers may be associated with other 
metabolic extra-articular effects, and may even affect cardiovascular mortality 
(Chapter 2b and 4). In the study presented in Chapter 4 dyslipoproteinaemia was 
found in patients with active disease. This included a reduced HDL and high LDL-3, 
which has been related to an increased risk of cardiovascular disease in population 
studies (Austin et al 1988, Regnstron et al 1992). A prospective epidemiological 
study is required to substantiate this.
Nail disease has been consistently found to be increased in patients with psoriatic 
arthritis versus those with psoriasis alone, and may be a susceptibility factor for the 
development of arthritis (Gladman et al 1986). It is of interest that eleven further 
patients had evidence of nail disease at follow-up, with a total percentage of 78% 
(Chapter 2b) and that 87% of the patients included in Chapter 2c had nail disease by 
the end of the study. The association of DIP joint disease with nail disease in the 
same digit has long been recognised (Bauer et al 1941). The study presented in 
Chapter 2a is the first to demonstrate this statistically (Jones et al 1994). A recent 
larger study has confirmed this finding (Kay et al 1997). A variant of psoriatic distal
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inerphalangeal arthritis has recently been described - psoriatic onycho-pachydermo- 
periostitis (Boisseasu-Garsaud et al 1996).
The periodicity or temporal relationship was assessed prospectively for the first time 
in Chapter 2c. A consistent temporal relationship between exacerbations and 
remissions of skin and joint disaese, skin and nail disease and joint and nail disease 
was found in only a minority of patients. This characteristic did not define a subset 
of joint disease or suggest a specific prognosis.
The relationship of the rheumatoid arthritis HLA DRB1 ‘shared epitope’ to 
susceptibility, severity and progression of psoriatic arthritis was assessed in Chapter 
2d. No significant increases in the prevalence of the ‘shared epitope’ was found in 
psoriatic arthritis versus controls and it was concluded that the ‘shared epitope’ does 
not significantly influence the susceptibility to psoriatic arthritis or the severity of 
disease in sero-negative patients. The lack of association with the SE and psoriatic 
arthritis is further evidence of its separate identity from rheumatoid arthritis. The 
under-representation of DR4 and specifically the *0401 allele compared with 
controls suggests that other HLA-DRB1 alleles may have greater importance, such 
as DR7. This allele has consistently been found to be increased in studies of psoriatic 
arthritis (McHugh et al 1987, Eastmond 1994). However, it is also strikingly over­
represented in psoriasis alone. It has been suggested that DR7 may act as a 
protective factor for the development of arthritis (Gladman 1995a).
A possible immunological explanation for the link between skin and joint disease in 
psoriatic arthritis was evaluated in Chapter three. The T lymphocytic infiltrate of 
psoriatic skin and inflamed synovium was examined for the presence of cutaneous 
lymphocyte antigen (CLA) positive cells that are known to occur in large numbers in 
inflamed skin. The data supported previous evidence that the CLA molecule is 
enriched only on skin-homing T lymphocytes (Picker et al 1990), similar to the
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results reported in another recent study of psoriatic arthritis (Pitzalis et al 1996). 
Differential expression of the CLA antigen represents the single most prominent 
difference between the T lymphocyte infiltrate in psoriatic skin and synovium.
Differences in the T lymphocyte infiltrate may be consistent with existing 
observations regarding the link between psoriasis and arthritis. For instance there is 
no association between the type or distribution of skin involvement and arthritis 
subgroup (Jones et al 1994 and Chapter 2a and b). Also, a pattern of joint disease 
typical of mutilating psoriatic arthritis may occur without skin disease or with nail 
disease only (O’Neill et al 1992). In the majority of patients the skin disease presents 
first and although up to 35% of patients report exacerbations of both skin and 
peripheral joint disease joint disease, this temporal relationship only occurs slightly 
more often than would be expected by chance (Gladman et al 1987, Chapters 2b and 
c).
CONCLUSIONS AND FUTURE WORK
Outcome
This Thesis demonstates that psoriatic arthritis is a heterogeneous disease in onset, 
expression and outcome. The arthritis may vary considerably in its pattern and has 
been divided into several subgroups (Moll and Wright 1973, Chapters 2a and b). It 
was once considered a benign disease. This has been shown to be a fallacy. 
Polyarthritis is most common in patients referred to rheumatologists (Chapters 2a 
and b, Wright 1992, Jones et al, 1994) and the majority of patients have progressive 
peripheral joint disease (Gladman et al 1995, Chapter 2b). Radiological damage in 
the hand is progressive in the majority of patients with psoriatic arthritis, especially 
those with widespread damage at baseline.
One of the problems in studying the disease is the lack of agreement between 
researchers on its definition and classification, and different interpretations resulting 
in apparently conflicting clinical data. This needs to be resolved urgently, and a 
formal epidemiological study lead by Deborah Symmons, (epidemiologist and 
Reader in Rheumatology at Manchester University) has been initiated to formally 
resolve this issue. The study will base its criteria for diagnosis on a concensus of 
opinion by International rheumatologists with an interest in psoriatic arthritis, and 
then formally evaluate the criteria by a prospective clinical study.
Mortality of disease in relation to the population is a vital outcome measure and the 
largest study has recently been published by Gladman’s group which had sufficient 
patients and controls to provide cause-specific standardised mortality ratios. This 
needs to be confirmed by British data of similar quality and quantity.
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Link Between Skin, Joint and Nail Disease
This Thesis shows that skin psoriasis and arthritis are not linked through a common 
mechanism involving CLA T lymphocyte interactions with E-selectin. This may 
instead be an important important immunological difference between the skin and 
joints in the disease. It remains possible that skin and joint disease in psoriatic 
arthritis could be linked through an undiscovered adhesion receptor for a particular T 
lymphocyte subset, or by a common T cell antigen.
The topographic association of nail disease and distal interphalangeal joint disease 
still requires explanation, and examination of the distal interphalangeal joint and 
nailbed tissue itself may be the only way of determining related immunopathology. 
Abnormalities of blood vessels, both quantitative and quantitative, may provide an 
explanation for the link between the nail and the adjacent DIP joints. Capillaroscpy 
is a useful clinical tool for examining this. The appearances of the vessels of the nail 
bed in affected and unaffected nails in patients with and without DIP joint disease or 
dactylitis could be compared. This clinical study could be linked to a study 
promoters and inhibitors of angiogenesis, the dysregulation of which may provide an 
explanation for the link.
Immunogenetics
The HLA system is likely to be functionally important in the initiation and 
perpetuation of inflammation in psoriatic arthritis. Study of linked polymorphisms 
with well-defined functions, such as TNFa is potentially exciting and may have 
direct implications for treatment (Al-Heresh et al 1997). The relative contribution of 
the HLA and identification of other candidate genes which may determine 
susceptibility and severity is currently being assessed by linkage studies in AS and 
RA. This would be a complex undertaking in psoriatic arthritis because of disease 
heterogeneity, and the presence of psoriasis. Some patients with psoriatic 
spondyloarthropathy are likely to be included in studies of ankylosing spondylitis
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and patients with rheumatoid arthritis and coincident psoriasis may be included in 
studies of rheumatoid arthritis. However, specific studies in psoriatic arthritis are 
required if a reliable genetic prognostic risk model is to evolve. This would require 
tightly defined diagnostic and classification criteria and a multicentre approach. As 
skin disease usually precedes joint disease, knowledge of genetic susceptibility 
factors in combination with mechanisms linking inflammation at separate sites may 
yet enable joint disease to be predicted and prevented.
Quality o f Life Measures
Psoriatic arthritis has a complex impact on a patient’s social functioning, disability 
and handicap. This impact is dependent on the activity and severity of both joint and 
skin disease. Although skin disease may not correlate closely with joint disease, and 
each may require separate triggers for their expression, an index encompassing both 
manifestations may be useful in determining the overall impact of the disease. It may 
also be useful in assessing the total response to therapeutic agents such as 
methotrexate and cyclosporin that may benefit both manifestations of the disease.
Therapy
The unpredictability of the course of peripheral disease and response to therapy in 
psoriatic arthritis is of major concern to both patient and rheumatologist. Patients 
need continuous access to multidisciplinary care, as well as appropriate early disease 
modifiying therapy. Good prognostic indicators are essential in justifying early 
intervention. Patients with psoriatic arthritis should be included in properly 
designed prospective therapeutic trials of single agents or combinations of agents to 
assess their efficacy and safely, and included in trials of new immuno-active agents.
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Derivation of PASI Score
This is a commonly used scoring system to combine the extent and severity of skin 
lesions (Camp, 1992)
Extent (%) Score Severity Score
<10 1 Nil 0
10-29 2 Slight 1
30-49 3 Moderate 2
50-69 4 Severe 3
70-89 5 Very severe 4
90-100 6
Extent Severity
Erythema Infiltration Desquamation PASI
Head A B C D
0.1(B+C+D)A
Arms A B C D
0.2(B+C+D)A
Trunk A B C D
0.3(B+C+D)A




Derivation of Nail Score
Devised for this study. Hands scored only 
Score = Number of nails with pits +
Number of nails with onycholysis +
Number of nails with hyperkeratosis or salmon patches +
Number of nails with "dystrophy"*
Total = 0 -40
* "Dystrophy" - defined here severe nail deformity involving both sides of the nail.
The score was recorded as follows:-
Right Left









DEVELOPMENT AND VALIDATION OF A MODIFIED 
SHARP’S INDEX FOR THE HANDS IN PSORIATIC 
ARTHRITIS
Radiographic erosions have been used as an important outcome measure in 
rheumatoid arthritis, particularly in the assessment of therapeutic agents (Kirwan 
1995). In rheumatoid arthritis, radiographic hand and wrist damage is thought to 
mirror the overall progression of damage at other joints (Scott et al 1986) and there 
is abundant literature regarding the pattern of damage, progression of damage and 
scoring methods (Fuchs and Pincus 1992; Wassenberg and Rau 1995). In early 
rheumatoid arthritis, 70% of patients have radiological change at three years; at ten 
years radiographic progression is invariable and by twenty years most patients have 
extensive progression despite therapy (Scott et al 1987). Few studies have examined 
this in psoriatic arthritis.
Studies evaluating hand radiographs in psoriatic arthritis have used various systems 
devised for rheumatoid arthritis. The ARA radiological scoring system has been 
used (Torre Alonso et al 1991 and Gladman et al 1987) as has the New York criteria 
(Veale et al 1994). In the prospective follow-up study presented in Chapter 2b, a 
modified version of Sharp’s 1971 scoring system has been used (Sharp et al 1971). 
The system has been validated in rheumatoid arthritis, includes the distal 
interphalangeal joints and is one of the most sensitive scoring systems to detect 
progressive changes (Sharp et al 1985, Pincus et al 1995). A detailed description of 
the index, its modification for psoriatic arthritis and validity is described below and 
should be read in conjunction with Chapter 2b.
Construct, Face and Content Validity
A radiological scoring system for the hands was required to score for the DIP joints 
and wrists as well as the PEP and MCP joints, with sub-divisions for severity of 
erosions and joint space narrowing, and a score for ankylosis. Sharp’s original 
scoring system (1971) was therefore selected as being the only system that met these 
criteria (Sharp et al 1971). It has been well validated in rheumatoid arthritis.
Quantitative differences
The modified Sharp’s index was used to calculate joint space abnormality (JSA) and 
erosion (ERO) scores and to determine the rates of their progression.
Joint space abnormality
In psoriatic arthritis joint space widening due to osteolysis can occur even after 
apparent radiographic ankylosis (pseudoankylosis) (Balakrishnan, Jones et al, 1996 
(see Appendix E)), a phenomenon observed in three patients. Furthermore ankylosis 
and gross jont widening due to osteolysis can occur at different joints in the same 
patient (Gladman et al 1993b). These factors make both ankylosis and gross 
widening probable end points of radiological progression in psoriatic arthritis. Hence 
Sharp’s joint space narrowing (JSN) score was modified, so both these extreme 
lesions were given maximum scores. The JSN score was renamed joint space 
abnormality (JSA) and was calculated as follows:-
1-focal, 2-<50% reduction, 3 - >50% reduction and 4 -ankylosed or widened.
Joints analysed: 14 finger joints, 5 CMC joints, trapezium-navicular, navicular- 
lunate, lunate triquetrum, triquetrum-hamate, hamate-capitate, capitate-navicular- 
lunate, radiocarpals and radioulnar joints. A total of 27 joints areas were assessed 
with a maximum score of 216 per patient.
The JSA index and the rate of progression was calculated as follows:-
Corrected joint space abnormality score (JSAc) = total JSA per film
_________________ X5
216 (maximum score)
Rate of progression of JSA = JSAc
Time in months from onset of psoriatic arthritis (Tl) 
Rate of progression of JSA (baseline to follow up) = JSAc
Time in months between baseline and follow up (T2)
Erosion
The severity of erosions was determined on a 5 point scale: 1 point for each erosion 
up to 4, and for erosions over and above 5 a score of 5 was allotted. The size fo the 
erosion was also taken into consideration to some extent and large denudations 
(>50% fo articular surface area) of articular surface were designated 5 points.
Joints analysed: 14 finger joints, 5 metacarpal bases, 6 carpal bones, lower end 
radius and lower end ulna. A total of 27 joints areas were assessed with a maximum 
score of 270 per patient.
The ratios used for analysis were calculated as follows:-
Corrrected erosion score (defect score, Dc) = total number of erosions per film
________________________  X4
270 (maximum score)
Rate of progression = Dc
T1




Evaluation of the radiographs also allowed documentation of the pattern of 
involvement and other radiological features of interest which have been reported as 
being characteristic of psoriatic arthritis. The following signs have been reported as 
differentiating PsA from RA:- phalangeal tufts, osteolysis, bony proliferation, 
periostitis, asymmetry, apparent joint space widening and bony ankylosis. Juxta- 
articular osteopaenia, soft tissue swelling, DIP and wrist involvement were also 
noted and malalignment was graded as moderate (subluxation) or severe 
(dislocation).
The cumulative scores for erosions and joint space abnormalities at baseline and at 
follow-up increased for all joints except for the joint space abnormality score for the 
proximal interphalangeal joint of the right hand (see Table 5, Chapter 2b). This may 
reflect the inclusion of joint space widening in the joint space abnormality score. For 
example, one patient with mutilating disease had radiographic ankylosis (score 4) 
followed by a reappearance of the joint space (score 0), although the latter
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represented an extension of the pathological process and should possibly have been 
scored as 4 for joint space widening. In this case the length of the phalanx should me 
measured and the contours of the joint carefully assessed so that the appropriate 
score is given.
In the process of scoring, comprehensive information regarding other features could 
be obtained. The progression of these features is detailed fully in Chapter 2b.
Criterion Validity
This requires significant correlations with gold standard or other accepted measures. 
There are no gold standards for the evaluation of hand radiographs in psoriatic 
arthritis. However, other outcome measures including total clinical joint damage 
scores and hand and wrist joint damage scores and the rates or their progression were 
correlated with Sharp’s erosion and joint space abnormality scores.
Discriminant Validity (Responsiveness)
This represents the capacity of an instrument to measure difference of change. The 
modified Sharp’s index is sensitive to change in a singe joint in the hand or wrist.
Reliability and Inter-observer variability
The radiographs in the study presented in Chapter 2b were scored by a single 
observer (CB) after training and reaching agreement with a radiologist (GE). 
Reliability was good. Fifteen radiographs were scored blindly by a second observer 
to assess inter-observer variability (SJ). Without training the differences were large; 
however the differences reduced after training. I recommend that in any large study 
of psoriatic arthritis using multiple scorers, the index is extensively piloted and 
tested first to reduce inter-observer variability.
216
Conclusion
The selection of the index and its modification was deemed sensible in terms of 
clinical knowledge, satisfying the requirements for credibility and relevance. It 
correlated with other measures of joint progression in psoriatic arthritis and was a 
sensitive measure of change. Reliability is good when a single observer is used to 
score all radiographs, but the complexity and detail of the index requires a 
comittment to training when multiple observers are used.
APPENDIX C
Modified Richie and Joint Swelling Scores
The modified Richie scores (70 joints) and joint swelling scores (66 joints) were 
recorded as follows:-
Right Joint Left




































Axial Disease was noted but not scored.
Swelling was either present (score 1) or absent (score 0).
Pain/tenderness was scored as follows: 0 = None; 1 = Minimal (positive response 
on questioning); 2 = Moderate (spontaneous response elicited); 3 = Severe 
(withdrawal by patient on examination)
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Disease Activity Score (DAS) Modified for Psoriatic Arthritis
A disease activity score combining three variables has been validated in rheumatoid 
arthritis (Assessing Joint Activity in Rheumatoid Arthritis, Eular 1993). No 
combined score has been validated for use in psoriatic arthritis, so the Eular score 
was assessed for use, and subsequently employed, in the study of Chapter 2c. The 
four variable disease activity score, using the patient’s global assessment as the 
fourth variable, was clearly inappropriate because this may also reflect skin activity.
In rheumatoid arthritis, a change of 1.08 represents a significant improvement or 
deterioration. Because psoriatic arthritis causes less pain and tenderness than 
rheumatoid arthritis, fewer joints are involved, and the acute phase response is less 
pronounced, a smaller difference between scores would be expected to represent a 
significant change. A single observer, the author, performed all the Ritchie and joint 
swelling metrology after intensive training and practice in the clinic and the intra­
observer variation was low. Hence, for the purpose of this study, any increase in the 
score was deemed to represent a deterioration in disease activity, and any decrease 
an improvement.
The disease activity score was calculated as follows 
Three variables:
DAS = 0.54* (square root (Modified Richie index))




Temporal Relationship Data (Chapter 2c)
The following graphs show the relationship between joint disease activity scores 
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ANALYSIS OF SYNOVIAL TISSUE AND SKIN IN PSORIATIC 
ARTHRITIS 
Information for Patients
We are investigating the link between skin and joint disease in psoriatic arthritis to 
try to improve our understanding of the disease which may lead to improvements in 
treatment in the future.
Synovial tissue is the lining membrane of the joint which becomes inflamed in 
psoriatic arthritis. We wish to examine the composition of the synovial tissue using 
new techniques in the laboratory. We also wish to examine the skin in a similar way.
The synovial biopsy involves removing a small piece of synovial tissue by inserting 
a sharp needle into the knee joint after has been anaesthetised with local anaesthetic. 
This is a routine procedure frequently used to investigate the type of arthritis. 
Following the procedure you will be required to rest your knee in the hospital for 
three hours after which you will be free to go home. If you experience any 
discomfort after the procedure please contact the hospital. This is uncommon but 
occasionally bleeding into the joint can cause inflammation.
Skin biopsy involves removing a small piece of skin form an area involved with 
psoriasis. It is a routine procedure in dermatology and will be performed by a 
dermatologist. It takes a few minutes.
Participation in this study is entirely voluntary and confidential. Should you feel that 
you are not able to take part please feel free to say so. This will not affect your 
continuing or future treatment in any way.
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ANALYSIS OF SYNOVIAL TISSUE IN RHEUMATOID ARTHRITIS
Information for Patients
Synovial tissue is the lining membrane of the joint which becomes inflamed in 
rheumatoid arthritis. We wish to examine the composition of the synovial tissue 
using new techniques in the laboratory.
The synovial biopsy involves removing a small piece of synovial tissue by inserting 
a sharp needle into the knee joint after has been anaesthetised with local anaesthetic. 
This is a routine procedure frequently used to investigate the type of arthritis. 
Following the procedure you will be required to rest your knee in the hospital for 
three hours after which you will be free to go home. If you experience any 
discomfort after the procedure please contact the hospital. This is uncommon but 
occasionally bleeding into the joint can cause inflammation.
Participation in this study is entirely voluntary and confidential. Should you feel that 
you are not able to take part please feel free to say so. This will not affect your 
continuing or future treatment in any way.
Consent
The aims and nature of the study have been satisfactorily explained to me and I 
agree to my participation.
Patient’s Signature: Date:
Signature of Witness: Date:
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PSORIATIC ARTHRITIS: OUTCOME OF DISEASE SUBSETS AND 
RELATIONSHIP OF JOINT DISEASE TO NAIL AND SKIN DISEASE
S. M. JONES,* J. B. ARMAS,* M. G. COHEN,* C. R. LOVELL,t G. EVISONf
and N. J. McHUGH*
* Royal National Hospital for Rheumatic Diseases, Upper Borough Walls, Bath BA11RL and
fRoyal United Hospital, Bath
SUMMARY
Subgroups of PsA have been described but their relationship to the mode of onset of arthritis, to DIP joint disease and to 
nail and skin disease remains controversial. Therefore, the pattern of disease was documented in 100 patients with PsA in 
whom the mode of onset was known. The patients were divided into six subgroups: monoarthritis; DIP joint disease only; 
oligoarthritis; polyarthritis; spondyloarthropathy and arthritis mutilans. Sixty-four patients changed pattern. Nail disease 
(67% of total) was more common in patients with DIP joint disease (27% of total) and was significantly associated with 
adjacent DIP joint disease. Skin and nail disease severity did not correlate with joint severity, joint activity or functional 
status, nor differ between subgroups. Therefore, the mode of onset does not predict outcome in the majority. The topo­
graphic association of nail disease and involvement of the adjacent DIP joints suggests a common local inflammatory 
mechanism.
K ey  w o r d s : Arthritis, Psoriasis, Nail dystrophy, Spondyloarthropathy, Classification.
The assocation between psoriasis and joint disease was 
first recognized by Alibert in 1818 [1] although radio- 
graphic evidence of PsA has been observed in medieval 
skeletons [2]. Despite its antiquity, the distinction of 
PsA from RA and its relationship to the seronegative 
spondyloarthritides have remained a subject for 
debate. The absence of RF in the majority of patients 
with psoriasis and arthritis led to recognition of PsA as 
a distinct entity [3]. The discovery that RA improves 
with the depletion of T helper lymphocytes secondary 
to HIV infection, whereas psoriasis or psoriatic arthro­
pathy get worse [4, 5] supports this distinction. Family 
studies were important in establishing the concept of 
the seronegative spondyloarthritides [6], which share 
common clinical features and have an increased fre­
quency of HLA B27 [7, 8]. However PsA has unique 
features which includes the predominance of a charac­
teristic peripheral arthropathy and a spondyloarthro­
pathy which differs radiologically from AS. In addition, 
HLA B27 is present in less than 50% of patients.
PsA has been divided into subgroups according to 
the distribution and number of joints involved [9]. It is 
unclear whether these subgroups are homogenous with 
time [10, 11]. Also, relatively few series of patients 
hvae been reported in which the relationship between 
the skin, nails and joints has been adequately studied, 
particularly in relation to the topographic association 
of nail and skin disease. In the present study we have 
investigated whether the mode of onset of joint disease 
predicts the ultimate pattern of disease expression. We 
have also assessed in detail the relationship between 
nail and DIP joint disease, and patterns of skin and nail 
involvement in relation to the severity, activity and 
subgroups of joint disease.
Received 21 February; revised version accepted 16 May 1994. 
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PATIENTS AND METHODS
In 1986 a clinic was established at the Royal National 
Hospital for Rheumatic Diseases, Bath to study joint 
disease in patients with psoriasis. We present a cross- 
sectional study of the first 100 patients to attend this 
clinic in whom the mode of onset was known. All 
patients had an inflammatory arthropathy and psoria­
sis. The presence of RF was not used as an absolute 
exclusion criterion because of its lack of specificity for 
RA and its low prevalence in the normal population. 
The majority of patients were referrals from other 
rheumatology clinics, some were new referrals from 
the general practitioner and a minority (less than 10%) 
were referrals from dermatology clinics. All patients 
were seen by a rheumatologist (NJM) and data were 
accumulated using a specially designed form.
The age of onset and the duration of psoriasis and 
arthritis, the family history, the mode and site of onset 
of joint disease and previous and current treatment 
were recorded. The mode of onset referred to the joints 
involved within the first 3 months of symptoms. This 
information was usually well recalled by the patient 
and in most cases confirmed by documentation in the 
rheumatology case notes. However, we acknowledge 
that the absence of a complete record of objective clini­
cal findings at onset may have resulted in an under­
estimate of the number and site of joints involved, 
particularly if some joints were significantly more 
severely involved than others. Conversely, some 
patients may have over estimated the number of 
involved joints if there was pain without objective clini­
cal findings. The initial presentation was subdivided 
using three methods. Firstly five groups were identified; 
monoarthritis, DIP joint disease only, oligoarthritis 
(two to four joints affected), polyarthritis (five or more 
joints affected), and spinal disease. Secondly, the
©  1994 British Society for Rheumatology
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patients were divided by joint size into small joint 
(including hands and feet), large joints of the limbs, 
axial (including the spine and chest wall), and combi­
nations of these. Thirdly, the patients were divided by 
anatomical region into upper limb, lower limb, spinal 
disease and combinations of these.
Peripheral and axial joint involvement was docu­
mented for each patient. The number of active joints 
was documented by a modified Ritchie index (to 
include DIP joints). An index of peripheral joint 
disease severity was obtained by counting the number 
of peripheral joints involved either clinically or radio- 
logically and assessed as mild (fewer than 10 joints), 
moderate (10-20 joints) or severe (>20 joints). The 
pattern of joint disease was analysed in a similar way to 
the mode of onset with the addition of arthritis muti­
lans as a  sixth subgroup. Although symmetry was not 
used to  distinguish subgroups, symmetrical joint 
involvement was defined in two ways; firstly by at least 
one identical joint being involved on both sides of the 
body and secondly in a method devised by Helliwell 
etal. [11]. In the latter method, the number of matched 
pairs of involved joints was related to the total number 
of matched and unmatched pairs and a ratio of 0.5 or 
greater defined symmetry. Functional assessment was 
made using the Stanford Health Assessment Question­
naire (HAQ) [12, 13].
The skin and nails were examined using a predefined 
protocol and performed under the supervision of a der­
matologist (CL). Psoriasis was classified as plaque 
(psoriasis vulgaris), discoid, guttate, localized pustular 
or a combination of these. The distribution of skin 
psoriasis was recorded and the current severity was 
graded according to the Psoriasis Area and Severity 
Index (PASI) score (range 0 to 72) [14]. A nail score 
was determined for each patient, and derived as fol­
lows. Each fingernail was assessed for pitting, onycho­
lysis, hyperkeratosis and severe nail deformity with 
involvement of both sides of the nail (‘dystrophy’). 
Each of the listed features scored one with a possible 
maximum nail score of 40.
Radiological evaluation was performed on clinically 
affected joints. The radiological protocol consisted of 
an anterior-posterior (AP) view of both hands and feet, 
lateral view of both heels, AP view of pelvis, AP view of 
lumbar spine (to include thoraco-lumbar junction) and 
a lateral view of the cervical spine in flexion. All films
TABLE I
Clinical features in 100 patients with PsA
No. of females 57
No. of males 43
Mean age (yr) (range) 49.7 (16-80)
Mean age at onset of skin lesions (yr) (range) 28.9 (3-70)
Mean age of onset of joint disease (yr) (range) 37.6 (5-70)
Psoriasis before arthritis 63
Simultaneous onset 19
Arthritis before psoriasis 18
Mean duration of psoriasis (yr) (range) 20.8 (1-61)
Mean duration of arthritis (yr) (range) 12.1 (1-53)
Family history of psoriasis 39
Nail lesions 67
Iritis 5
were examined by a radiologist (GE) and by a rheu­
matologist (NJM). The detailed radiology of periph­
eral joints, axial and sacro-iliac joints will be reported 
elsewhere.
All information was entered on an Apple Macintosh 
computer. Statistical analysis was performed using 
standard software packages. The %2 test was used for 
comparing discrete variables between subgroups and 
Student’s r-test for comparing continuous variables for 
parametric data; the Mann-Whitney U test was used 
for non-parametric data. Spearman’s rank coefficient 
was used for correlation analysis.
RESULTS 
Clinical characteristics
A ge and sex distribution o f  psoriasis and arthritis. 
The general characteristics of the study group includ­
ing the age and sex distribution are given in Table I. 
Ninety-nine were seronegative for RF (less than 80IU 
by nephelometry).
M ode o f  onset and outcome o f  disease subsets. The 
outcome of disease in relation to the mode of onset is 
summarized in Table II. Ninety per cent of 39 patients 
presenting with a monoarthritis, 79% of 24 patients 
with an oligoarthritis and 20% of 25 patients with a 
polyarthritis changed pattern. Six of 10 patients pre­
senting with spinal symptoms developed a spondyloar- 
thropahy. In total, 64 patients changed pattern, 62 of 
whom had progression of their disease. Of the four 
patients who remained in the monoarthritis group 
three had involvement of one knee and one had disease 
confined to a single PIP joint. Two patients had appar­
ent regression of their disease with a polyarthritis at 
onset and subsequently only evidence of an oligoarthri­
tis. Four patients who presented with spinal symptoms 
developed a peripheral arthritis without spon­
dyloarthropathy.
The distribution of the site and the type of joint 
disease at onset are shown in Table III. Fifty-three 
patients presented with small joint disease which was 
more frequent in females (P<0.01) as was upper limb 
disease at onset (P<0.05). Thirty-one of these (24 
females, seven males, P<0.01) presented with hand 
disease which was the most common site of onset. 
Axial onset was more frequent in males (P<0.01) and 
those presenting with spinal disease were significantly 
younger (mean age 41.8 yr, s .d . 6.9) than the oligoar­
thritis (mean 47.9 ± 14.7) (P<0.05) or polyarthritis 
(mean 50.5 ± 15.0 yr) (P<0.02) groups. The mean ages 
for the monoarthritis and mutilans groups were 
48.2 ± 12.1 yr and 59.0 ± 16.0 yr respectively.
Only one patient, included in the oligoarthritis 
group, had the synovitis acne pustulosis hyperostosis 
osteomyelitis syndrome (SAPHO) [15]. Table IV 
shows the disease duration, HAQ scores and use of 
DMARDs of the subgroups. Not unexpectedly, the 
polyarthritis group had a significantly worse functional 
outcome defined by HAQ scores than the oligoartic- 
ular and monoarthritis groups combined (P<0.05) and 
had also used more disease-modifying therapy 
(P<0.01), had a longer disease duration (P<0.01) and
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TABLE II
Evolution of disease subsets
Outcome
Mode of onset Mono DIP Oligo Poly Spond Arthritis mutilans Total
Monoarthritis (mono) 4 0 13 22 0 0 39
DIP joint disease only 0 1 1 0 0 0 2
Oligoarthropathy (oligo) 0 0 5 18 0 1 24
Polyarthropathy (poly) 0 0 2 20 0 3 25
Spondyloarthropathy (spond) 0 0 1 3 6 0 10
4 1 22 63 6 4 100
more erosions (P<0.001) than the oligoarticular group. 
Of those with peripheral arthritis, patients with more 
severe disease had longer disease durations. Those 
with arthritis mutilans had the longest disease duration 
followed by poly arthropathy, with the monoarthritis/ 
DIP joint disease only and oligoarthropathy groups 
having the shortest disease durations.
The frequency of symmetry depended on the 
method employed. When only one identical contralat­
eral joint was required to define symmetry, all 63 of the 
polyarthritis group and six of 22 of the oligoarthritis 
group had symmetrical disease. When Helliwell’s 
method was used, 51 of 63 patients in the polyarthritis 
group and four of 22 patients in the oligoarthritis group 
had symmetrical disease.
Relationship between joint disease and skin and nail 
involvement. The distribution of the specific types of 
skin and nail disease are shown in Table V. This distri­
bution is similar to that in the general psoriatic popula­
tion [16]. There was no association between the type or 
distribution of skin involvement and arthritis sub­
group, nor was there any relationship between the 
activity of psoriasis and joint severity, activity or func­
tional status. However, there was a significant correla­
tion between the number of involved joints (joint 
score) and functional status (HAQ score). There was a 
significant correlation between PASI and the nail 
scores (P<0.001) and nail disease increased with the 
duration of psoriasis (P<0.02) (Table VI).
Sixty-seven per cent of patients had psoriatic nail 
disease, which is a greater frequency than that found in 
psoriasis alone and reflects that found in previous stud­
ies [17]. All patients with hyperkeratosis or ‘dystrophy’ 
had either pitting, onycholysis or both. The nail score 
was significantly greater in those who developed pso­
riasis before arthritis or simultaneously (P<0.05). Nail
TABLE III 
Type and site of joint disease at onset by sex
Joint disease M F Significance Total
Small 18 35 (P<0.01) 53
Large 12 17 ( n .s .) 29
Lower limb 18 24 ( n .s .) 42
Upper limb 11 27 (P<0.05) 38
Axial 9 1 (P<0.01) 10
Small and large 3 4 ( n .s .) 7
Small and axial 1 0 ( n .s .) 1
Spinal and peripheral disease 1 0 ( n .s .) 1
Upper and lower limb 6 3 ( n .s .) 9
disease occurred in all subgroups (Table III). There 
was no correlation between nail severity and the sever­
ity of arthritis. Males tended to have more severe skin 
and nail disease than females, but this was not 
significant.
Twenty-seven per cent of patients had clinical or 
radiological evidence of DIP joint disease in their 
hands which is less than in other series [18]. Those with 
DIP joint disease tended to have a longer disease dura­
tion than those without (means 15.6 and 11.0 yr 
respectively) but this was not significant. DIP joint 
disease occurred in all subgroups except spondyloar­
thropathy and monoarthritis, but only one patient had 
DIP joint disease exclusively (Table III).
Nail disease was more common in patients with DIP 
joint involvement (85 vs 60%) (P<0.02). Patients with 
nail disease in a specific digit were significantly more 
likely to have DIP disease in the adjacent joint than 
those without nail disease in that digit (PcO.001). 
Patients with nail disease on one side were also more 
likely to have DIP disease on the same side than those 
with no nail disease on that side (P<0.05). Patients 
with DIP joint disease also tended to have more severe 
nail disease, but this did not reach significance.
DISCUSSION
Attempts to classify PsA have been complicated by 
the overlap between subgroups, the importance given 
to extraosseus abnormalities, including the SAPHO 
syndrome [15], the definition of symmetry, the 
relationship of DIP joint disease to the subgroups and 
the temporal change in the pattern of arthritis.
Moll and Wright, based on their own descriptive 
work [19-22] and radiological studies by Avila et al. 
[23] described five clinical patterns: (i) ‘classic’ PsA 
confined to DIP joints of hands and feet (5%); (ii) 
arthritis mutilans with sacro-iliitis (5%); (iii) symmet­
ric polyarthritis, indistinguishable from RA (15%); (iv) 
asymmetric oligoarthritis (70%); and (v) spondylo­
arthropathy (5%) [24]. Further studies and review 
articles reaffirmed these subgroups [9,25-30], 
although the overlap between subgroups and possible 
evolution from one subgroup to another was noted 
[31]. A more recent study using radionucleotide scan­
ning concluded that all patients with peripheral arth­
ritis should be grouped together, the 
spondyloarthropathy group retained and a new group 
added, comprising rare patients with extra-articular 
osseous disease, including patients with SAPHO [11].
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TABLE IV























Monoarthritis (mono) 4 1 3 6.8 24.8 0.41 0 3 (75) 0
DIP joint disease only 1 1 0 10 10 0.125 0 1 (100) 4(100)
Oligoarthropathy (oligo) 22 8 14 6.6 14.5 0.49 9.1 13 (59) 3 (9)
Polyarthropathy (poly) 63 25 38 13.9 20.2 0.87 50.8 45 (71) 19 (30)
Spondyloarthropathy (spond) 6 6 0 13.7 19.5 0.65 33 2 (33) 0
Arthritis mutilans (AM) 4 1 3 21.5 30 1.34 75 3 (75) 4(100)
Total 100 43 57 12.5 20.6 0.77 40 67 27
Subgroup comparisons: duration of PsA: poly vs oligo (/-test), P = 0.007; oligo vs spond, P -  0.038 HAQ score: poly vs oligo + mono 
(/-test), P<0.05; use of DMARDs: poly vs oligo (x2 test), P<0.01.
Applying this classification to our patients, 94 were 
grouped together, six remained in the spondylarthritis 
group and only one belonged to the extra-articular 
osseous group. Radionucleotide scanning may have 
revealed more patients with extra-articular osseous 
abnormalities, but this is not practical in a clinical set­
ting. Whilst the extra-articular osseus group including 
SAPHO should be recognized, its relative rarity makes 
its separate classification difficult to justify, a point also 
made by Veale etal. [32]. Other attempts at reclassifica­
tion include that by Gladman et al. who initially 
increased the number of groups to seven [33], but later 
in a review of 220 patients, proposed a spectrum of 
disease patterns and severity [10]. Most recently three 
groups have been suggested [32], similar to those pro­
posed by Kammer et al. [34], with the spondyloarthro­
pathy group retained and peripheral arthritis divided 
: into two subgroups: asymmetric arthritis and symmet­
ric polyarthritis. The groups are loosely defined in 
terms of the assessment of symmetry and the number 
of joints involved, but the classification may prove use­
ful clinically.
We have divided our patients into six subgroups: 
monoarthritis; DIP joint disease alone; oligoarthritis; 
polyarthritis; spondyloarthritis and arthritis mutilans. 
The three patients with monoarthritis would be 
included in Moll and Wright’s asymmetrical oligoartic- 
ular subgroup, but the lack of progression of disease 
beyond one knee and the absence of DIP disease dis­
tinguished them from the rest of the subgroups. The 
mean disease duration for the monoarthritis subgroup 
was similar to that of the oligoarthritis subgroup but 
about half of the mean for all patients, so it is possible 
that the patients in these subgroups may have pro­
gression of their disease and change subgroup. It is 
striking that, for those with peripheral arthritis, those
TABLE V
Pattern of psoriasis and nail disease
Type of psoriasis (%) Type of nail disease (%)
Plaque 79 Pitting 74
Scalp 70 Onycholysis 70
Discoid 10 Hyperkeratosis 34
Guttate 4 Severe nail deformity 5
Pustular 3 (‘dystrophy’)
with more extensive and severe joint involvement 
(arthritis mutilans and polyarthropathy groups) had 
longer disease durations than the DIP joints disease 
only, oligoarthritis and monoarthritis groups. This 
raises the possibility that the number of joints involved 
is a function of disease duration. The homogeneity of 
the spondyloarthropathy group in this study, with all 
six patients presenting with spinal symptoms and the 
absence of DIP joint disease, supports the view that this 
subgroup should be retained [11, 32].
The subgroup frequencies initially reported by Moll 
and Wright, who found a majority of patients in the 
asymmetrical oligoarticular group has not been con­
firmed in other series. In our study, the ratio of oli­
goarthritis (including monoarthritis patients to make 
studies comparable) to polyarthritis was 1 to 2.3. Glad­
man etal. found that oligoarthritis was far less common 
than polyarthritis with a ratio of 1:2.2 [33] and the pre­
ponderance of patients with polyarthritis has sub­
sequently been confirmed by Wright [9]. However, in a 
recent study of 100 patients, Veale et al. found the 
asymmetrical oligoarthritis subgroup most common, 
although 11 patients with an asymmetrical polyarthritis 
were included in this group [32]. When these patients 
were included in the polyarthritis group, the ratio of 
oligoarthritis to polyarthritis was 1.0:1.1.
The use of both the number of joints involved and
TABLE VI 





Joint score vs HAQ 0.458 <0.001
Joint score vs nail score 0.12 N.S.
Joint score vs PASI -0.029 N.S.
Joint score vs joint activity -0.033 N.S.
HAQ vs nail score -0.103 N.S.
HAQ vs PASI -0.022 N.S.
PASI vs nail 0.361 <0.001
PASI vs active joints 0.053 N.S.
Nail vs active joints 0.131 N.S.
HAQ vs active joints -0.046 N.S.
Nail score vs duration psoriasis 0.26 0.013
HAQ, Stanford Health Assessment Questionnaire; PASI, 
Psoriasis Area and Severity Index score.
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symmetry to define the oligoarticular and polyarticular 
subgroups has proved difficult in other series [34, 35]. 
Obviously, the fewer joints involved, the more likely 
the disease is to be asymmetrical but a small number of 
patients will inevitably have a symmetrical oligoarthri­
tis or an asymmetrical polyarthritis. The difficulty is 
illustrated by the differing results of the two methods 
employed in this study and we therefore did not use 
symmetry to define our subgroups.
The rarity of pure DIP joint involvement and its 
occurrence over the spectrum of disease patterns has 
been previously noted [32, 36]. In our series DIP joint 
disease occurred in all subgroups except spinal disease 
and the monoarthritis group, and three patients had 
DIP joint involvement exclusively. The association of 
DIP joint disease with nail disease in the same digit has 
long been recognized, although detailed analysis has 
not been performed. This study confirms that there is a 
topographical association of nail disease with DIP joint 
disease when analysed for each digit and for each hand.
The evolution of disease patterns from oligoarthritis 
to polyarthritis group is a further matter of debate. 
Whereas Gladman has suggested that this is common 
[37], Helliwell et al. found that only 5% changed pat­
tern [11]. In this study, 64% of patients presenting with 
monoarticular or oligoarticular disease developed 
polyarthritis. It could be argued that the patients 
changed pattern early in the course of their disease 
before reaching a plateau, although the significantly 
greater disease duration for the polyarthritis group 
suggests that the number of joints involved is a function 
of disease duration. We have embarked on a long-term 
prospective study of patients attending the clinic to 
further evaluate the evolution of disease between 
subgroups.
Although the attempts to define clinical subgroups 
of joint disease have added greatly to our clinical per­
ception of PsA, it has had limited impact on our under­
standing of the pathogenesis. The lack of any 
serological markers for the disease, adds to this diffi­
culty. In addition, there are no clearcut HLA associ­
ations related to specific subgroups of joint or skin 
disease, although the association of the class II antigens 
HLA-DR7 to peripheral disease and HLA-DR4 with 
erosive disease requires further elucidation [38]. The 
association of nail disease and DIP joint disease is poss­
ibly the only clinical evidence that there is a peripheral 
biological link between events in the skin and the joint. 
Research into disease mechanisms at a genetic and cel­
lular level is needed to elucidate the true relationship 
between psoriatic skin, nail and joint disease.
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EXPRESSION OF THE CUTANEOUS LYMPHOCYTE ANTIGEN 
AND ITS COUNTER-RECEPTOR E-SELECTIN IN THE SKIN AND 
JOINTS OF PATIENTS WITH PSORIATIC ARTHRITIS
S. M. JONES, J. DIXEY,* N. D. HALLf and N. J. McHUGH
Royal National Hospital fo r  Rheumatic Diseases, *Bath Institute fo r  Rheumatic Diseases and 
t School o f Pharmacy and Pharmacology, University o f  Bath, Bath
SUMMARY
We hawe investigated whether the skin-homing T lymphocytes identified by the cutaneous lymphocyte antigen (CLA) are 
increaseed in the synovial membrane of patients with psoriatic arthritis. Twenty-six synovial samples (13 psoriatic arthritis, seven 
rheumaitoid arthritis, six osteoarthritis) were obtained from involved knees. Lesional skin biopsies were taken from nine of the 
patientss with psoriatic arthritis and six patients with psoriasis alone. All samples were single- and dual-stained for CLA and 
CD3 (tco identify T lymphocytes) using HECA-452 (anti-CLA) and anti-CD3 monoclonal antibodies. E-selectin expression was 
also dettermined. The percentage of dual-stained lymphocytes was significantly greater in psoriatic skin than in synovium 
(P < 0.(001) and similar between psoriatic and rheumatoid synovium. There was no significant difference in the percentages of 
CLA-pcositive cells in psoriatic skin in patients with psoriatic arthritis compared with psoriasis alone. The intensity of endothelial 
E-selecttin expression was significantly greater in skin psoriasis than in synovium (P < 2 x  10-5), and rheumatoid synovium had 
significaantly greater expression than psoriatic synovium (P < 0.05). However, there was no significant correlation between 
E-selecttin expression and the percentages o f CLA-positive lymphocytes. This study provides further evidence that the CLA 
antigen; is enriched on skin-homing lymphocytes. Conversely, the link between skin and joint inflammation in psoriatic arthritis 
does noot seem to be explained by increased trafficking of CLA T cells to psoriatic synovium.
K ey  w gords: Psoriatic arthritis, Synovium, T cell, Cutaneous lymphocyte antigen (CLA), E-selectin.
Psoriaisis is an inflammatory and proliferative skin 
disordeer with a prevalence of 1.5-3%. Approximately 
20% ojf patients with psoriasis develop a characteristic 
,form ojf arthritis that has several patterns [1-5]. Some 
j individiuals present with joint symptoms first, but in the 
jmajoriity, skin psoriasis presents first. About one-third 
tof patiients have simultaneous exacerbations of their 
^kin amd joint disease [6], and there is a topographic 
| relationship between nail and distal interphalangeal 
jjoint dlisease [4, 7]. Gerber and Espinoza [8] postulated 
I that ‘moxious substances’ may traffic between the sites, 
j  linking their involvement. Although the inflammatory 
processses which link skin, nail and joint disease remain 
; elusive?, an immune-mediated pathology is implicated, 
j  Imimunopathogenic mechanisms involving T lym- 
phocyttes in psoriasis and arthritis appear similar. Both 
the skiin and synovium are infiltrated with activated 
T lyrmphocytes [9, 10], with a preponderance of 
CD4RlO+ cells, known to migrate preferentially to 
periphceral tissues [10]. There are known associations 
with imajor histocompatibility haplotypes [11,12]. Both 
psoriassis and arthritis increase in severity with the 
depletiion o f T-helper lymphocytes secondary to HIV 
infecticon [13, 14], and both improve in response to 
immumotherapy such as cyclosporin A.
The- skin is a functionally unique immune site with 
apparently a specific homing mechanism for T cells. 
The cmtaneous lymphocyte antigen (CLA), defined by
Submiitted 21 August 1996; revised version accepted 5 December 
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the monoclonal antibody HECA-452, identifies a 
population of skin-homing memory T cells [15]. The 
receptor for CLA on dermal endothelium is the 
inducible cell adhesion molecule E-selectin [16], a 
protein which also acts to tether neutrophils during 
their initial rolling interaction with the blood vessel 
wall at the onset of an inflammatory response [17, 18]. 
It has been proposed that E-selectin on venules at sites 
of acute inflammation supports neutrophil recruitment, 
whereas in sites of chronic inflammation in the skin it 
mediates accumulation of CLA-positive T cells [16].
The principal aim of the current study was to 
determine whether skin and joint disease in psoriatic 
arthritis may be linked through the inappropriate 
expression of CLA molecules, E-selectin or both. We 
have therefore investigated the percentages and 
distribution of skin-homing (CLA-positive) T lympho­
cytes and their counter-receptor E-selectin in the skin, 
synovium and peripheral blood of patients with 
psoriatic arthritis and appropriate controls.
MATERIALS AND METHODS
The study was approved by the Bath and South West 
Ethical Committee. Written consent was obtained for 
biopsies.
Patients
Thirteen patients with psoriatic arthritis and 
synovitis of a knee were recruited from a psoriatic 
arthritis clinic. Clinical information including the age, 
sex, duration of psoriasis and arthritis, subgroup of 
joint disease, presence of erosions, degree of knee 
synovitis, skin severity, periodicity of skin and joint
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diseasse, ;and the presence of nail disease was recorded. 
All paatients had active psoriasis and were seronegative 
for rhieuimatoid factor.
Comtrols included samples from seven patients with 
seropcosiitive rheumatoid arthritis (RA) defined by the 
Ameriicatn College of Rheumatology [19], six patients 
with CDsteoarthritis and six patients with psoriasis alone. 
No p*ati<ent or control had received an intra-articular 
steroitd Injection within 3 months of obtaining synovial 
samplles..
lmmvmo\histochemistry
Sarmpie collection. (1) Synovium: Biopsies were taken 
from knee joints by a standard blind needle biopsy 
techniique using a Polley’s needle after local anaesthe­
sia. A.t least six samples of synovial membrane were 
obtaimed from different regions of the suprapatellar 
pouclh. Paraffin sections were obtained for descriptive 
histollogy. Samples from two of the patients with RA 
and tfhr<ee of the six patients with osteoarthritis were 
obtaimed at the time of arthroscopy or joint 
replacement.
(2) 1 S k in : Elliptical skin samples were obtained from 
nine jpatients with psoriatic arthritis, eight of whom 
had cjonicurrent synovial biopsies, and six patients with 
psoritasiis alone, recruited from a dermatology clinic. A 
musciuloskeletal history and joint examination were 
perfoirrmed to confirm the absence of arthritis in the 
latter- patients. Biopsies were taken from lesional edges 
of thee m ost active accessible plaques. In one patient, 
the skim biopsy was taken from a plaque directly on the 
involwed knee.
Fuirther control tissue included three samples of 
normial skin from healthy volunteers, one sample of 
lesiomal skin from a patient with severe eczema, and a 
samp)le of normal tonsil.
Preeparation o f sections. Tissue sections of skin and 
synowiuim were mounted on cork with 5% polyvinyl 
alcohiol (PVA), snap frozen in liquid nitrogen and 
stored a t — 70°C. The cork was mounted onto a metal 
chuck with PVA and 8 ^m sections were cut on a
cryostat at — 25°C. Sections were mounted serially on 
4-well glass slides, air-dried for 1 h and fixed in acetone 
at room temperature for 10 min, wrapped in tin-foil 
and stored at — 20°C prior to use. Histology was 
checked every 10 sections using a rapid staining 
technique (Diffquick). Synovial specimens without 
clearly defined synovial lining cells, and skin specimens 
without identifiable epidermis and dermis, were 
discarded.
Materials. The antibodies and other reagents used 
are listed in Table I. The monoclonal antibody 
HECA-452 was provided by Dr Louis Picker, 
University of Texas, USA.
Single-staining fo r  CD 3 and CLA. CD3 populations 
were quantified using anti-CD3 supernatant (un­
diluted) or control mouse IgG (dilution 1 in 500) and 
alkaline phosphatase/monoclonal anti-alkaline phos­
phatase (APAAP) complexes using a standard method 
described by the manufacturer (Dakopatts).
Sections were stained for CLA using HECA-452 (rat 
IgM) and a standard biotin/streptavidin-alkaline 
phosphatase technique: (1) blocking step for 20 min 
with human AB serum in 5% solution with 
Tris-buffered saline (TBS); (2) 1 h incubation with 
HECA-452 monoclonal antibody (rat IgM) at 1/30 
dilution or control rat IgM (1/100 dilution); (3) 30 min 
incubation with biotinylated species-specific anti-rat 
immunoglobulins at 1/50 dilution; (4) 30 min incuba­
tion with streptavidin-alkaline phosphatase at 1/50 
dilution; (5) Fast red/substrate for 15-20 min at room 
temperature. All reagents were diluted in TBS and 
100 /d of diluent used for each section. Each stage was 
followed by washing for 1-2 min in TBS. Finally, the 
sections were lightly counterstained with haematoxylin 
and mounted.
The HECA-452 monoclonal antibody is not T-cell 
specific, but also identifies related E-selectin ligands on 
high endothelial venules (HEVs), neutrophils and 
monocytes. Therefore, double fluorescence staining 
was used to estimate the percentage of CLA-positive 
T lymphocytes.
TABLE I
Antibodies, reagents and their sources
Antibcody'/conjugates Reactivity Isotype Source
Immumohiistology
H E C A -452 CLA Rat IgM L. Picker
A n ti-C D 3 . CD3 M ouse IgG Own laboratory
Rat Ig M  (control) Undefined Myeloma rat IgM Serotec
Mouses Ig G l (control) Undefined M ouse IgG l Sigma
Anti-rrat IgG s Rat Igs— all subclasses Rabbit Dakopatts
Anti-rmoinse IgG M ouse Igs— all subclasses Polyclonal Dakopatts
Anti-rmouise IgG -TR ITC  conjugate M ouse IgGs Polyclonal Sigma
FITC-comjugated streptavidin N A N A Dakopatts
ALP-cconjugated streptavidin N A N A Dakopatts
A n ti-E  selectin (clone H4/18) E-selectin M ouse IgG l R and D  Systems
A n ti-C D 34 C D 34 M ouse IgG l Dakopatts
A P A A P Alkaline phosphatase M ouse IgG l Dakopatts
Flow icytom etry
FITC—H EC A -452 CLA Rat IgM L. Picker
FITC control Undefined Rat IgM L. Picker
PE-comjitgated anti-CD3 CD3 M ouse IgG Dakopatts
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Fluorescence double-staining. Sections were double­
stained for CLA and CD3 using HECA-452 and 
anti-CD3 supernatant and fluorescein isothiocyanate 
(FITC) and tetramethylrhodamine isothiocyanate 
(TRITC) conjugates, respectively, and appropriate 
non-reactive control monoclonal antibodies. Each 
serial 4-well slide had a control section, single-stained 
sections for CLA and CD3, and a double-stained 
section. The incubation steps for double-staining were:
(1) 20 min blocking step with human AB serum in 5% 
solution with phosphate-buffered saline (PBS); (2) 
45 min incubations with anti-CD3 supernatant (un­
diluted) and goat TRITC anti-mouse IgG (1 in 50); (3) 
20 min blocking step with 5% normal mouse serum 
(NMS); (4) HECA-452 monoclonal antibody (1/30 
dilution); (5) 45 min incubation with rabbit biotin- 
ylated species-specific anti-rat immunoglobulins (1/50); 
(6) FITC-streptavidin (1/50). All antibodies were 
diluted in PBS and each stage was followed by washing 
for 1-2 min with PBS. The sections were mounted 
using l,4-diazabicyclo(2,2,2)octane (DABCO) as an 
interface.
Three psoriatic synovial sections were similarly 
double-stained for macrophages using anti-CD68 
instead of anti-CD3.
Sections were stained in duplicate or triplicate, 
blinded to the diagnosis and scored by two invest­
igators (SJ and JD). The numbers of single- and 
double-stained T lymphocytes were assessed in the 
dermis of the skin and sublining layer of the synovium. 
Sequential fields were studied using an eyepiece 
orientated along the dermo-epidermal junction or 
synovial lining layer. A section was only scored if the 
singly stained section was of equivalent intensity to the 
dual-stained section. Inter-observer variability was 
within 10%.
Determination and quantitation o f E-selectin ex­
pression. The anti-E-selectin monoclonal antibody was 
used followed by the APAAP complex, according to
the protocol described by the manufacturers (Dako­
patts), followed by haematoxylin counterstaining. 
Endothelial morphology was confirmed in longitud­
inally cut vessels by the endothelial cell marker 
anti-CD34. Anti-E selectin was used at a dilution of 
1/200, anti-CD34 and APAAP at 1/50. Vessels in the 
dermis of the skin and synovial sublining were scored 
in sequential fields. The number of vessels, the 
proportion of E-selectin-positive vessels and the 
intensity of staining were determined on an arbitrary 
scale as follows: 0 = no staining detected; 1 = minimal 
staining; 2 = moderate staining; 3 =  strong staining. 
The mean intensity was computed for each section. The 
density of the surrounding inflammatory infiltrate was 
also determined using the following scale: 0 =  no 
inflammatory infiltrate; 1 = small inflammatory 
infiltrate; 2 = moderate inflammatory infiltrate; 
3 = dense inflammatory infiltrate.
Flow cytometry
Sample collection. Ten millilitres of venous blood 
were taken from 12 patients with psoriatic arthritis, six 
with RA and six normal controls. All the psoriatic 
arthritis and RA patients had clinical evidence of active 
synovitis. Three of the psoriatic arthritis patients were 
included in the immunohistological study (Table II, 
patients 3, 4 and 7).
Materials. The reagents used are listed in Table I. 
The FITC-conjugated HECA-452 monoclonal anti­
body and a control FITC-conjugated rat IgM with 
unspecified reactivity were donated by Dr Picker and 
used undiluted.
Methods. Mononuclear cells (MNC) were separated 
from 10 ml of heparinized whole blood using a 
standard lymphoprep gradient. Briefly, 10 ml of 
heparinized blood were taken from each patient. The 
separated MNCs were washed with medium, counted 
and resuspended in RPMI and 10% fetal calf serum, 
and pre-incubated with 50 ^1 of undiluted normal
TABLE II




Duration o f  
arthritis 
(yr)

















skin and joint 
exacerbations
1 59 F 27 28 Mutilans y 2 3 4.2 n 0 n
2 62 F 18 10 Polyarthritis y 3 3 4.8 n 0 n
3 53 M 24 36 Polyarthritis y 1 2 4.2 y 4 y
4 40 M 6 16 Polyarthritis y 2 2 4.4 y 17 n
5 38 M 7 8 Oligoarthritis n 1 2 2.1 y 6 n
6 20 F 6 8 Oligoarthritis n 3 1 2.7 y 7 y
7 30 M 26 9 Polyarthritis n 1 3 4.1 y 0 y
8 62 M 22 22 Polyarthritis y 3 3 1.2 y 5 n
9 42 F 7 20 Oligoarthritis n 1 1 0.6 y 0 n
10 40 M 12 12 Oligoarthritis n 2 2 2.1 n 0 n
11 48 M 20 33 Polyarthritis y 2 2 2.4 y 18 n
12 46 F 15 30 Polyarthritis y 2 2 0.5 y 7 y
13 34 F 6 <  1 Polyarthritis y 3 Trivial 0 y 3 n
Patients 3 and 7 had insufficient synovial lymphocytes for quantitative assessment.
Paired skin samples were available on patients 1-8.
Historical skin severity and knee synovitis are graded on a three-point scale: 1 =  mild; 2 =  moderate; 3 =  severe. 
*Reference [28].
•(•Reference [4],
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humain serum. A total of 5 x 105 cells were used per 
test. TThie following reagents were added: (1) anti-CD3,
(2) pphycoerythrin (PE)-conjugated anti-mouse im- 
munoogl<obulins (1/50) and (3) FITC-conjugated 
HEC2A-452 monoclonal antibody (undiluted) with 
appropriate controls minus one or more reagents. After 
30 miin incubation, the cells were resuspended in PBS 
containing 1% paraformaldehyde.
Flcow cytometry was performed using a Becton-Dick- 
insoni FACStar Plus with an air-cooled argon laser and 
Conssorlt 32 computer. Gating was performed by setting 
the tlhreshold with reference to the relevant negative 
contrrol.. The percentages of CLA-positive circulating T 
lymplhocytes in the peripheral blood of patients with 
psoriaatiic arthritis, RA and normal controls were 
determined.
Data i analysis
Daata. were analysed using a Hewlett Packard 
persconail computer with software packages including 
M icrosoft EXCEL and STATMOST. Normality 
testimg was performed prior to analysis. Duncan’s test 
for nmultiple comparisons was used for the various 
patietnt groups. The Mann-Whitney U-test was used to 
comppare all the psoriatic skin versus the synovial 
samp3les. The Wilcoxon signed rank test was used for 
paireed psoriatic skin and synovial data. Spearman’s 
rank coefficient was used for correlation analysis.
RESULTS
CliniicaH characteristics 
Thie patients represented a spectrum of disease 
severrity for both joint and skin disease (Table II). 
Therce were six females and seven males, mean age 44 
(range 20-62 yr) and mean duration of arthritis 15 yr 
(range 6-27) and psoriasis 18 yr (range 0-36). One 
patieint (patient 13) had trivial psoriasis only that at the 
time o f synovial biopsy did not reach the criteria for a 
PASH score. The immunohistological data were 
assesssed in relation to clinical parameters.
Immiumohistology
T-tlymphocyte populations. The distribution of 
T lyrmphocytes in each sample was quantified prior to 
doutble-staining (Table III). Eight synovial samples (six 
ostecoarthritis, two psoriatic arthritis) did not have 
sufficciemt lymphocytic infiltration to determine accu­
rately the percentages of CLA-positive T cells. The two 
psoriiatiic arthritis patients had only mild synovitis at 
the tiimie of biopsy. For the six osteoarthritis patients, 
only isolated lymphocytes were present, with an 
occassional double-stained cell. Apart from the osteo- 
arthrritiis group, the mean numbers of T cells per field 
(T-ceell density) were similar in the other four patient 
groujps. There was a weak negative correlation between 
the TT-cell density in synovium and the duration of 
arthrritiis, but this was not significant. There was also a 
weak positive correlation between the degree of 
synowittis clinically in psoriatic arthritis and the T-cell 
densiity, but this was not statistically significant.
Immunohistological distribution o f the CLA antigen. 
The CLA antigen was present on many cell types 
within the synovium, including T cells, vascular 
endothelium, neutrophils and macrophages. Its pres­
ence on macrophages was also confirmed by double­
labelling with an anti-CD68 monoclonal antibody. In 
the skin, CLA-positive lymphocytes were observed in 
all lymphocytic areas, both in perivascular lymphoid 
aggregates around superficial dermal vessels, immedi­
ately below the stratum basale and in the more diffuse 
cellular infiltrate. Other skin cell types also stained for
TABLE III
T-lymphocyte densities and percentages o f  CLA-positive cells in 
psoriatic arthritis, rheumatoid arthritis synovium and psoriatic skin
Sample number
Number o f  
T cells per 
HPF ( x 40) 
mean (range)







1 18 (11-32) 107 11.2
2 20 (13-26) 101 4
3 <  1 N D N D
4 92 (32-231) 369 3.8
5 10 (8-11) 39 15
6 38 (16-55) 269 3.3
7 8 (1-39) 631 7.1
8 4 (1-13) 159 34
9 <  1 N D N D
10 25 (12-40) 253 7.5
11 11 (1-53) 310 4.2
12 11 (3-21) 157 5.7
13 9 (5-13) 53 11
Mean (s .d .) 22 (25) 307 (173) 9.7 (8.9)
RA  synovium
1 (surgical) 1 (0 -45) 362 14
2 44 (33-52) 261 2.7
3 16 (9-25) 197 10
4 7 (3-11) 51 3.9
5 41 (19-67) 285 4.9
6 (surgical) 27 (11-65) 348 14.4
7 30 (21-38) 180 2.2
Mean (s .d .) 24 (16.4) 
Psoriasis in psoriatic
241 (108) 7.4 (5.3)
arthritis*
1 10 (5-14) 52 51.9
2 11 (6-16) 56 46.4
3 17 (7-34) 121 41.3
4 21 (13-26) 170 50.6
5 23 (3-58) 132 56.1
6 35 (19-66) 283 57.6
7 12 (6-24) 167 32.3
8 25 (11-40) 197 48.2
9 35 (13-47) 212 42.9
Mean (s .d .) 19 (9.6) 147 (74) 47.5 (7.9)
Psoriasis
1 26 (6-15) 104 43.3
2 36 (24-39) 254 57.8
3 11 (8-20) 100 38
4 20 (9-28) 256 39.5
5 6 (2-11) 51 60.8
6 24 (17-39) 166 75.3
Mean (s .d .) 21 (10.1) 155 (85.5) 52.4 (14.7)
N D , not done.
*Psoriatic synovial samples 1-8 are paired with psoriatic arthritis 
skin samples 1-8.
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F ig .  1. Percentages o f T  lymphocytes that are C L A  positive in 
psoriasis with and without arthritis, eczema, normal skin, psoriatic 
arthritis synovium, rheumatoid arthritis synovium and tonsil.
HECA-452 including macrophages, po lym orpho­
nuclear leucocytes, vascular endothelial cells and 
Langerhans cells.
C L A /C D 3  double-staining. The percentages of 
C L A /C D 3 double-stained lymphocytes in patient 
groups and control tissue are shown in Table III and 
Fig. 1. Representative results o f  fluorescence double- 
staining o f  CD3 and CLA for psoriatic skin and 
synovium are shown in Fig. 2a-d . There was a 
significant correlation between the density o f  the 
inflammatory infiltrate and the percentages o f  CLA- 
positive T cells (P  <  0.05).
The following comparisons between disease groups 
were made: (a) all skin ( A  =  19) and all synovial 
samples (A  =  18); (b) psoriasis (A  =  15) and psoriatic 
arthritis synovium (A = 1 1 ) ;  (c) psoriatic arthritis 
synovium ( A  =  9) and RA synovium ( A  =  7); (d) 
paired psoriatic arthritis synovial m embrane and skin 
samples (A  =  7); (e) psoriasis in patients with arthritis 
( A  =  8) and those without arthritis  ( A  =  6).
The percentages o f  lymphocytes double-stained for 
C LA  and CD3 were significantly greater in (a) skin 
than synovium (P < 10 6) and (b) psoriasis than 
psoriatic arthritis synovium (P =  0.01). For paired skin 
and synovial samples from psoriatic arthritis patients, 
the percentages o f  double-stained lymphocytes were
also significantly greater in skin than  synovium 
(P < 0.02). In one paired sample of psoriatic skin and 
synovium (patient 8), the percentage expression was 
48.5 and 34%, respectively.
There were no significant differences between the 
percentages o f  double-stained lymphocytes in psoriatic 
arthritis synovium compared with RA synovium . In 
skin psoriasis, there were no significant differences 
in the percentages o f  CLA-positive lym phocytes in 
patients who had arthritis compared with those  with 
psoriasis alone. The percentages in the three samples o f  
normal skin and from one sample o f  eczem atous skin 
were similar (all 60%), but much less in tonsil (2.5%).
There were no significant associations between cny 
clinical param eter and the percentages o f  double- 
stained lymphocytes in synovial tissue. There were no 
significant associations between the degree o f  synov tis 
clinically and the percentage o f  double-sta ired  
lymphocytes. In particular, there were no significant 
differences between the percentages o f  double-sta ired  
lymphocytes in the four patients who had coincident 
exacerbations o f  their skin and joint disease, and those 
in whom there was no apparent temporal association. 
The patient with the greatest percentage o f  double­
stained lymphocytes in synovium (34% ) did have 
simultaneous exacerbations o f  his skin and  joint 
disease.
E-selectin expression. The mean num ber o f  blood 
vessels per field, the percentage of  positively stained 
vessels, the E-selectin intensity and the density o f  the 
perivascular infiltrate are shown in Table IV. 
C om parisons between the percentages o f  positive 
vessels, E-selectin intensities, numbers o f  vessels and 
perivascular infiltrates were made in the following 
groups: (a) all skin (A =  18) and all synovial samples 
( A  = 1 6 ) ;  (b) all psoriasis ( A  = 1 5 )  and psoriatic 
arthritis synovium ( A  = 1 0 ) ;  (c) psoriatic arthritis 
synovium ( A  =  10) and RA synovium ( A  =  6); (d) 
paired psoriatic arthritis synovial mem brane and skin 
samples ( A  =  6); (e) psoriasis in patients with arthritis 
( A  =  8) and those without arthritis ( A  =  6).
The results for the disease group com parisons for the 
intensity o f  E-selectin expression were as follows: (a) 
E-selectin expression was significantly greater in skin 
than synovium (P < 2 x 10 6) and (b) in skin psoriasis 
com pared with psoriatic synovium (P < 2  x  10~5); (c) 
E-selectin expression was significantly greater in RA 
synovium com pared with psoriatic arthritis synovium 
(P < 0.05); (d) in paired skin and synovial samples 
from patients with psoriatic arthritis, E-selectin 
expression was significantly greater in skin than 
synovium (P < 0.018); (e) there was no significant 
difference in E-selectin expression in the skin of 
patients with arthritis com pared with those without 
arthritis. When the numbers o f  positive vessels were 
used instead o f  E-selectin intensity, the results of  these 
comparisons were similar. In 3/10 psoriatic arthritis 
synovial samples and 1/7 RA synovial samples, no 
E-selectin expression was seen. Minute quantities only 
o f  E-selectin were detected in osteoarthritis synovial 
membrane. In skin, E-selectin was expressed in all
JONES E T  AL:. CLA AN D  E-SELECTIN EXPRESSION IN PsA 753
samples throughout the dermal vessels, including the 
deep dermal vasculature, and was present in all 
samples. E-selectin expression in skin and synovium is 
shown in Fig. 3.
The numbers o f  vessels per field were significantly 
greater in synovium than all the skin samples, including 
the three samples o f  eczema and normal skin 




F ig .  2. Photomicrographs o f fluorescence dual staining o f psoriatic skin and psoriatic arthritis synovium, (a) T R IT C  anti-CD3-labelled  
lymphocytes in skin psoriasis (stained red; green filter) (original magnification x2 0 ); (b) F IT C  H ECA-452-labelled cells in psoriasis (original 
magnification x 20). The m ajority o f T  lymphocytes in the aggregate are C L A  positive, (c) T R IT C  anti-CD3-labelled lymphocytes in psoriatic 
arthritis synovium (stained red; green filter) (original magnification x 4 0 ); (d) F IT C  HEC'A-452-labelled cells in psoriatic arthritis synovium  
(stained green; red filter) (original magnification x 40). Almost all o f the lymphocytes are C L A  negative. A  rare pair o f dual-stained lymphocytes 
are shown (long arrows). A non-lymphocytic cell labelled with the H E C A -452  monoclonal antibody is also shown (short arrow). The bar 
represents 100 /on.
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T A B L E  IV
Num ber o f vessels per field, expression o f E-selectin and density o f perivascular infiltrate in psoriatic arthritis, rheumatoid arthritis sy novium
and all skin samples
Sample number
Num ber o f vessels 
per H P F  ( x 20) 
(mean)










1 10 30 33 1 1.93
2 4.3 18 50 0.65 1.35
3 N D N D N D N D N D
4 4.3 13 0 0 0.85
5 N D N D N D N D N D
6 4.2 25 16 0.2 0.76
7 7.1 50 0 0 1.2
8 8.75 70 13 0.65 1.35
9 N D N D N D N D N D
10 6.5 65 35 0.54 1.37
11 4.5 18 22 0.22 1.22
12 10 10 0 0 0.2
13 10 10 20 0.2 1.3




N D N D N D N D N D
2 5 10 50 0.7 0.7
3 5.5 11 9 0.09 0.36
4 N D N D N D N D N D
5 15.3 92 64 1.38 1.63
6 (surgical) 5.9 142 48 0.77 0.77
7 2.3 7 0 0 2.86
8 6.9 104 62 1.31 1.14
Mean ( s .d .) 6.8 (4.4) 61 (59) 38.8 (27.5) 0.71 (0.58) 1.24 (0 .9)
Psoriasis in psoriatic arthritis*
1 3 9 100 2.44 1.56
2 5 45 100 2.06 0.66
3 8.3 33 100 1.82 1.39
4 3.9 27 100 2.44 1.19
5 6 30 100 2.67 1.8
6 6.6 39 87 1.66 1.27
7 4.8 43 100 1.95 1.02
8 11.3 102 84 1.95 1.22
9 5 15 100 2.87 2.13
Mean ( s .d .) 6 (2.5) 40.3 (27.7) 96.8 (6.4) 2.21 (0.41) 1.36 (0.43)
Psoriasis
1 2.5 10 100 1.6 1.7
2 2.8 14 100 1.29 1.86
3 1.5 12 100 2.5 1.25
4 4 16 94 1.81 1.44
5 4.2 21 100 2.48 1.29
6 3.7 46 100 1.6 1.33
Mean ( s .d .) 3.7 (1.0) 28.8 (13.3) 99 (2.4) 2.09 (0.5) 1.53 (0.25)
Eczema
1 5.4 27 89 2.3 1.78
Norm al
1 3.7 11 18 0.18 0.73
2 2 10 80 0.9 0.6
Mean ( s .d .) 2.9 (1.2) 10.5 (0.71) 49 (43.8) 0.54 (0.51) 0.67 (0.09)
*Psoriatic synovial samples 1-8 are paired with psoriatic arthritis skin samples 1-8. 
All samples correspond to those in Table I I I .
when only psoriatic skin was analysed (P < 0.04). 
However, there were no significant differences between 
the numbers o f  vessels per field between any o f  the 
remaining disease groups.
There were no significant differences in the density 
o f  the perivascular infiltrates between the patient 
groups. F o r  psoriatic arthritis synovium, there was a 
significant correlation between E-selectin expression
and the density o f  the inflammatory infiltrate 
(P < 0.005). For all the disease groups combined, there 
was a weak positive correlation between E-selectin 
expression and the density o f  the inflammatory 
infiltrate, but this was not significant. There were no 
significant correlations between E-selectin intensity and 
any clinical parameter or the percentages o f  CLA- 
positive T cells.
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CLA-positive T  cells in peripheral blood. Flow 
cytometry results for T lymphocytes double-stained for 
CD3 and CLA are shown in Fig. 4. Patients with RA 
had slightly greater percentages o f  double-stained cells 
(median 4.8, range 2 .6-8 .4% ) than those with psoriatic 
arthritis (median 2.9, range 1.4—5.8%) and four normal 
control patients (median 2.0, range 1.1-5.7). The 
differences between the disease and normal control 
groups were not significant.
D ISC U SSIO N  
Patients with psoriatic arthritis provide a unique 
opportunity for studying tissue-specific hom ing mech-
{a) V' %
t .  k.
kp|
anisms that contribute to chronic inflammation. We 
have obtained paired samples o f  chronically inflamed 
skin and synovium from such patients, spanning all the 
patterns and severities o f  peripheral joint disease with 
the com m on features o f  knee synovitis and active skin 
disease. O ur major finding is that there is a significantly 
greater percentage o f  CLA-positive lymphocytes in 
psoriatic skin com pared with synovium in psoriatic 
arthritis, and tha t this difference is independent o f  the 
clinical characteristics. The data  confirm previous 
evidence that the CLA molecule is enriched only on 
skin-homing T lymphocytes [15] and are similar to the 








F ig . 3.— Differing intensities o f E-selectin expression on vascular endothelium in (a) psoriasis, (b) rheumatoid arthritis synovium and (c) psoriatic 
arthritis synovium. A typical vessel in each section is indicated by the arrows. The bar represents 100/m i.
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HECA - 452
F ig . 4.— A representative two-dimensional flow cytometric profile o f  
lymphocytes from the peripheral blood o f a patient with rheumatoid 
arthritis. The upper left quadrant shows CD3-positive H E C A -452- 
negative lymphocytes, the upper right quadrant shows dual-stained 
C D3-positive/H ECA -452-positive lymphocytes and the lower right 
quadrant shows single-stained CD 3-negative/HECA-452-positive  
lymphocytes. In this sample, 4 .8%  o f CD3-positive lymphocytes are 
dual-stained for H E C A -452 .
arthritis  [20], Differential expression o f  the CLA 
antigen represents the single most prominent difference 
between the T-lymphocyte infiltrate in psoriatic skin 
and synovium. Furtherm ore, there was no significant 
difference in the numbers of CLA-positive T  lympho­
cytes in peripheral blood between psoriatic arthritis, 
RA and normal healthy control patients. Therefore, 
there does not appear to be any circulating clonal 
expansion o f  CLA-positive lymphocytes in patients 
with psoriatic arthritis.
The lack o f  association between the expression of the 
CLA  molecule in psoriatic skin and synovium may be 
consistent with existing observations regarding the link 
between psoriasis and arthritis. F o r  instance, there is 
no association between the type or distribution of  skin 
involvement and arthritis subgroup [4], Also a pattern 
o f  joint disease typical o f  mutilating psoriatic arthritis 
may occur without skin disease or with nail disease 
only [21]. In the majority of patients, the skin disease 
presents first and exacerbations o f  both skin and joint 
disease are only coincident in ~  30% of  patients [6], We 
have included two patients with simultaneous exacer­
bations o f  skin and joint disease, one o f  whom had a 
higher percentage o f  CLA-positive lymphocytes than 
any other synovial sample; however, the intensity of 
expression was noted to be less than  in skin psoriasis. 
In previous work, one sample o f  liver was found to 
have 40% CLA-positive T  lymphocytes [15]. Our 
patient had a severe active synovitis in his knee, 
suggesting that during acute inflammation general 
mechanisms might override specific homing mechan­
isms.
E-selectin is upregulated on the vascuhr ndo- 
thelium of  inflammatory skin lesions [22] a  ^ wll as 
other inflammatory sites [17]. The increased imentty of  
its expression in psoriatic skin com pand  with 
synovium found in the present study is similar tc that 
previously reported by some [23], but not otlers[20]. 
Although the increased expression o f  E-selectii ii skin 
may have bearing on the greater expression o f  3LA 
on lymphocytes in skin, there was no sgnicant 
correlation between E-selectin expression inc the 
percentage o f  CLA-positive lymphocytes. I-se:ctin 
also binds neutrophils via the sialyl Lewis >; rniety, 
so its expression could reflect neutrophil dapdesis 
prominent in psoriatic skin, but not synoviim The 
reduction in mean vascular E-selectin intinsiy in 
psoriatic arthritis compared with RA was als> shilar 
to that found previously [24]. We have alsc stdied 
E-selectin expression in osteoarthritis and foind mall 
quantities, similar to that found in the ncmal 
synovium o f  amputees [25].
The C LA  antigen is not specific to psoriisis but 
occurs in high percentage in normal inc all 
inflammatory skin conditions, as we have burJ by 
studying normal skin and eczema. The renarable 
similarity in the percentages o f  CLA-positivelymho- 
cytes in all our patients also suggests that the nolcule 
is not specific to psoriasis, but is globally peseit on 
the majority o f  T  lymphocytes in all skin, indperient 
of the lymphocyte density. C L A  is not prser. on 
virgin T cells, but is upregulated on a subet )f T 
cells undergoing the virgin to memory tranilim in 
secondary lymphoid tissues [26], U pregu la t io ro f  'LA 
occurs in a highly regulated tissue-selective mamer. 
For example, CLA is upregulated on over hJf c' the 
T cells undergoing the virgin to memory traisitfn in 
skin-associated peripheral lymph nodes, but >n swer 
than 10% of  transitional T cells in the mucosaof mall 
bowel. In addition, CLA expression seems to b futher 
upregulated when memory-effector T  cells as reacti­
vated in skin, indicating that the local micrcnvron- 
ment at the time of T-cell activation acts to nflence 
the homing receptor repertoire o f  the esitant 
memory-effector cells.
In conclusion, our study supports  the hypotbsi;that 
the CLA population of lymphocytes is esenially 
specific to skin, even when skin and an extractanous 
site o f  inflammation occur simultaneously in he ame 
patient, as in psoriatic arthritis. Therefore, thre s no 
evidence to suggest that skin psoriasis and artriti are 
linked through a common mechanism involvig 'LA 
T-lymphocyte interactions with E-selectin. Itrenains 
possible that skin and joint disease in psoria t ia r t  ritis 
could be linked through an undiscovered dhsion 
receptor for a particular T-lymphocyte subset orby a 
com m on T-cell antigen. The topographic  assoiatfn of 
nail disease and distal interphalangeal joint dieas*still 
requires explanation, and examination o f  te dstal 
interphalangeal joint and nailbed tissue itsel m;y be 
the only way o f  determining related immunopthoogy. 
As skin disease usually precedes joint disase, 
knowledge o f  genetic susceptibility factrs and
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mechhamisms linking inflammation at separate sites may 
yet ecnaible joint disease to be predicted and prevented.
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